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Abstract 
 
 
The demand for O-glucuronides as potential therapeutic products and biomarkers 
continue to increase. However, large-scale synthesis of O-glucuronides remains a 
challenge for the industry, and has prompted the development of an alternative synthetic 
routes. This dissertation extends from a previous enzyme engineering work that had 
introduced a site-specific mutation E504G in β-glucuronidase (β-GUS), resulting in a 
functional glucuronylsynthase (Syn). However, the synthetic activity of Syn is low and 
leaves ample scope for improvement. The work described in this thesis aims to produce 
a more efficient glucuronylsynthase using different enzyme engineering approaches.  
Two separate strategies were employed to achieve our objective. The first strategy 
engages a two-step process where the β-GUS is first engineered to have higher activity 
in the presence of excess substrate; 10–20 times its Km. This is followed by site-specific 
mutation E504G to convert the β-GUS variant into a Syn. The second strategy engineers 
the glucuronylsynthase directly. 
 
Chapter 3 describes the attempt to improve the activity of the native enzyme in the 
presence of t-BuOH, a solvent that was found to improve the chemistry of the 
glucuronylsynthase chemoenzymatic reaction. The engineering attempt produced a 
potential variant with a mutation at its C-terminal region, L561S, that is more active in 
the presence of the solvent. This mutation appears to be a determinant mutation. 
Biophysical characterization of the enzyme revealed that this improvement is not due to 
increased stability in t-BuOH, while our analysis of the crystal structure suggests that 
the mutation improved the activity by increasing loop flexibility at the C-terminal 
region. Subsequently, I incorporated E504G into the β-GUS variant, but this did not 
translate into a better glucuronylsynthase variant. Chapter 4 describes the second 
strategy.  
 
Two mutations, H162Q and Y160G, at the N-terminal region were found to boost 
the synthetic activity but this was not accompanied by improvement in their 
thermostability nor solvent stability. However, combining the results from the 
biophysical characterization experiments and observations from the structural 
ABSTRACT 
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examination on 3K4D, it can be inferred that the mutations promote glucuronylsynthase 
activity by modulating the active site of the Syn so that it would favour the glucuronyl 
donor substrate. Therefore, these mutations would serve as concrete starting points for 
further evolution program of the Syn.  
 
Chapter 5 explores the potential reason that could account for the lack of success 
in transposing the potency of L561S to the glucuronylsynthase system. The work here is 
driven by the hypothesis that translational misincorporation introduced contaminating 
wild-type during enzyme expression. Essentially, this chapter highlights the potential 
pitfall of the glucuronylsynthase system and describes potential strategies to avoid this 
pitfall. Finally, Chapter 6 builds upon the results from E-GUS engineering and explores 
the mutational tolerance of β-GUS. Its mutational tolerance is compared with another 
enzyme that is structurally less complex (β-lactamase, TEM-1). In addition, its 
mutational tolerance with different substrate is also compared. This exercise attempts to 
provide insights into the elements that would drive the adaption process of the β-GUS. 
Consequently, we expect this study to facilitate future directed evolution studies of the 
E-GUS and the glucuronylsynthase.  
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-F : Fluorine leaving group 
1FGlcA : D-D-glucuronyl fluoride 
β-GAL : β-galactosidase 
β-gluc : β-glucuronide 
β-GUS : β-glucuronidase, wild-type enzyme 
2xYT : 2x-yeast tryptone media 
AA : Amino acid 
Ac : Acetyl 
AEBSF : 4-(2-aminoethyl) benzene sulfonyl fluoride hydrochloride 
ataS : Pseudomonas Aeruginosa arylsulfatase 
CD : Circular dichroism 
CMO-DHEA : Dehydroepiandosterone O-(carboxymethyl)oxime 
CMO-DHEA gluc : Dehydroepiandosterone O-(carboxymethyl)oxime-β-D-
glucuronide 
DHEA : Dehydroepiandosterone 
DMSO : Dimethylsulfoxide 
DNA : Deoxyribonucleic acid 
E. coli : Escherichia coli 
E504A : β-GUS with position E504 mutated to alanine 
E504G : β-GUS with position E504 mutated to glycine 
E504S : β-GUS with position E504 mutated to serine 
ePCR : Error-prone PCR 
ePCR-StEP : Error-prone PCR – staggered extension PCR 
eq. : Equivalence 
ESI : Electron spray ionization 
Et : Total amount of enzyme 
Et : Ethyl 
F : Fluorescence 
F- : Fluoride ion 
GH : Glycoside hydrolase 
H3PO4 : Phosphoric acid, 85% 
HPLC : High performance liquid chromatography 
IPA : Isopropyl alcohol 
IPTG : Isopropyl β-D-thiogalactopyranoside 
ITC : Isothermal titration calorimetry 
K2HPO4 : Dipotassium hydrogen phosphate; potassium phosphate 
(dibasic) 
KH2PO4 : Potassium dihydrogen phosphate; potassium phosphate 
(monobasic) 
LB : Luria-Bertani media 
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LBA100 : LB media or LB agar plate with 100 Pg/mL of ampicillin 
LBK50 : LB media or LB agar plate with 50 Pg/mL of kanamycin 
LCMS or LC/MS : Liquid chromatography-mass spectrometry 
lit. : Literature values 
M/Z : Mass to charge ratio 
M9 : Minimal media M9 salts 
Me : Methyl 
MM : Michaelis-menten 
mQH2O : Milli-Q water 
Na2HPO4 : Disodium hydrogen phosphate; sodium phosphate 
(dibasic) 
NaH2PO4 : Sodium dihydrogen phosphate; sodium phosphate 
(monobasic) 
NaOH : Sodium hydroxide 
NaPi : Sodium phosphate buffer 
Ph : Phenyl 
pNPGlcA/pNPGA : Para-nitrophenyl-β-D-glucuronide 
pNPgal : Para-nitrophenyl-β-D-galactoside 
pNPGlc/pNPG : Para-nitrophenol-β-D-glucoside 
RT : Room temperature 
rxn : Reaction 
SDS : Sodium dodecyl sulfate 
SDS-PAGE : Sodium dodecyl sulfate - polyacrylamide gel 
electrophoresis 
StEP : Staggered extension PCR 
Syn : Glucuronylsynthase 
t-BuOH : t-butanol 
t1/2 : Half-life 
TEMED : N,N,N',N'-tetramethylethylenediamine 
tret : Retention time 
UDP : Uridine 5'-diphosphate 
UDPGT/UGT : Uridine 5'-diphospho-glucuronosyltransferase 
UV : Ultraviolet spectrum 
WT : Wild-type 
X-gluc : 5-bromo-4-chloro-3-indolyl-E-D-glucuronic acid 
YENB : Yeast extract-nutrient broth media 
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qC : degree Celcius 
∆H : binding enthalpy 
Oem : emission maximum wavelength 
Oex : excitation maximum wavelength 
Å : Angstrom 
au : arbitrary units 
c : shape of sigmoidal curve of an isothermal titration 
calorimetry (ITC) binding isotherm (= et x Ka) 
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R : correlation coefficient in non-linear regression 
R2 : coefficient of determination in linear regression 
s : second 
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PM : micromolar 
Pm : micrometer 
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V : volts 
vol. : volume 
v : velocity 
vo : initial velocity 
v/v : volume per volume 
Vmax : maximum velocity of the enzymes 
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Nomenclature 
 
 
A. Reactions 
 
The substrates used in this thesis are structurally complex. They exhibit a very 
rich chemistry due to the large number of stereoisomers that they possess. This thesis 
generally follows the nomenclature outlined by the IUPAC guidelines. Nonetheless, we 
will provide a summary of the nomenclature used for the chemical compounds and the 
main reactions that will be encountered throughout the thesis. The reactions that 
concern this thesis are shown in Figure N-1. 
  
 
Figure N-1:  Reactions that are discussed in this thesis are the hydrolysis and synthesis of glucuronides. 
	
“Glucuronides” is a trivial name for a class of glycosides. Glucuronide substrates 
have two moieties, generally called the glycone and aglycone components. The two 
components are linked by a glycosidic bond, which takes the form of -O bridge. 
Specifically, glucuronides consists of a glucuronyl and a general aglycone component, 
which are linked by an –O glycosidic bond. The hydrolysis of glucuronides generates a 
glucuronic acid and a general aglycone. The reverse process synthesizes the –O 
glycosidic bond. This will be referred to as conjugation or glucuronylation. The 
nomenclature for the two components, as depicted in Figure N-2, is detailed in the next 
two sections.  
X = UDP, F-
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Figure N-2: Components in a glucuronide. It 
consists of a glycosyl group called glucuronic 
acid and an aglycone component (circled blue).	
 
 
B. Glycosyl groups 
 
The monosaccharide that concerns this thesis is E-D-glucopyranosiduronic acid or 
E-D-glucuronic acid (GlcA), which differs from E-D-glucose (Glc) at C6 position 
(Figure N-3), where the hydroxyl group has been oxidized to a carboxylic acid. This is 
one of the hydrolysis products that will feature frequently in this thesis. Figure N-3 
shows the open chain (Fisher projection) and the 6-membered cyclic configuration of 
the two compounds.  
	
 
Figure N-3: Numbering conventions and derivation of the E-D-glucuronic acid (GlcA). The glucuronic 
acid is essentially a glucose oxidized at the C6 position. 
 
Following IUPAC guidelines, the numbering for the monosaccharides begins at 
the aldehyde chain in the Fisher projection. The stereochemistry at the highest-number 
chiral centre (C5) provides the reference point for the definition of the stereochemistry 
at the other stereocentres. The symbols “D” and “L” refer to the configuration at this 
carbon itself. A monosaccharide is classed as “D” sugar if the hydroxyl group on this 
carbon is positioned on the right. “D” and “L” are related as enantiomers and the “D” 
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form is the more common of the two in nature. It is the form that is applicable to this 
thesis. Therefore, only the “D” sugars were represented in Figure N-1. 
 
Simple sugars often exist in their 6-membered cyclic configuration (pyran). This 
is generated when the C5 hydroxyl group forms an intramolecular bond with the 
aldehyde (C1) resulting in ring closure. This forms a new chiral centre at C1, which is 
also known as the anomeric carbon. The stereochemistry at C1 of the pyran form is 
defined by prefixes “D” and “E”. Its absolute configuration is also defined by its 
orientation relative to C5. If the hydroxyl group on this anomeric carbon is cis to the 
substituent C5, the sugar will be known as the E-anomer. The corresponding glycosides 
derived from these monosaccharides will be known as glucosides and glucuronides 
respectively (Fig N-2). 
 
The hydroxyl group at the anomeric carbon can be substituted for another 
functional group. Nevertheless, the naming convention remains the same. For example, 
the D-D-glucuronyl fluoride (1FGlcA) is similar to the D-D-glucuronic acid except that 
its anomeric substituent is a -F rather than a -OH group (Figure N-4). The 1FGlcA is the 
synthetic substrate used for this work and will be also be called the glucuronyl donor 
in glucuronylation reactions. Where reference is made to general glycone group donors, 
they are simply termed glycosyl donor. 
 
	
Figure N-4:  E-D-glucuronic acid, D-D-glucuronic acid and D-D-glucuronyl fluoride  
 
 
C. Aglycone groups 
 
The other component in the E-D-glucuronide is the aglycone. This is either the 
leaving group in the hydrolysis reaction, or an acceptor substrate for the conjugation 
reaction. They are termed acceptor substrates because they accept the sugar ring in 
glycosylation reactions. For glucuronylation, it is generally known as glucuronyl 
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acceptors. There are two types of acceptors- alcohol acceptors and steroid acceptors. In 
both cases, the center for the conjugation reaction happens at a –OH functional group. 
Figure N-5 depicts some acceptors that will be referred to in the thesis. The two main 
steroids used for this work are dehydroepiandrosterone O-(carboxymethyl)oxime 
(CMO-DHEA) and testosterone. Since the systematic names are too long, the common 
names and abbreviations will be used. 
 
 
Figure N-5: The aglycones discussed in this thesis. Acceptors of glucuronyl donors in glucuronylation 
reactions or leaving group in the hydrolysis reaction. para-nitrophenol (pNP) is the leaving group in the 
substrate used to monitor hydrolysis in this thesis. 
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1. Introduction  
 
1.1. Preamble 
 
This chapter details the aims of this thesis and the strategies that will be employed 
to achieve these aims. We will also give a background on the enzymes that concern this 
thesis.  In the interest of readers who may not be familiar with the naming conventions 
of the glycone and aglycone groups in glucuronides and glycosides, a description of 
these and their chemical transformations has been provided in the preceding section- 
Nomenclature. The last part of this chapter aims to provide an overview of the thesis. 
 
 
1.2. Background 
 
Glucuronide synthesis plays an important role during detoxification in the human 
body1–3. This process is known as glucuronidation or glucuronylation. It is a major 
biochemical reaction in Phase II xenobiotic metabolism where exogenous substances 
are converted to glucuronides. Xenobiotics may take the form of drugs or 
pharmaceutics, dietary intake, or various kinds of chemicals. Figure 1-1 illustrates the 
fate of xenobiotics and the metabolites in the xenobiotic metabolism pathway.  
 
The biochemical reaction for glucuronylation in eukaryotes is catalyzed by the 
uridine 5’-diphosphoglucurunosyl transferases (also known as uridine glucuronosyl 
transferase), UDPGTs/UGTs (E.C. 2.4.1.17)3,4. UDPGT is a glycosyltransferase that 
catalyzes the conjugation of the metabolites from Phase I to glucuronides5,6. This 
modification generates a polar conjugate with increased hydrophilicity and serves to 
facilitate elimination via biliary excretion7. Alternatively, biliary excretion (excretion by 
bile) may lead to the recycling of xenobiotic metabolites in an enterohepatic cycle2,8–10. 
This occurs in the intestines where glucuronides from Phase II are degraded by the 
enzymes of the intestinal microflora11,12. This regenerates the glucuronic acid that will 
be used as a nutrient source and the native xenobiotic. Native xenobiotic will be 
reabsorbed into the bloodstream to re-enter the liver and the metabolic pathway. This 
recycling prolongs a drug therapeutic life and is an important feature in drug 
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development for the assessment of novel drug potency 
(pharmacokinetics/pharmacodynamics studies)8,13.  
 
 
 
Figure 1-1: The fate of xenobiotic and its metabolite. After Phase II metabolism, glucuronylated products 
can be eliminated or used as a feedstock by intestinal bacteria. Inset shows biotransformation in Phase II. 
 
Since glucuronides are major products of xenobiotic metabolism, its presence can 
serve as an indicator of drugs or xenobiotics consumption. Thus, they are extensively 
applied as standards and biomarkers. Detection and quantification of glucuronide 
conjugates have become established protocols for monitoring of drug intake and 
pharmacological evaluation in various fields including sports drug testing14, detection of 
agricultural residues15,16 and in drug development8. Consequently, this creates a 
significant demand for various glucuronide conjugates. There has also been growing 
interest in the development of glucuronide pro-drugs for therapeutic purposes17–19 in 
recent years. Glucuronide metabolites or E-glucuronides can sometimes appear more 
potent than the drugs that are currently available. Evidence of this can be found in the 
glucuronide of morphine conjugate, morphine-6-glucuronide20,21, which is currently in 
phase III clinical trials for application in post-operative analgesic therapy. Glucuronides 
therefore offer renewed options in medicinal chemistry. As such, the demand for 
glucuronide synthesis continues to exist, creating a need for cleaner and more efficient 
synthesis of glucuronides.  
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1.2.1.  Glucuronide synthesis 
 
The production of glucuronides using traditional methods of chemical synthesis is 
challenging22,23. Chemical syntheses of glucuronides are generally based on derivations 
of the Koenigs-Knorr reaction24 but these often suffer from poor yields (~ 30%)23,25–28. 
These methods are complicated by undesired side reactions due to the low reactivity of 
glucuronic acid as a glycosyl donor. In addition, this approach requires multiple 
protection/de-protection steps of the glucuronic acid to provide control of regio-
selectivity in the glucuronylation.  
 
Understanding the glucuronylation process in human body has opened up new 
options for the preparation of glucuronides using enzymatic methods. The use of 
glycosyltranferases29 for the synthesis of glycoproducts was the first chemoenzymatic 
route to be considered. UDPGTs are glycosyl specific and they are able to catalyze the 
glycosidic bond formation with a high degree of control over the regio- and stereo- 
specificity.  Although this approach provides a method for mild and stereospecific 
single-step synthesis, its application has been limited by two major reasons. Firstly, 
UDPGTs occur naturally as membrane bound enzymes that are anchored to the 
endoplasmic reticulum membrane22,30. Hence, they are very sensitive and unstable 
under laboratory conditions. Secondly, they are substrate-specific to the acceptors, 
which limits the range of substrates that can be used as starting materials31.	 The nature 
of its machinery coupled with its low stability imposes a limit to its scalability for 
process chemistry and restricts the procedure to small-scale syntheses (~1 mg). 
Furthermore, the UDPGTs are Leloir enzymes that depend on sugar-nucleotide donors 
(uridine 5’-diphosphoglucurunosyl, UDP) to drive the glycosidic bond formation32,33. 
Enzymatic methods using UDPGTs may require the synthesis of natural or unnatural 
diphosphate sugar donor analogue34,35, which are difficult to prepare. The yields of 
these reactions are mostly around 20–40%35,36 and their preparation is encumbered by 
the instability of the diphosphate sugar donors. This further restricts the applicability of 
UDPGTs for industrial application.  
 
The drawbacks of using UDPGTs can be circumvented using an alternative 
enzymatic approach – the glycosynthase. Glycosynthases37 have been developed by the 
Withers’ group to synthesize E-glycoside linkages38–40. These enzymes are derived from 
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the engineering of E-glycosidases so that their hydrolytic pathway is rendered inactive 
and that the hydrolytic function can subsequently be reversed. This concept had been 
adopted by the McLeod group to design a feasible enzyme from E-glucuronidase 
(E-GUS) that could be used in chemoenzymatic glucuronylation of alcohol acceptor 
substrates41,42. This thesis will expound on these early investigations.  
 
 
1.3. Enzymes: β-GUS and glucuronylsynthase 
 
This thesis will first engineer a native enzyme, E-glucuronidase (E-GUS) 
(EC 3.2.1.31) to have different kinetic properties. A E-GUS variant will then be 
converted to a synthetic enzyme (glucuronylsynthase) via a site-specific mutation 
E504G. This section describes the two enzymes and how their functions and 
mechanisms relate to each other. 
 
1.3.1. The various forms of E-glucuronidase (E-GUS) 
 
E-GUS is an exoglycosidase and a member of the glycosidase enzyme family that 
catalyzes the hydrolysis of glycosidic bonds. It is a carbohydrate active enzyme and is 
classified in the Carbohydrate-Active Enzymes (CAZy) database as a member of 
Glycoside Hydrolase Family 2 (GH 2)43,44. The enzyme cleaves a terminal E-glucuronic 
acid residue. As in most glycosidases, E-GUS is glycosyl specific i.e. specific for the 
glucuronic acid, but is promiscuous with the aglycone moiety. Hence, key binding 
residues are those that interact with the glycosyl ring. As such, the binding behavior, 
kinetics and catalytic rate can be altered by modifying these residues or nearby residues.  
 
There are two commonly studied forms of E-GUS: the human form45 and the 
bacterial E. coli form46. The two isoforms have similar overall fold and share 50% 
sequence similarity45,47. However, there are several key differences. The human E-GUS 
exists as a lysosomal enzyme in mammalian cells. It is synthesized in the endoplasmic 
reticulum and then transported into the lysosomes48 with the aid of 
phosphotransferases49. It breaks down complex glucuronides known specifically as 
glycosaminoglycans (GAGs). It also has a narrow pH range of pH 3–5. We were more 
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interested in an enzyme that works with simpler glucuronides and under milder 
condition. Hence, the human E-GUS was not suitable for our experiments but it was 
used as a reference for sequence and structure comparison with the bacteria ortholog. 
 
The bacterial form of E-GUS was more suitable for our work. It is commonly 
expressed by gut bacteria such as E. coli that uses it to harvest the glucuronidated 
products that enter the enterohepatic cycle after Phase II xenobiotic metabolism. This 
was demonstrated by Novel et al. in experiments that showed that E-GUS synthesis in 
E. coli was induced in the presence of E-glucuronide and glucuronates50,51. Hence, the 
E. coli E-GUS caters to simpler substrates compared to the human ortholog. Its substrate 
range includes simple glucuronyl conjugates of chemicals such as alcohols, drugs and 
steroids. These are similar to the glucuronides that we would like to investigate. 
Therefore, the E. coli version of the E-GUS was used for the work that will be discussed 
in this thesis. 
 
1.3.2. Glucuronylsynthase activity of engineered β-GUS  
 
The E. coli E-glucuronidase (E-GUS) contains two catalytic residues, E413 as a 
general acid/base catalyst, and E504 as a nucleophile in its substrate binding pocket 
(Figure 1-2a)47,52. The catalytic machinery is similar to the other members of retaining 
glycoside hydrolases53,54, and occurs through a hybrid Sn1/Sn2 mechanism55–57. The 
carboxylate anion E504 initiates the catalysis via Sn2 attack on the anomeric carbon of 
glucuronide. This displaces the aglycone residue and results in the formation of a 
glucuronyl-enzyme covalent intermediate of a different anomeric configuration. E413 
acts as a general acid/base catalyst that first acts as the proton donor to the leaving 
group. In the second step, it deprotonates a water molecule or a hydroxylated compound 
for displacement of the glucuronyl-enzyme bond. Thus, the E-GUS enzyme is 
regenerated with a net retention in configuration of the E-D-glucuronic acid (GlcA) 
product.  
 
The glucuronylsynthase is generated by site-specific mutagenesis at E504 to a 
non-nucleophilic residue that renders the residue incapable of nucleophilic attack at the 
C1 position. Glucuronylation is achieved through substrate-assisted catalysis in the 
presence of a glycosyl donor of an opposite anomeric configuration relative to the 
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native substrate and that has a good leaving group at C1 such as a fluoride substituent. 
The E413 residue activates alcohol substrates (acceptor) that would displace the 
anomeric leaving group. Since the E504 is incapable of nucleophilic attack, the 
hydrolytic pathway is also disabled. This allows the glucuronide product to accumulate 
(Figure 1-2b). The McLeod group investigated the mutations EÆA/G/S to derive the 
glucuronylsynthase system using D-D-glucuronyl fluoride (1FGlcA) as the glycosyl 
donor42. In their study, they have found that the mutation EÆG at position 504 was the 
most efficient. E504G variant was finally used as the glucuronylsynthase (Syn).  
  
 
 
Figure 1-2: Schemes depicting enzymatic mechanisms. (a) Mechanism of E-GUS. (b) Proposed 
mechanism of the glucuronylsynthase. 
 
In cells, synthetic reactions are often coupled with reactions that would release 
large amounts of energy, usually in the form of ATP hydrolysis to drive the reactions. 
For example, the synthesis of glycosides occurs through catalysis by transferases that 
require activated sugar nucleotide diphosphates as co-factors. In the case of the 
(a) 
(b) 
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glucuronylsynthase, the reaction is driven by the F- substituent as a good leaving group, 
where the 1FGlcA mimics the covalent intermediate in the wild-type reaction. Hence, 
the availability of the 1FGlcA substrate to drive the synthetic reaction is important. It is 
also used in excess, primarily to overcome product inhibition41. The efficiency of the 
glycosynthase reaction is partly dependent on the absence of competing hydrolytic 
reaction. In particular, minute presence (1%) of the parent hydrolase may reduce the 
efficiency of the synthetic reaction as it hydrolyses the glucuronide products. Therefore, 
it is important to eliminate the sources of hydrolysis. 
 
A major source of the parent hydrolase in the glucuronylsynthase system is 
translational misincorporation, which had been quoted for several glycosynthase 
systems38,58. However, its effects have not been known to adversely impact the synthetic 
reactions. At the start of this project, this had not been known to have an impact on the 
glucuronylsynthase system. However, during the course of our work, we have found 
that the effects of translational misincorporation can be a relevant issue for the 
glucuronylsynthase system and we have found ways to reduce its extent. 
 
 
1.4. Specific aims of the project 
 
The general aim of the project is to improve the glucuronylsynthase enzyme. 
Using the recombinant enzyme E504G, Wilkinson et al. was able to achieve 
glucuronylation of simple acceptor substrates such as of 2-phenylethanol (Figure 1-3) 
with yields of 96% (~ 700 mg)41. However, the turnover rate (kcat) and efficiency 
(kcat/Km) are low; the reaction takes three days. In addition, the current 
glucuronylsynthase system does not demonstrate the same efficiency for different 
acceptor alcohols. Although its kcat with 2-phenylethanol is 1.4 min-1, its turnover rate 
for the more structurally complex steroid (CMO-DHEA) is ten-times slower. This 
leaves considerable scope for improving the glucuronylsynthase system. Hence, this 
thesis will be aimed towards the following:  
(i) To develop a better enzyme for the synthesis of E-glucuronides by evolving 
E. coli E-glucuronidase using two different approaches (Scheme I and II) of 
Figure 1-4. We will prioritize the first approach (Scheme I), which will involve 
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two steps. At the same time, we will work on the development of a suitable 
screening  assay for the second approach.     
(ii) To characterize the enzymatic properties of the mutant enzymes and gain better 
understanding of how they function. 
(iii) To gain a better understanding of the glucuronylsynthase system and generalize 
our understanding to facilitate future studies on glycosynthases. 
 
 
Figure 1-3: Examples of glucuronylsynthase reactions using engineered E-GUS (E504G) enzyme. 
 
 
 
Figure 1-4: Two distinct approaches for the engineering of E-GUS to obtain an improved 
glucuronylsynthase. 
 
 
 
Scheme I: Two-step indirect approach  Scheme II: One-step direct approach 
Evolve E-GUS for higher activity at 
higher substrate concentration 
 Site specific mutagenesis of E-GUS 
504 (EÆ G) to create 
glucuronylsynthase 
Site-specific mutagenesis  
introduces point 
mutation 
504 (EÆG) 
  
Evolution of 
glucuronylsynthase 
 
Synthetic activity acquired due to 
E504G 
 
Improved glucuronylsynthase 
   
Improved glucuronylsynthase   
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1.5. Basis and hypothesis for the two-step strategy  
 
As part of the 2-step approach that was outlined in Section 1.4, the E. coli E-GUS 
enzyme will first be evolved. The wild-type E-GUS has a low Km (200 PM)59–61, which 
allows it to bind and process substrates rapidly at low concentrations. Evolving the 
wild-type E-GUS to have higher activity at high substrate concentrations typical of 
synthesis experiments (10–100 mM) will possibly generate a variant that is more 
suitable for industrial application. The major advantage of this approach is that the 
assay is simple, quick and sensitive. Screening can be performed using E-D-para-
nitrophenyl-glucuronide (pNPGlcA), which is commercially available. Upon 
hydrolysis, this liberates chromogenic para-nitrophenolate (pNP) that can be monitored 
on a spectrophotometer at absorbance wavelength 405 nm (yellow) (Figure 1-5). The 
disadvantage, however, is the cost of the substrate. This prohibits us from screening at 
100 mM substrate concentration, but still allows us to screen at concentrations that is 10 
to 20-times the Km of the wild-type E-GUS (2–4 mM). In the second step of the 
two-step approach, an improved E-GUS enzyme can be converted to a 
glucuronylsynthase by incorporating a mutation at position 504. This can be done by 
site-specific mutagenesis.  
 
 
Figure 1-5: Scheme of the reaction in E-GUS screening assay. Screening assay for E-GUS can be 
performed using para-nitrophenol glucuronide (pNPGlcA) by monitoring the liberation of 
p-nitrophenolate at 405 nm 
 
Our basis for the two-step approach is grounded on observations that the enzyme 
has specificity constant kcat/Km approaching diffusion limit. However, not all enzymes 
with kcat/Km approaching diffusion limit have high Km, suggesting that there may be 
room for improvement in the kcat and Km of the enzyme. If we can increase the Km of the 
wild-type by 4 to 5-fold without changing the enzyme specificity constant kcat/Km, we 
may be able to simultaneously increase the kcat of the enzyme by the same degree. An 
enhancement in the kcat might indicate that there is an increase in the hydrolysis rate in 
para-nitrophenyl 
glucuronide 
(pNPGlcA) 
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the parent enzyme, which may indicate more efficient base catalysis by E413. Higher 
base catalytic rate by E413 may translate to higher synthetic rate when we incorporate 
the E504G mutation for the acquisition of synthetic activity. 
 
The two-step strategy outlined in Scheme I has not been attempted before. 
Attempts to improve glycosynthases had often been done by directly evolving the 
recombinant i.e. the glycosidase with inactivated nucleophilic residue62–66. Considerable 
effort had been put into the development of a suitable high-throughput screening assay 
for the glycosynthase libraries64,65,67–70. However, many of the methods that have been 
developed are also specifically tailored for the detection of the glycosyl substrates or 
type of glycosides involved in a particular glycosynthase system62,64,67,69,71. To date, 
there is no viable high-throughput screening assay system that can be adopted for the 
glucuronylsynthase system. Development of high-throughput screening assays for 
glucuronyl systems (results unpublished) had been complicated by the low activity of 
glucuronylsynthase. This means that an assay has to be sensitive enough to overcome 
interfering effects, or a more active glucuronylsynthase has to be obtained for the 
development of a high-throughput screening assay.  
 
The two-step strategy that is proposed is a unique approach and has never been 
reported before. More importantly, it offers an alternative that circumvents the need for 
the development of a high-throughput assay for glucuronylsynthase. The most reliable 
screening method for the glucuronylsynthase method would be the high-performance 
liquid chromatography (HPLC) or liquid chromatography mass spectrophotometry 
(LCMS) method equipped with 96-well plate automation. The latter became available in 
the middle of the project, and enabled the initiation of the second approach (Scheme II, 
Figure 1-4).  
 
 
1.6. Research Design and Approaches 
 
We will apply protein engineering techniques to achieve the aims outlined in 
Section 1.4. Many of these techniques have been described in the literature. This 
section gives a review of the technologies that are available and details how we will 
adopt them to design suitable engineering approaches.  
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1.6.1. A review on protein engineering 
 
Enzymes in nature can offer unparalleled sophistication as biocatalysts because 
they are highly specific and efficient. However, like the glucuronylsynthase, many 
natural enzymes require modifications before they can be used for practical 
applications. The application of natural enzymes may often be constrained by stability 
issues or incompatible function. Consequently, they may require adaptation for 
application in chemoenzymatic reactions. 
 
Attempts at adapting or improving enzymes for practical applications can be 
chronicled in three stages72. The first stage involved the isolation and application of 
natural enzymes in various industries, e.g. therapeutic drugs and fine chemicals 
production. The second was set off by the advancement in genetic manipulation 
methods that allows site-specific mutations to be encoded. As a result, natural enzymes 
could be tailored for generating synthetic intermediates in multi-step reaction schemes 
and the use of biocatalysts became more prevalent. The latest development in 
biocatalysis has been dominated by efforts to develop molecular biology techniques for 
the manipulation of genes to enhance enzyme properties. This has led to increased 
capability in protein engineering. There are three approaches to engineer an enzyme. 
These are the rational, semi-rational or bioinformatics approach and evolutionary 
approach73.   
 
1.6.1.1. Rational and semi-rational approaches 
 
The rational approach is “knowledge-based” and incorporates mutations 
specifically74. This is usually referred to as site-specific mutagenesis. Usually, rational 
approach is applied using a 3D enzyme structure or a reliable model75. It requires 
detailed structural information and a good understanding of the enzyme function. Most 
of the time, the approach relies heavily on the computational predictions of an enzyme’s 
molecular dynamics and behavior. This was the approach used to create the 
glucuronylsynthase, where EÆA/G/S were created specifically at E504. We will use 
this method to introduce interesting mutations that were found in the literature and in 
the second step of the two-step approach when we convert an improved E-GUS into a 
glucuronylsynthase. 
 
CHAPTER 1 
	
 — 12 — 
Likewise, semi-rational approaches also utilize computational prediction powers 
and a structure to guide a researcher76,77. However, it is less specific. Some knowledge 
of the enzyme structure and function is required so that appropriate sites can be selected 
for mutagenesis. Examples of semi-rational approach include site-saturation 
mutagenesis or site-directed mutagenesis. It is considered to be semi-rational approach 
in that it requires knowledge of the enzyme structure and mechanism, but it “blindly” 
randomizes the positions of interest. Prediction and modeling softwares such as 
CUPSAT78, FTMap79 and Swiss-Model80,81 are used to facilitate decision making on 
target choice.  
 
There are several strategies that can be used to randomize positions of interest in 
site-saturation mutagenesis (SSM). These exploit the codon degeneracy of amino acids. 
The most common strategy introduces mutations using the NNK codons (N = a/c/g/t, 
K = c/g) and encodes the canonical 20 amino acids82. The codons can be changed 
according to preference to incorporate fewer codon combinations and amino acids. For 
example, the NDT codon (D = a/g/t/) encodes only 12 amino acids, but represents a 
balanced mix of the diverse chemical structure of the amino acids. There are also 
options to randomize several sites at the same time. The strategy depends on the 
purpose of the library and the screening effort that the researcher can manage. An NNK 
codon library will involve more screening effort than the NDT library83. Libraries that 
randomize several sites at the same time will also require more screening effort. A 
program such as CASter 2.0 assists such endeavors by optimizing codon usage and 
calculating the optimal library screening size84.  
 
1.6.1.2. The evolutionary approach 
 
The third approach to protein engineering is an evolutionary approach. It is also 
known as directed evolution85–87. This approach imitates natural evolution and is a 
powerful engineering technique. It is the least reliant on computational predictions and 
modeling. It does not require prior knowledge of an enzyme structure88. Instead, it may 
facilitate understanding of an enzyme structure and function.  
 
Directed evolution involves two steps that are iterated (Figure 1-6). The first step 
generates the diversity of a library using random mutagenesis methods. These are 
typically error-prone PCR (ePCR)89,90 and DNA recombination of libraries91–95. Error-
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prone PCR is a highly efficient method for introducing variations into a genetic pool 
with a good control over the mutation rates. The libraries are typically created using a 
mutagen (such as high Mn2+ concentrations) in the PCR reactions. The second step 
applies an assay to screen or select for improved clones (potential hits). Improved 
clone(s) are used to create the diversity for subsequent generations. There are three 
options for this:  
(i) Improved clones can either be recombined using a DNA recombination technique 
such as DNA shuffling95,96 or Staggered Extension PCR (StEP)93,97. 
(ii) A combination of StEP and ePCR (ePCR-StEP) can be employed to 
simultaneously recombine mutations from previous cycles and introduce new 
random mutations.  
(iii) The most improved clone is used as the template to generate another ePCR 
library.   
 
 
Typically, one complete cycle is one round of selection or screening of a 
generation where a variant with a desired property is picked for subsequent iterations.  
 
Figure 1-6: Typical process in directed evolution experiments. Experiments involve repetitive cycles of 
library generation and screening/selection 
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The process is iterated until a desired property is obtained or when convergence 
(fixation of mutations and marginal improvements/diminished returns) is reached. 
 The advantages of directed evolution lie in the fact that it does not require any 
prior knowledge of enzyme structure and mechanism. It sometimes reveals interesting 
mutations that may not have been picked up by rational or semi-rational approaches 
Recombination during iterative cycles is an effective way to accumulate beneficial 
mutations. However, the success of in vitro evolution is dependent on various factors 
such as recombination efficiency, mutation rates, library size and screening capacity. 
This is linked to the availability of a rapid but reliable screening procedure and the 
enzyme being investigated. A larger multi-domain enzyme is likely to involve more 
effort. Attempting to enhance the kcat and Km of an enzyme that is already high will also 
be challenging. In such cases, an important aspect of the engineering endeavor will 
involve strategies to adapt the three different approaches to optimize the screening 
effort. 
 
1.6.2. Combining protein engineering strategies for E-GUS evolution 
 
The E-GUS enzyme is a large tetrameric protein (68 kDa, 603 amino acids per 
subunit)47. Its evolution would involve larger screening effort compared to other 
enzymes in our laboratory. To achieve our aims in Section 1.3, we will adopt all three 
approaches to design libraries that can optimize engineering effort. Rational engineering 
will be used to incorporate an E504G to produce the glucuronylsynthase. Rational 
engineering will also be used to introduce mutations from other directed evolution 
experiments that were performed on the E-GUS59–61,98–103. We will be using a 
combination of semi-rational engineering and a hybrid of semi-rational design/directed 
evolution (or targeted evolution) approach to evolve the enzyme. Targeted evolution 
applies random mutagenesis on specific regions of the enzyme. Mutations identified in 
the different regions can then be strategically recombined. Hence, targeted evolution 
would allow us to sample a sequence space more thoroughly.  
 
For both approaches, we will use the structure of E. coli E-GUS, obtained by 
Wallace et al. to guide us (Figure 1-7a)47. The bacterial enzyme essentially comprises 
three domains: (i) the N-terminal resembling a sugar-binding domain that is 
180 residues long, (ii) an immunoglobulin-like E-sandwich domain that is 96 residues 
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long, and (iii) the C-terminal domain made up of residues 274 through to 603, which 
forms the αE-barrel (TIM-barrel) (Figure 1-7b). The first two domains are not known to 
have catalytic function but they are important structural elements of the enzyme. 
However, a small section of the loop from Domain I interacts with the active site 
(Figure 1-7a, inset). The C-terminal domain (TIM-barrel) is the catalytic domain and 
contains the active-site residues E413 and E504.  
 
 
 
 
	
Figure 1-7: Structure of E. coli E-
glucuronidase. (a) The crystal 
structure of a subunit of E-GUS 
(PDB ID = 3K46). Coloured light 
red is Domain I; blue, Domain 2 
and in brown is the αE barrel 
domain. Catalytic residues E413 
and E504 are represented as 
spheres. Inset: Interaction of 
Domain I and the active site. (b) 
Positions of Domain 1 and 3 
relative to each other. Domain 1 
and 2 are important for 
maintaining the structural 
integrity of a subunit. 
 
E-GUS is glycosyl specific. Hence, mutating sites that interact with the glycosyl 
moiety will likely change its activity. These sites were identified from the interaction of 
the E. coli E-GUS with an inhibitor glucaro-G-lactam (PDB ID: 3K4D). The structure of 
this inhibitor is very similar to the glucuronic acid (Figure 1-8), and serves as a suitable 
(a) 
(b) 
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enzyme-glycosyl complex model to deduce important glycosyl binding sites. Table 1-1 
summarizes the initial target residues. The position of the target residues relative to the 
inhibitor is shown in Figure 1-9. 
	
	
Table 1-1:  Priority 
mutations to be 
considered for site-
saturation mutagenesis 
that were derived from 
structural analyses  
Residue Codon 
N412 NNK 
D163 NNK 
L361 NNK 
R562 NNK 
M447 NNK 
T509 NNK 
Figure 1-8: Structures of glucuronic acid and glucaro-G-lactam. 
 
 
Figure 1-9: Positions of prioritized sites for saturation mutagenesis and other binding sites that are 
important for glycosyl binding. Inset: Position of N412 relative to E413 and glucaro-G-lactam (GDL). 
 
Residue D163 is from an extruding Domain I loop that is implicated in glycosyl 
binding. It forms salt-bridge interaction with R562, which is also implicated in glycosyl 
binding. L361 marks the start of the disordered region in the crystal structure that forms 
an overhang over the active site. Residue N412 is a polar residue next to the general 
acid/base catalyst E413 and may yield interesting observation. Targeting these residues 
should change the kinetic parameters of the enzyme at high concentrations of substrate. 
V446, M447 and F448 residues are not involved in glycosyl binding but they form 
hydrophobic interaction with the leaving group (aglycone). One of these, M447 is 
positioned at the surface (mouth of the barrel) and may facilitate departure of the 
leaving group product. Hence, this was chosen as a target as well. T509 was picked up 
from the literature59,99,101,102. This residue appears to change the specificity of the 
Glucaro-δ-lactam  
(Inhibitor in crystal 
structure) 
Glucuronic acid 
(Glycosyl group in  
β-D-glucuronide) 
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enzyme for other glycoside substrates, e.g. galactoside, xyloside, and glucoside59,99,102, 
and to increase thermostability101. 
 
Since we aim to change the catalytic activity, random mutagenesis will be 
performed on regions that are in the TIM-barrel (Figure 1-10). This is with the 
exception of Domain 1 loop, which points into the active site and that is directly 
involved in glycosyl binding. The DE barrel offers considerable potential for altering 
catalytic activity because of the numerous flexible loops that connects the D-helices and 
E-sheets, which form the frame of the TIM-barrel. The dynamics of flexible loop has 
often been associated with increased enzyme plasticity and altered affinity104–107. 
Targeting such region is very likely to alter kinetic parameters. We will exploit the 
flexibility offered by E-GUS loops in the active site to tailor the enzyme for higher 
activity. The regions (Figure 1-11) that will be targeted for random mutagenesis are the 
(i) disordered loop, (ii) the loop from Domain I that interacts with the active site and 
(iii) regions in the TIM barrel domain.  
 
 
Figure 1-10: View of Domain III (TIM-barrel) of E-GUS from the bottom. D-helices and core E-sheets 
form the DE barrel and is held by a hairpin loop at the base. Insets show the approximate position of the 
active site in the barrel and the side view of the TIM-barrel reveals the interconnecting flexible loops. 
 
The disordered loop is made up of residues 360-370. It is interesting not only 
because it is highly flexible, but it is also implicated in interactions with symmetry 
mates.47 It interacts with the active site of an adjacent subunit. In addition, this loop is 
also unique to the bacterial ortholog. Jain et al. have found that in the sequence 
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alignments of the E. coli E-GUS and the human E-GUS, the residues 360-377 in the 
bacterial ortholog is absent from the human seqeuence45. These two observations 
suggest that the disordered loop is important for catalytic activity. Targeting this loop 
either by targeting the loop in itself or by engineering the loop as part of the TIM-barrel 
region may yield interesting observations (mutations that improve activity). The TIM 
barrel can be further divided into two parts: from residue K286 up to the nucleophilic 
residue E504 and the C-terminal region from E504 onwards (Figure 1-11). Dissecting 
the region to a smaller fragment may allow for more thorough search of the sequence 
space at this region. 
 
The E hairpin structure at the bottom of the barrel may also be investigated by 
itself or as part of a larger sequence space (Figure 1-11). The C-terminal contains an 
extended mobile loop (V548-S579) that is ~ 30 amino acid long. It is flexible and this 
region seems to be important for modulating activity. In several other directed evolution 
experiments on E-GUS, mutations were found at N566-K568, Q585 S550, G559, 
F58260,99 and various other sites in this region. Mutations from different regions can be 
recombined in the penultimate round. Finally, we can consider random mutagenesis on 
the whole gene and screen a small fraction of the library to see if there are any 
interesting mutations from other parts of the enzyme that is not targeted.     
 
 
1.7. Overview of the thesis 
 
The aim of the thesis is to evolve the E-GUS so that it can be converted to a more 
competent glucuronylsynthase. There are two approaches for this: a two-step indirect 
approach and a one-step direct approach. The approaches and the basis were described 
in Sections 1.3 and 1.4. The two-step indirect approach is conceptually different from 
other glycosynthase engineering approaches. It was appealing because it could 
potentially overcome screening limitations in the one-step direct approach. The 
shortcoming of this approach is that its outcome depended on whether the enhancement 
observed for the E-GUS was translated across to the glucuronylsynthase enzyme. We 
would only know if the approach was successful at the end, when we incorporate the 
E504G mutation.  
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The work for the E-GUS evolution is described in Chapter 3, where we evolved 
the glucuronidase activity in two different stages. The first stage evolved E-GUS under 
mild conditions (30–37 qC, pH 7.0–7.5), which had been used for the development of 
the glucuronylsynthase system. The second stage was conducted in harsher condition 
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when it was discovered that the addition of t-BuOH as a solvent improved the process 
chemistry of the glucuronylsynthase enzyme.  Although we did not find any improved 
variants from the first stage, the second yielded several promising mutations that could 
be converted to a glucuronylsynthase (Chapter 4). 
 
When we converted one of the improved variants from Chapter 3 into a 
glucuronylsynthase, we did not see improved synthase activity. This led to two separate 
experiments. The first continued the engineering work using the second approach (one-
step direct approach). This is described in Chapter 4.  The second study sought to 
understand the possible reason behind this failure. Our work here was first led by 
observations that different batches of purified glucuronylsynthase enzymes had different 
synthetic activity. In some cases, the synthetic activity could not be observed. This led 
to a review on the growth and expression systems/conditions that had been used. As a 
result, we found that translational misincorporation may limit the efficiency of the 
glucuronylsynthase enzyme. The systematic study that led to this conclusion is detailed 
in Chapter 5. 
 
The penultimate chapter (Chapter 6) consolidates the observations from site-
saturation mutagenesis (SSM) of E-GUS that was performed prior to the 
commencement of the E-GUS evolution. Our effort with SSM had not yielded any 
enhanced E-GUS variant but we could draw several conclusions about their roles of the 
sites. We substantiated this deduction by expanding the study to investigate the effects 
of targeting the same sites to enhance its promiscuous activity. This was done by 
conducting parallel screens on E-D-glucuronide and E-D-glucoside that led to a clearer 
understanding on the active site of E-GUS, particularly its tolerance towards mutations 
(mutational tolerance). We extended the cause of this work to study the mutational 
tolerance of the entire enzyme. This lends several insights on how the tetrameric, multi-
domain enzyme tolerates amino acid changes. Finally, Chapter 7 provides an outlook 
for the glucuronylsynthase system based on the work described in Chapters 3 through 6. 
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2. Materials and methods  
 
2.1. Preamble 
 
This chapter describes the procedures that were used to perform the experiments 
for this dissertation. The equipment, chemicals and reagents are also described in this 
chapter. A complete list of suppliers and manufacturers of equipment, kits, chemicals 
and reagents is attached in Appendix A and B. Recipes of culture media, buffers and 
other reagents used in this study are given in Appendix C. The preparation of most of 
these reagents was adopted from the laboratory manual by Sambrook and Russell1.  
These will be referred to in relevant sections.  
 
2.2. Materials 
 
Generally, all chemicals and reagents used for preparative work were of analytical 
grade. Milli-Q water (mQH2O) was obtained from Reagent Water System (Millipore). 
Chromatography gradient-grade methanol was used for Liquid Chromatographic-Mass 
Spectrophotometry (LCMS) analyses. Solvents and buffers are passed through 0.4 µm 
filter using vacuum pump. All reagents, plastic wares and glasswares used for molecular 
biology work were sterilized by autoclaving using ASB270BT autoclave (Astell 
Scientific). Chemicals that are heat sensitive or flammable were filter sterilized using 
0.2 Pm membranes (Sartorius Minisart).  
 
Oligonucleotides were purchased from Integrated DNA Technologies (IDT, 
Coralville, USA).  Appendix D lists the primers and the corresponding chapters where 
they have been used. Kits that were used for preparative molecular biology work were 
obtained from Qiagen, Bioline and Promega. Restriction enzymes used for cloning work 
were purchased from New England Biolabs (NEB) Inc.  
 
The substrates used for the directed evolution of E-glucuronidase (E-GUS) in 
Chapter 3 are para-E-D-nitrophenyl glucuronide (pNPGlcA) and 5-bromo-4-chloro-3-
indolyl-E-D-glucuronic acid, cyclohexylammonium salt (X-gluc). pNPGlcA was 
purchased from Acros Organics and X-gluc was purchased from Thermo Fischer 
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Scientific. The glycosyl substrate, D-D-glucuronyl fluoride (1FGlcA), and the steroid 
acceptor substrates – testosterone and O-carboxymethyloxime dehydroepiandosterone 
(CMO-DHEA) – were synthesized by the McLeod research group (Australian National 
University, ANU).  
 
 
2.3. Bacterial strains 
 
 Cell lines with gusA gene knocked-out were used for growth and expression. 
These were BW251422 and GMS407(DE3)3. BW25142 was the primary cell line used. 
It has a recA- genotype, which eliminates the possibility of recombination between 
chromosomal and plasmid genes. This strain also has the non-specific endonuclease 
endA gene knocked-out (endA- genotype), which eliminates problems associated with 
plasmid preparation. 
 
The cell line was purchased from E. coli Genetic Stock Centre (Yale) and stored 
as 50% glycerol stock at -80 °C. BW25142 was constructed by allele replacement 
technique4, which took advantage of conditional requirement of a ߨ  protein for 
replication. This resulted in the loss of a major portion of the gusA gene resulting from 
the insertion of the pir, and the disorientation of the transcription direction, which 
generated a gusA- strain (E-GUS incompetent).  
 
The ߨ  factor was supplied by a vector containing the conditional replicon 
oriRR6KJ or by strains carrying pir gene, which transcribes the ߨ protein4,5. A mutant pir 
gene (pir-116) was inserted into an M13 cloning vector that contains gusA and 
kanamycin resistant genes (M13KmR), but lacked oriRR6KJ replicon6. The mutation at 
116 confers a higher copy number, but is otherwise similar to pir. The insertion of pir 
gene disrupted the gusA gene and removed three quarter of the gene (Figure 2-1). It 
gave rise to M13KmR'gusA phage upon transduction with a reversed transcription 
direction. Transfecting the M13 into an E. coli rep mutant yields recombinant ΔgusA, 
KmS as a result of primary and secondary cross-over events during integration of the 
M13 into the E. coli chromosome4,7.  
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GMS407(DE3) was used initially to prepare the glucuronylsynthase enzyme for  
process chemistry development in the organic laboratory8–10. The strain is derived from 
BL21(DE3), which has a recA- genotype. Except for harbouring gusA-, its genotype 
resembles that of BL21(DE3). It is commonly used for high-level protein expression. 
Since it harbours a lacUV5 promoter and the gene for T7 RNA polymerase11, it is 
compatible with T7-based expression vectors (pET vectors) (Novagen, Darmstadt, 
Germany). BL21 is a lysogen of bacteriophage ODE3, which contains the lacUV5 
promoter and the gene for T7 RNA polymerase.  
 
 
Figure 2-1: Knocking out the gusA gene in the BW25142 cell line. The BW25142 cell line was 
created by inserting a pir gene between MluI at 596 and MluI at 1294 in the reverse direction.  
 
2.3.1. Preparation of electrocompetent cells. 
 
This procedure was adopted from the laboratory manual by Sambrook and 
Russell1. Frozen glycerol stock of bacterial cells (BW25142 or GMS407(DE3)) from     
-80 qC was streaked onto Luria-Bertani (LB) agar plate with no antibiotics (Appendix 
C). The plate was incubated at 37 qC for 16 h to allow the cells to grow. One single 
colony was picked and inoculated in 10 mL of LB media without antibiotics. Inoculum 
was grown for 16 h in an orbital shaker set at a shaking speed of 200 rpm and 37 qC.  
4 mL of overnight culture was then subcultured in a 2 L baffled flask containing 
800 mL of fresh of YENB (Appendix C) medium. The culture was grown in a 37 qC 
orbital shaker with an agitation speed of 200 rpm until the optical density at 600 nm 
(OD600) reached 0.4-0.6 OD600 reading was taken on CO8000 cell density meter (WPA 
Biowave). The culture was rapidly cooled to 4 qC on ice and left to stand for 30 min. 
Meanwhile, the centrifuge, centrifuge bottles and all solutions that would be used in 
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proceeding steps were pre-chilled to 4 qC in a refrigerator.  The culture was then 
centrifuged at 4, 000 rpm in pre-chilled VWR R9A rotor for 20 min at 4 qC. The clear 
supernatant was discarded. The cell pellet was washed by resuspending it first in     
250–350 mL of chilled sterile mQH2O in gentle swirling motion on ice. The volume 
was then topped-up to 800 mL with chilled sterile mQH2O and cells were pelleted again 
using the same centrifugation setting. The washing step was repeated using cold sterile 
10% glycerol. The cell pellet after this step was gently resuspended in 500 PL of cold 
sterile 10% glycerol. Homogenous cell resuspension was then distributed in 50 PL 
aliquots and snap frozen in ethanol dry ice bath. The tubes containing the 
electrocompetent cells were stored for no longer than nine months in -80 qC, and 
retrieved when they were needed. The competency of the cell was checked by 
transforming 1–10 ng of pJWL1030/gusA plasmid using electroporation method12,13.  
All batches of e-competent cells prepared were also checked for contamination by 
diluting one tube of e-competent cells in 500 PL LB and plating 50 PL on LBA100 and 
LBK50 agar plates. 
 
2.3.2. Electrotransformation 
  
 Plasmid DNA made up to 10 ng/PL or double stranded DNA from ligation 
reactions were e-transformed into 50 PL of e-competent cells with v/v ratios of 1:50 and 
1:10 respectively in 1 cm electroporation cuvette. Electroporation was performed using 
BioRad MicropulserTM preset at V = 2.5 kV and electroporation time W = 5 ms. E-
transformed mixtures were immediately recovered in 1 mL of YENB shaking at 200 
rpm, 37 °C for 1 h. 50 PL of recovered e-transformation mixtures were then plated on 
LB or M9 (Appendix C) agar plates supplemented with 50 Pg/mL of kanamycin (LBK50 
or M9K50). Agar plates were then incubated overnight at 37 °C for isolation of single 
colonies.  
 
 
2.4. Plasmids and vectors 
 
This section describes the general procedures for plasmid manipulation, 
visualization and quantification. Then, a description of the vectors used in our 
experiments will be given. This will be followed by a description of the construction of 
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pJ401/gusA plasmid, which is the parent gene for the evolution and engineering 
program of this dissertation. The general procedures for plasmid manipulation, 
visualization and quantification are also covered. Lastly, we will describe the 
construction of pJ401/gusA.  
 
2.4.1. Description of expression vectors 
 
Expression vector pET28a 
 
The expression vector pET28a(+) belongs to the series of pET28 vectors from 
Novagen® (Merck KGaA, Darmstadt, Germany), which are T7-based14. It carries a 
kanamycin resistance gene, T7lacpromoter and an N-terminal 6×His-Tag extension. It is 
a low-copy, non-leaky expression vector. The lac operon (lacUV5) and the T7 
bacteriophage transcription system control its transcription. The lac operon is the 
weaker transcription factor that can be influenced by lactose and the T7 promoter is a 
strong promoter, which can be influenced irreversibly by isopropyl-E-D-1-
thiogalactopyranoside (IPTG).  Therefore, it is suitable for high-yield protein expression 
using IPTG.  
 
Expression vector pJWL1030 
 
In-house constitutive vector pJWL1030 modified from pCY76 and pJJKmf15 is a 
high-copy number vector. The constitutive expression cassette was isolated from 
pCY76, which was constructed to overexpress non-toxic genes constitutively in E. 
coli16. The isolated expression cassette was then ligated to the backbone of pJJKmf, 
which conferred it with kanamycin resistance17. It has a leaky lac promoter, which 
allows constitutive expression of a target gene that had been cloned into it. It also has a 
strong ribosome binding site (RBS) and translation initiation region that can improve 
protein expression. It is compatible with the BW25142 cell line but it does not have a 
His-Tag to facilitate purification using affinity chromatography method that will be 
described in Section 2.7.1.2. It was initially used to prepare plasmids but was later 
phased out when we stopped using the pET28a/GMS407(DE3) system for expression.  
 
Expression vector pJ401 
 
The main expression vector used was pJ401. The vector is compatible with both 
BW25142 and GMS407(DE3) host cells. It uses kanamycin as a selectable marker and 
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it is a high copy plasmid because its replication origin is pUC. Expression is repressed 
by the product of a lacI gene and is inducible by IPTG under the influence of a T5 
promoter18. Like the pET28a and pJWL1030, it has a strong ribosome binding site 
(RBS) to improve protein expression. The vector backbone pJ401 was obtained from 
pJ401/ataS (arylsulfatase from Pseudomonas Aeruginosa) plasmid that was purchased 
by the McLeod group from DNA2.0 Inc.  
 
2.4.2. General restriction cloning procedures 
 
Restriction endonuclease enzymes and calf intestinal alkaline phosphatase (CIP) 
were bought from New England Biolabs Inc. (NEB) and supplied by exfreezer. 
T4 DNA ligase was bought from NEB, Fermentas or Invitrogen Technologies 
(Invitrogen).  
 
Approximately 3–4 Pg of supercoiled plasmid DNA or polymerase chain reaction 
(PCR) products were double digested with 10–20 U of appropriate restriction enzymes 
at 37 °C for 3 h. Before commencing digestion of PCR products, they were first treated 
with 20 U of DpnI at 37 °C for an hour to remove DNA templates. As the reaction 
buffer for DpnI digestion was compatible with the restriction enzymes used in this 
thesis, the DpnI treated samples could be used directly for double digestions. In 
addition, for the digestion of PCR products, an additional 2.5–5 U of restriction enzyme 
was supplemented after three hours of initial digestion, and the reaction continued for 
an additional 1 h. This step was added to ensure optimal digestion of the PCR products 
because the sizes of cut and uncut products of PCR products are hard to discriminate. 
Digestion product that would be used to provide the vector backbone was subjected to 
CIP treatment. Digestion reaction of the vector backbone was first stopped by heat 
inactivating the restriction enzymes at 65 °C for 30 min. 10 U of CIP was then added to 
the heat inactivated product and incubated at 37 °C for 1 h. As in the case for DpnI 
treatment, the reaction buffer for CIP treatment was compatible with the digestion 
reaction. Hence, purification was not required between the two steps.  
 
Digested products and CIP-treated digested products were extracted from DNA 
agarose gels that had been subjected to DNA gel electrophoresis. Bromophenol blue 
(BPB) loading dye for DNA agarose gel electrophoresis (Appendix C) was added to the 
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DNA products in volume ratio of 1:5 (BPB:DNA). Samples were then loaded into 0.8% 
1× SB-agarose gel of dimensions 125 mm x 80 mm x 30–50 mm (width x length x 
depth) (Appendix A) supplemented with 5 Pg/L of ethidium bromide or 1x RedSafeTM. 
Electrophoresis was performed for 40 min at 120 V and 300 mA in 1× SB buffer in a 
horizontal mini tank. The gels were then viewed on blue LED array box for 
fluorescence.  The bands corresponding to the size of the desired fragments were 
excised and gel purified. Gel purification was performed using Promega Wizard® SV 
Gel and PCR Clean-Up kit. Products were eluted in 30 PL of nuclease-free water 
supplied in the kit.  
 
The purified vectors and inserts were ligated using T4 DNA ligase from Thermo 
Scientific and NEB. A molar ratio of 3:1 (insert:vector) was used for the ligation 
reaction. 100 ng of the vector was used. The insert amount was calculated using the 
following equation (Equation 2-1): 
100 ng of vector x size of insert in kb
size of vector in kb
 x	 3
1
                             (2-1) 
 
20 PL of ligation reaction mixture containing 1.5 U of T4 DNA ligase, 1× Ligase 
reaction buffer supplied along with the ligase, 100 ng of vector and the calculated 
amount of insert, and sterile water was set up. Ligation was performed at 16 °C for 18 h. 
Ligation product was then PCR purified using the Wizard® SV Gel and PCR Clean-Up 
System kit from Promega. Purified ligation products were eluted in 30 PL of water. 
Ligation products were e-transformed into the appropriate host cell using the protocol 
described in Section 2.3.2. 
 
2.4.3. Cell culture and isolation of plasmid DNA  
 
Single colonies or a stab of frozen glycerol stock was inoculated in 4 mL of LB 
growth media supplemented with 50 Pg/mL of Kanamycin. Cells were grown overnight 
(18–20 h) at 37 °C in an orbital shaker with an agitation speed of 200 rpm. For 
cultivation of bacterial cells harboring low copy plasmid vector backbone (pET28a), 
10 mL of cultures were grown in sterile 50 mL conical tubes under the same condition 
as the 4 mL cultures. 50% glycerol stocks of cell cultures were made for long-term 
storage in -80 °C by adding 625 PL of sterile 80% glycerol to 375 PL of cultures. 
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Supercoiled DNA plasmids were extracted from 1.5 mL (medium and high copy 
plasmid, pJ401 and pJWL1030) or 8 mL (low copy plasmid, pET28a) overnight 
cultures using QIAprep® Spin Miniprep kit (QIAGEN) or Bioline Isolate II DNA 
extraction kit. DNA plasmids were eluted in sterile mQH2O and stored long-term in       
-20 °C freezer.  
 
2.4.4. DNA visualization and quantification 
 
DNA visualizations were performed using 0.8–1% agarose gel electrophoresis as 
described in Section 2.4.2. For visualization, gels were viewed under strong UV 
(254 nm) and the images were taken using UVI Pro electronic system. 
 
Concentrations of the DNA were quantified using NanoDrop® ND-1000 
spectrophotometer by observing the absorbance at 260 nm. A plasmid DNA volume of 
2 PL was used for quantification. A260/A280 and A260/230 ratios were noted to ensure 
minimal protein and carbohydrate contamination. Ratios ~ 1.8 were taken as indication 
of acceptable quality. 
 
2.4.5. Construction of plasmid pJ401/gusA 
 
The plasmid pJ401/gusA was constructed from pET28a/gusA and pJ401/ataS with 
C-terminal HisTag (sulfatase gene from Pseudomonas Aeruginosa). pET28a/gusA was 
first constructed from pET28a/gusA(L2V) that was obtained from the McLeod group9. 
The plasmid pET28a/gusA(L2V) was first PCR amplified and reversed engineered 
(VÆL) by standard polymerase chain reaction (PCR) as described in Section 2.5.1 
using high-fidelity Phusion-HF polymerase and oligodeoxy-nucleotide primers carrying 
NdeI and EcoRI restriction endonuclease sites – pgusf (5’–
cgcggcagccatatgttacgtcctgtagaaacc–3’) and pgusr (5’–ggtggtggtggaattctcattgtttgcc–3’) 
(restriction sites underlined) – to obtain pET28a/gusA. The PCR product corresponding 
to the band fragment at ~ 1.8kb was purified by 1% DNA agarose gel electrophoresis. 
Purified PCR products and pET28a/gusA(L2V) were double digested with NdeI and 
EcoRI. Double digestion product of pET28a/gusA(L2V) was then CIP-treated. Ligation 
was performed as described in Section 2.4.2. Ligation products were e-transformed into 
BW25142. Eight single colonies were picked and their plasmids were isolated. Clones 
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harbouring pET28a/gusA were used for the construction of pJ401/gusA with N-terminal 
HisTag. Plasmids pJ401/ataS and pET28a/gusA were double digested in XbaI and 
EcoRI and cloned according to the cloning procedures described in Section 2.4.2. 
Figure 2-2 maps the plasmids of pET28a/gusA, pJ401/ataS and the resulting 
pJ401/gusA, and the positions of NdeI, EcoRI, XbaI and the 6×HisTag in the plasmid.  
 
 
Figure 2-2:  Plasmid maps of pDNAs used for pJ401/gusA construction. Plasmid maps of pET28a/gusA, 
pJ401/ataS and resulting pJ401/gusA. The fragment between XbaI and EcoRI in pET28a/gusA contains 
the RBS, 6×-HisTag and the gene. This fragment was inserted into pJ401 between XbaI and EcoRI to 
replace the ataS gene.  
 
 
2.4.6. Construction of plasmid pJ401/syn 
 
Plasmid pJ401/syn was constructed using the dual-tube megaprimer method that 
will be described in Section 2.6.2. The primers used to generate two types of 
glucuronylsynthase (rare and common) in Chapter 5 are GUS-E504G(common)             
R’ (5’–cgccgtaaccggtgatgataatcggc–3’) and GUS-E504G(rare) R’ (5’–
acgccgtatccggtgatgataatcggc –3’); underlined are the codons encoding glycine. 
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2.5. Polymerase chain reaction (PCR) 
 
2.5.1. Primer design 
 
Primers of ~ 30 base pairs (bp) in length were designed with the help of 
OligoCalc Properties Calculator, a web-based computational software. This software 
computes the melting temperature Tm and primer GC content. The Tm of primers were 
around 50–60 °C and the GC contents were around 50%. Where primer pairs were used, 
they were partially overlapped but fully complementary. The forward and reverse 
primers for assembly PCR that were used for library construction of targeted random 
mutagenesis were designed so that the adjoining fragments had significant overlap. The 
primers used are listed in Appendix D.  
 
2.5.2. Standard Polymerase Chain Reaction (PCR) 
 
Standard PCR was performed to amplify a gene for the purpose of checking new 
constructs, to create flanking non-mutagenic PCR fragments for library construction and 
to check for the presence of inserts in DNA plasmids. Colony PCR was performed to 
check for the presence of inserts after constructs were made. For amplification to build 
new constructs or libraries, high-fidelity polymerase Phusion-HF (Finnzyme, NEB) was 
used. Taq polymerase (Roche) or BioTaqTM (Bioline) were used to check for the 
presence of inserts in plasmids or in colony PCR.  
 
Standard PCR was carried out in reaction mix of 50 PL total volume containing 
25–50 ng plasmid DNA, 1.25 PM of forward and reverse primer, 200 PM dNTP mix, 
1× Taq reaction buffer containing 1.5 mM MgCl2, and 2.5 U of DNA polymerase. PCR 
cycling was done on any of the thermocyclers listed in Appendix A. Reaction mixture 
was heated at 95 °C for 2 min, followed by 30 cycles of denaturation at 95 °C for 30 s, 
annealing at 55 °C for 30 s and extension at 68 °C or 72 °C for 1–2 min (30 s/kb for 
Phusion-HF and Biotaq, and 1 min/kb for Taq). A final extension at 72 °C was 
performed for 10 min and the PCR products were stored at 4 °C. For colony PCR, 1 PL 
of resuspended cell mixture prepared by resuspending one single colony in 10 PL of 
sterile water was used as the template in place of plasmid DNA. The protocol used was 
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similar to the basic PCR except that a longer initial denaturation step of 5 minutes was 
used to ensure lysis of the cell. Table 2-1 lists the cycling conditions. 
 
Table 2-1: Thermo cycling conditions for standard and colony PCR. 
Initial denaturation 95 °C or (98 °C for Phusion) 2 – 5 mins 
30–35 cycles 
Denaturation 
Annealing 
 
95 °C or (98 °C for Phusion) 
Average Tm of primers ~ 55°C 
 
30 s 
30 s 
Extension 72 °C or (68 °C for Phusion) 
1 min/kb for Taq amplification, 
30 s/kb for Phusion  and 
BioTaqTM amplification 
Final extension 
Hold 
72 °C or (68 °C for Phusion) 
4 °C 
10 min 
∞ 
 
2.5.3. DNA Sequencing 
 
DNA sequencing was done using Sanger sequencing method. Each PCR reaction 
consisted in 20 PL mixtures of sterile mQH2O, 150–350 ng of plasmid DNA, 
3.2 pmol primer, 1 PL BigDye® Terminator and 1× sequencing buffer supplied by the 
ACRF Biomolecular Resource Facility (BRF), The John Curtin School of Medical 
Research (JCSMR) in the Australian National University (ANU). The cycling 
conditions are listed in Table 2-2. 
 
Table 2-2: Thermo cycling conditions for Sanger sequencing. 
Initial 
denaturation 
95 °C 5 min 
30–50 cycles 
Denaturation 
Annealing 
Extension 
 
96 °C  
50 °C 
60 °C 
 
10 s 
5 s 
4 min 
Hold 4 °C ∞ 
 
PCR products were cleaned up using ethanol precipitation method detailed in the 
guidelines given by BRF19. Sequencing reaction clean-up reagent was prepared fresh by 
mixing 62.5 PL 95% ethanol, 3 PL 3 M sodium acetate pH 4.6 and 14.5 PL of sterile 
mQ H2O. 80 PL of the sequencing clean-up reagent was mixed thoroughly with 20 PL 
of sequencing PCR products. The mixture was then left to stand at room temperature 
(RT), in the dark, for 15 min. DNA is pelleted by maximum speed centrifugation for 
30 min at RT. The supernatant was then discarded. Pellets were washed with 200 PL of 
freshly prepared 70% ethanol and centrifuged at maximum speed for 20 min. The 
supernatant was removed and air-dried in the dark for 1–2 hours. Cleaned-up 
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sequencing samples were then sent to BRF for sequence processing. The DNA 
sequencing chromatograms were then viewed and analyzed using Sequencher 4.10.1 
(Gene Codes Corp).  
 
2.6. Library construction and enzyme engineering methods 
 
This section describes the procedures to engineer sites specifically or to generate 
libraries randomized at single sites (site-saturation mutagenesis) or random libraries of a 
region in the gene. This is followed by a description of library construction methods for 
the introduction of random point mutations using various random mutagenesis methods. 
This includes the fragment assembly procedure that was used to assemble fragments for 
targeted random mutagenesis. The post processes (e-transformation and analysis of 
mutant libraries) is described at the end of this section  
  
2.6.1. Site-specific mutagenesis 
 
Stratagene’s QuikChange® method (QCM) was used to introduce site-specific 
mutations for rational design of variant T509A (Chapter 3) and the codon bias usage 
experiment of E504G (Chapter 4). High fidelity polymerase Phusion-HF was used for 
amplification. Reaction mixture of 50 PL containing 25 ng of plasmid template, 1 PM 
of forward and reverse primer, 200 nM of dNTP, 1× Phusion-HF buffer containing 
1.5 mM MgCl2 and 2 U of Phusion-HF was first set up on ice. The reaction was then 
carried out in a thermocyler using the cycling conditions listed in Table 2-3. 
 
Table 2-3: Thermo cycling conditions for site-specific mutagenesis using Strategene’s QuikChange®. 
Initial denaturation 98 °C  2  min 
25 cycles  
Denaturation 
Annealing 
 
98 °C  
58 °C (± 3 °C calculated Tm) 
 
30 s 
60 s 
Extension 
72 °C 
68 °C 
5 s 
20 s/kb  
Final extension 68 °C  
72 °C 
10 min 
10 min 
Hold 4 °C ∞ 
 
PCR product was purified using Wizard® SV Gel and PCR Clean-Up System kit 
from Promega and eluted using nuclease-free water. Wild-type plasmid template was 
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then removed by treating the purified sample with 10 U of DpnI at 37 °C for 3 h. 2 U 
was added and the treatment was continued for a further 3 h at 37 °C. DpnI treated 
product was PCR-purified and eluted in 30 PL of nuclease-free water. 5 PL of the 
purified PCR product was e-transformed into BW25142 e-competent cells. 
 
2.6.2. Site-saturation and site-directed mutagenesis 
 
Site saturation mutagenesis was performed to create single-site saturation libraries 
used for the study of mutational tolerance in Chapter 6. The mutagenic primers were 
encoded with NNK codon degeneracy (N = all four deoxyribonucleotides adenine 
(a)/cytosine (c)/guanine (g)/thymine (t), and K = g/t). Two megaprimer PCR methods 
developed separately by Fang’s (dual-tube) and Reetz’s (single-tube) groups were 
attempted.  
 
The first method attempted was the single-tube method reported by Sanchis et 
al.20 from Reetz’s group. For this method, the PCR reactions were performed in single 
tubes using a 2-stage amplification protocol. Reactions were set up in final volumes of 
50 μl containing 50–100 ng of template and 5 pmol of forward and reverse primers, 200 
nM of each dNTP and 1 U of Phusion-HF in 1× Phusion-HF buffer containing 
1.5 mM MgCl2. The amplification protocol was as such: initial denaturation at 98 °C for 
3 min, 5 cycles of 30 s denaturation at 98 °C and 30 s annealing at 55 °C (± 3 °C of the 
calculated Tm of the oligonucleotides designed), extension 30 s/kb according to the 
megaprimer size at 72 °C.  This was followed by 20 cycles of initial denaturation and 
extension using cycling conditions as described for the first stage. A final extension of 
2 min/kb at 68 °C was performed. The mutation frequency obtained was around            
50–60% and the library sizes generated from this method were between 100–300 
transformants. This was not very efficient and attempts to optimize various parameters 
including using Pfu polymerase and increasing the extension duration of the thermo 
cycling conditions did not improve the efficiency of the method significantly. Hence, 
we attempted the dual-tube method developed by Tseng et al.21  
 
The dual-tube method was adapted to generate libraries with mutagenesis 
efficiencies between 75% and 90%. The library sizes generated using this method were 
between 2000 and 4000 transformants. Reactions were set up in final volumes of 50 Pl 
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containing 50–100 ng of wild-type plasmid DNA template and 1 pmol of each 
mutagenic primer and flanking primer, 200 nM of each dNTP and 1 U of Phusion-HF in 
1× Phusion-HF buffer containing 1.5 mM MgCl2. Thermocycling was performed in two 
stages. After the first stage, 2.5 PL of the reaction mixture was added to another tube 
47.5 PL of the following mixture: 25 ng of wild-type plasmid DNA template, 200 nM 
of each dNTP and 1 U of Phusion-HF in 1× Phusion-HF buffer containing 1.5 mM 
MgCl2. The cycling conditions are summarized in Table 2-4. 
 
Table 2-4: Thermo cycling conditions for site-saturation and site-directed mutagenesis. 
Initial denaturation 98 °C  2  min 
18 cycles (Stage I) 
Denaturation 
Annealing 
Extension 
 
98 °C  
55–58 °C (± 3 °C calculated Tm) 
72 °C 
 
30 s 
60 s 
30 s/kb 
megaprimer 
Hold until Stage II 4 °C ∞ 
25 cycles (Stage II) 
Denaturation 
Annealing and extension of 
megaprimer 
 
98 °C  
68 °C  
 
30 s 
20 min 
Final extension 
68 °C  
72 °C 
20 min 
20 min 
Hold 4 °C ∞ 
 
PCR product was purified using Wizard® SV Gel and PCR Clean-Up System kit 
from Promega and eluted using nuclease-free water. Wild-type plasmid template was 
then removed by treating the purified sample with 10 U of DpnI at 37°C for 3 h. 2 U 
was added and the treatment was continued for a further 3 h at 37 °C. DpnI treated 
product was PCR-purified and eluted in 30 PL of nuclease-free water. 5 PL of purified 
PCR product was e-transformed into BW25142 e-competent cells. 
 
2.6.3. Error-prone PCR (ePCR) 
 
Random mutations were introduced in the gene using error-prone PCR (ePCR) 
with unbalanced concentrations of MgCl2 and MnCl2 and high amounts of low-fidelity 
Taq polymerase.  The ePCR protocol was adapted from Cadwell et al.22 and Arnold et 
al.23 5 mM of MgCl2 was used compared to the concentration of 1.5 mM in standard 
PCR reactions to stabilize non-complementary pairs that resulted from random 
introduction of mutations. A higher amount of Taq polymerase was also used to 
encourage nucleotide extension beyond the positions of the base mismatch22. MnCl2 
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was used to reduce the specificity and fidelity of the DNA polymerase, thereby 
increasing the error rates.  
 
An ePCR reaction was set up in the PCR reaction buffer without MgCl2 supplied 
by Roche at a final concentration of 1×. Each reaction consisted of 50 ng of plasmid 
DNA, 1.25 PM of forward and reverse primers each, 5 mM of MgCl2, 0.2 mM of each 
dNTP mix and 5 U of Taq polymerase (Roche). 0.05–0.5 mM of MnCl2 was added 
depending on the desired mutation rate. The cycling conditions were identical to the 
standard PCR cycling parameters described in Section 2.5.2.    
 
2.6.4. Staggered extension process (StEP) 
 
StEP is an in vitro recombination process that was first described by Zhao et 
al.24,25 A short extension time was used to generate short fragments from a pool of 
mutant DNA due to incomplete extension, which were then used as annealing templates 
in the subsequent cycle. This allowed for template swapping. Mutations from different 
generations or fragments were recombined using this procedure. Proofreading 
polymerases Phusion-HF and Pfu were used to maintain the fidelity during shiffling. A 
StEP reaction consisted of a pool of plasmid DNA in equal proportion (total amount 50 
ng), 1.25 PM of forward and reverse primers each, 5 mM of MgCl2, 0.2 mM of each 
dNTP, 1.5 mM MgCl2 (Phusion) or 2.5 mM MgSO4 (Pfu) and 1 U of Phusion-HF or 
2.5 U of Pfu polymerase (Roche). The cycling conditions are listed in Table 2-5. 
 
Table 2-5: Thermo cycling conditions for StEP. 
Initial denaturation 94 qC (or 98qC for Phusion) 5 min 
120 cycles 
Denaturation 
Annealing 
Extension 
 
94 qC (or 98 qC for Phusion) 
55 qC 
72 qC 
 
10 s 
5 s 
3-5 s 
Final annealing 
Final extension 
55 qC 
72 qC 
2 min 
10 min 
 
2.6.5.  Staggered extension process with error-prone steps (StEP- ePCR) 
 
StEP-ePCR combines shuffling and the introduction of random mutations in one 
reaction. The PCR reactions were set up as described for StEP procedure. The cycling 
conditions were identical to ePCR with the exception that an extension time of 5–8 s 
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rather than 30 s was used. The extension time depended on the fragment shuffled. 
Longer extension time was used to shuffle longer fragments.  
 
2.6.6. Assembly PCR for targeted random mutagenesis 
 
Assembly PCR was performed to assemble the mutagenic and non-mutagenic 
PCR products for the creation of targeted random mutagenesis libraries. Non-mutagenic 
PCR products were created using the standard PCR method described in Section 2.5.2. 
These would flank the mutagenic fragment on either or on both sides. The 5’–flank was 
created using pgus401f (Appendix D) as the forward primer and a reverse primer that 
partially overlapped the 5’–end of the mutagenic fragment. The 3’–flank was created 
using pgusr as the reverse primer and a forward primer that partially overlapped the 3’–
end of the mutagenic primer. Mutagenic fragments were created using ePCR, StEP or 
StEP-ePCR described above. When the mutagenic fragment was found at either end of 
the gene, the forward or reverse primer used in the mutagenic PCR steps was pgus401f 
or pgusr while the other primer would correspond to the start or the end to the targeted 
region.  Figure 2-3 illustrates the assembly process for two cases: when the mutagenic 
fragments are between non-mutagenic fragments, and when the mutagenic fragment 
was found at one end. 
 
The fragments were separated using DNA gel electrophoresis, excised and gel 
purified using Wizard® SV Gel and PCR Clean-Up System kit from Promega. 
Fragments that were 300–1000 base pairs in length were separated on 1% SB-agarose. 
Fragments that were 100–300 base pairs in length were separated on 1.6% SB-agarose. 
 
Assembly reactions were set up using 20 ng of each gel purified fragments from 
the first PCR reactions as the templates. The templates were annealed by the overlap 
between the fragments. Amplification of the annealed products was initiated by forward 
primer for the 5’ fragment pgus401f and pgusr primer (reverse primer for the 3’ 
fragment). The extension step in the assembly PCR reaction was carried out by 2 U of 
Pfu polymerase and 1× Pfu buffer containing 2.5 mM MgSO4. The cycling conditions 
are listed in Table 2-6. 
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Table 2-6: Thermo cycling conditions for StEP-ePCR. 
Initial denaturation 95 °C  3 mins 
30–35 cycles 
Denaturation 
Annealing 
 
94 °C 
Average Tm of primers ~ 55 °C 
 
15 s 
40 s 
Extension 
68 °C 
72 °C 
2 min (~1 min/kb) 
2 min (~1 min/kb) 
Final extension 
68 °C 
72 °C 
10 min 
10 min 
Hold 4 °C ∞ 
 
	
 
 
 
Figure 2-3: Schematic illustration 
of PCR approaches to generate 
random libraries. epPCR: error-
prone PCR, nmPCR: non-
mutagenic PCR. Target regions 
for random mutagenesis are 
illustrated in light blue and the 
error-prone PCR amplification 
products of these regions are 
illustrated in the same light blue, 
with dotted foreground. Flanking 
regions for nmPCR are 
illustrated in dark blue. 
Overlapping regions are shaded 
in diagonal stripes. Arrows 
depict the forward (Æ) and 
reverse (Å) primers used to 
generate the fragments for 
assembly PCR. Vertical errors 
represent the restriction sites. (a) 
The megaprimer approach is 
performed in two PCR reactions, 
and (b-c) the triple step 
procedure involving separate 
generation of error-prone and 
non-mutagenic products and 
subsequent assembly of the 
fragments.  Two different 
assembly methods are shown- 
one involving the assembly of 
two fragments (shown in (b)), 
which is useful for targeted 
mutagenesis at a terminal region. 
The other, shown in (c) 
assembles three fragments and 
applies to libraries directing 
evolution within the gene. In 
green: vector backbone.  
 
	 
 
(b) 
(c) 
(a) 
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Figure 2-4 shows the failed attempt to generate sufficient products from whole-
gene megaprimer method (Figure 2-4a), a failed assembly PCR attempts (Figure 2-4b) 
and successful attempts (optimized conditions) in generating assembly products for 
library generation (Figure 2-4(c-d)) using mutagenic fragments from various 
concentrations of MnCl2 (Figure 2-4d). Assembled products corresponding to the band 
at ~ 1.8 kb were then gel purified (Figure 2-4(c-d)). They were then cut with NdeI and 
EcoRI restriction endonucleases and cloned into pJ401(+6×HisTag) vector backbone.  
 
 
Figure 2-4: DNA visualization of PCR amplification products for targeted random mutagenesis. (a) 
Inefficient mutagenic PCR in generating whole-gene from megaprimers with random mutations. (b) 
Failed attempt at assembly PCR reaction produced fragments of various sizes. (c) Successful attempt at 
assembly PCR reaction with a desired band at 1.8 kb. (d) Assembled PCR product and mutagenic 
fragments ( ~ 700 bp) generated using different concentrations of mutagen MnCl2. 
	
2.6.7. E-transformation for library generation 
 
Ligation or PCR products were e-transformed into BW25142 e-competent cells 
according to the procedures in Section 2.3.2. Recovered e-transformation mixtures were 
pelleted and resuspended in 800 PL sterile 10% glycerol. Library glycerol mixtures 
were then snap frozen in 100 PL aliquots and kept in -80 °C. These were thawed when 
needed for library growth and expression.  
 
2.6.8. Analysis of mutant library 
 
Colony PCR or basic PCR was performed to ensure the presence of plasmids 
harbouring the mutant genes. The average mutation frequencies of the libraries were 
estimated by sequencing eight to twelve randomly selected colonies. The mutation 
frequency was expressed as the means and standard deviation of the number of 
mutations found.  
(a) (b) (c) (d) 
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2.7. Preparation of lysates and assays for E-GUS library screening 
 
This section describes the library screening procedures for E-GUS engineering 
and directed evolution. Two different methods for the cultivation and preparation of cell 
lysates are first given. This is followed by a description of the X-gluc colony agar plate 
screening assay, the pNPGlcA screening assay in the presence and absence of t-BuOH, 
and para-nitrophenyl-E-D-glucoside (pNPGlc) screening assay. 
 
2.7.1. Cultivation and preparation of lysates for E-GUS screen 
 
Libraries for directed evolution were grown in sterile 96-well microtitre plates by 
inoculating single colonies per well or using the culture dilution method developed by 
Dr. Bradley Stevenson during his time in this laboratory26. Generally, overnight cultures 
of libraries were grown in sterile 96-well microtitre plates at 37 °C for 16–18 hours in 
an orbital shaker shaking at 200 rpm (pre-culture plates). 10 PL of overnight cultures 
were then inoculated in 150 PL of LBK50 and grown for 3 h at 37 °C, shaking at 
200 rpm, to a confluence of ~ 0.6 OD600. 50 PL of 2 mM IPTG was added into the sub-
saturated culture. IPTG induction was performed at 30 °C overnight in an orbital shaker 
set to a speed of 180 rpm. Subculture plates were then frozen at -80 °C.  
 
2.7.1.1. Single colony method 
 
In the single colony method, single colonies were picked and inoculated into 96-
well round bottom microtitre plates containing 200 PL of LBK50. Libraries were grown 
at 37 °C in orbital shakers shaking at 200 rpm for 16–18 h. 10 PL of overnight cultures 
were then sub-cultured and induced with 0.5 mM IPTG at 30 °C for 12–14 h. 
Pre-culture plates were then stored at 4 °C so that potential hits can be isolated.  
 
2.7.1.2. Culture dilution method  
 
The culture dilution method was employed to screen ePCR and ePCR-StEP 
libraries where the library sizes were large. For this method, the cell density of the 
recovered e-transformation mixture was first determined. Serial dilution mixtures 1:1, 
1:10, 1:20 and 1:50 of a 10% library transformant glycerol aliquot were made and 
50 PL of each diluted mixtures was propagated on M9 agar plates supplemented with 
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50 Pg/mL of kanamycin (M9K50). The number of colony forming units (cfu) per PL of 
transformation mixtures were enumerated from the dilutions that gave 20–300 cfu and 
averaged. The remaining library of transformants was then diluted to 1 or 2 cfu per 
100 PL of LBK50. Diluted cell culture was dispensed into sterile 96-well microplates so 
that each well contained 200 PL of dilution mixtures (2–4 cfu per well). These plates 
were the primary screening plates. The number of sterile wells (wells that did not 
contain any colonies) after overnight growth was enumerated. The number of colonies 
per well was confirmed by substituting this number into the Poisson distribution 
function given by Equation 2-2.  
Pr = e
-μμr
r!
                                                   (2-2) 
where Pr is the probability of a well having r number of cells when the mean number of 
cells per well is P. The actual mean number of cells per well was calculated based on 
the number of sterile wells, i.e. when r = 0. The probability of encountering a well with 
r = 0–10 transformants for a library grown with mean number of cells per well, P = 4, is 
plotted in Figure 2-5a. The cumulative distribution function is plotted in Figure 2-5b. 
 
 
Figure 2-5: Poisson distribution of cells in liquid culture when µ = 4. (a) The distribution of cells 
containing r number of cells in a well, and (b) the cumulative distribution of the distribution.  
 
Secondary screen was performed on the wells from primary screening that 
harboured potential hits. Culture from selected wells were streaked and grown on 
M9K50 plates. Single colonies were then picked and grown in 200 PL LBK50 as in the 
single-colony method. The number of colonies to be inoculated from each well 
depended on the mean number of cells per well in the primary screen. As illustrated in 
Figure 2-5b, for a mean of four cells per well, ~ 99% of wells would contain nine or 
fewer clones. To maximize the chance of picking all clones present in a selected 
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primary well, ten colonies from each primary wells were isolated and inoculated for 
secondary screen.  
 
2.7.2. E-GUS blue-white screen 
 
X-gluc  colony agar screen was used to check if clones were active or inactive. An 
aliquot of culture containing 300 transformants was evenly distributed on M9K50 agar 
plates supplemented with 10 PM of IPTG to induce expression and 4–8 mg/100 mL of 
X-Gluc. 4–8 mg/mL of X-gluc solutions were prepared in neat DMSO of molecular 
biology grade and then mixed in molten M9 agar solution containing 50 Pg/mL of 
kanamycin and 10 PM of IPTG.  Colonies were grown at 37 °C overnight. Colonies that 
turned blue were considered as clones that have E-GUS activity.  
 
2.7.3. E-GUS buffer screening assay 
 
Thawed culture from subculture plates was diluted 20-times (10 PL into 190 PL) 
in 50 mM NaPi, pH 7.4 buffer (Appendix C). Diluted subculture was then further 
diluted eight times in 70 PL of 50 mM NaPi, pH 7.4 buffer. Cells was lysed with 80 PL 
of 0.025 kU/PL of rLysozyme® in 50 mM NaPi, pH7.4. Lysis was performed at room 
temperature on plate rocking shakers set at a speed of 1, 000 rpm/s for 15 min. Whole 
cell lysates were kept temporarily on ice to ensure that they were not inactivated. If 
plates were used to compare with tert-butanol (t-BuOH) screen for residual activity, cell 
debris were pelleted down by centrifugation at 3, 700 rpm for 5 min at room 
temperature. Whole cell lysates or cleared cell lysates were kept temporarily on ice to 
ensure that they were not inactivated.  
 
Whole cell lysate or clarified cell lysate was added to the assay buffer (50 mM 
NaPi, pH7.4) at a 1:10 v/v ratio. To start the reaction, 100 PL of 2–4 mM pNPGlcA 
prepared in the assay buffer was dispensed into each well using an 8-channel 
micropipette. The progress of reaction was followed using wavelength 405 nm on 
SpectraMax® M2e microplate reader.  
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2.7.4. E-GUS tert-butanol (t-BuOH) screening assay 
 
Thawed culture from subculture plates was diluted 20-times (10 PL into 190 PL) 
in 50 mM NaPi, pH 7.4 buffer. The diluted culture was then further diluted 2–3 times 
with 40 PL of 50 mM NaPi, pH 7.4 buffer. Cells was lysed win 80 PL of 0.025 kU/PL 
of rLysozyme® in 50 mM NaPi, pH7.4. Lysis was performed at room temperature on 
plate rocking shakers set at a speed of 1, 000 rpm/s for 15 min. Cell debris were pelleted 
down by centrifugation at 3, 700 rpm for 5 min at room temperature. Cleared cell 
lysates were kept temporarily on ice to ensure that they were not inactivated.  
 
Cleared cell lysate was added to 80 PL of assay buffer containing 25 or 31.25% t-
BuOH in 50 mM NaPi, pH7.4 at a v/v ratio of 1:4. Samples were incubated at 28 °C 
(room temperature) for 20 min. To start the reaction, 100 PL of 2–4 mM pNPGlcA 
prepared in assay buffers containing 20% or 25% t-BuOH was dispensed into each well 
using 8–channel micropipette. The progress of reaction was followed for 10–20 minutes 
using wavelength 405 nm on SpectraMax® M2e microplate reader. For residual activity 
screening, 20 PL of t-BuOH incubated sample was diluted in 80 PL of 50 mM NaPi, 
pH7.4 buffer. The reaction was initiated by adding 100 PL of 2–4 mM pNPGlcA 
prepared in buffer without t-BuOH and the activities with and without t-BuOH were 
compared.  
 
2.7.5. E-GUS and E-glucosidase screening assay for mutational tolerance study 
 
Thawed culture from subculture plates was diluted 20-times (10 PL into 190 PL) 
in 50 mM NaPi, pH 7.4 buffer. Cells was lysed in 100 PL of 0.025 kU/PL of 
rLysozyme® in 50 mM NaPi, pH7.4. Lysis was performed at room temperature on plate 
rocking shakers set at a speed of 1, 000 rpm/sec for 15 min and then kept on ice 
temporarily. For E-GUS assay, whole cell lysates were further diluted five-times and 
then added to 80 PL of buffer at a v/v ratio of 1:4. The reaction was initiated by adding 
100 µL of 1.6 mM pNPGlcA. The E-glucosidase assay was carried out using 100 PL 
whole cell lysate and 100 PL of 9 mM pNPGlc. Progress of the reactions were followed 
at 405 nm on SpectraMax® M2e microplate reader.  
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2.8. Preparation of lysates and assays for glucuronylsynthase library 
screening 
 
 
This section describes the library screening procedures for glucuronylsynthase 
engineering and directed evolution. The method for library cultivation and preparation 
of cell lysates are first given. This is followed by a description of the screening assay in 
20% t-BuOH to isolate potential hits that may be more kinetically competent. 
 
 
2.8.1. Cultivation and preparation of lysates for glucuronylsynthase screen 
 
Single colonies were picked from M9K50 agar plates supplemented with IPTG and 
X-gluc as described in Section 2.7.2. Single colonies were inoculated into 96-well 
round bottom microtitre plates containing 200 PL of LBK50. Libraries were grown at 
37 °C in orbital shakers shaking at 200 rpm for 16–18 h. Preculture plates were then 
stored at 4 °C so that potential hits can be isolated. Subculture plates were made by 
transferring 40 PL preculture into 360 PL 2xYT50 (Appendix C) and then induced with 
0.5 mM IPTG at 30 °C for 12–14 h in sterile deep well-plates. Subculture was first 
grown for 3 h at 37 °C, shaking at 200 rpm to a confluence of ~ 0.6 OD600 and then 
adding 100 PL of 2 mM IPTG. IPTG induction was performed in an orbital shaker set 
to a speed of 180 rpm. Induced cell culture was then harvested at maximal speed for 20 
min and frozen at -80 °C. 
 
2.8.2. Glucuronylsynthase tert-butanol (t-BuOH) screening assay 
 
Into each well, 100 PL of 50 mM 3-(N-morpholino)propanesulfonic buffer 
(MOPS-NH4+), pH 7.4 buffer (Appendix C) was added to resuspend the cell pellets. 
Cells was lysed by adding 100 PL of 0.05 kU/PL of rLysozyme®, prepared in the assay 
buffer, into the resuspension mixtures. Lysis was performed at room temperature on 
plate rocking shakers set at a speed of 1, 000 rpm/sec for 20 min. Cell debris was 
pelleted down by centrifugation at 3, 700 rpm for 10 min at room temperature. Cleared 
cell lysates were kept temporarily on ice to ensure that they were not inactivated.  
 
Cleared cell lysates were transferred to reaction assay plates (96-deep well plates). 
400 PL of reaction mixture containing 2 mM acceptor substrate CMO-DHEA (~ 0.6 
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mg/mL) and 6 mM D-D-glucuronyl fluoride as the glucuronyl donor substrate was 
dispensed into each well containing the cell lysates. The substrates were prepared in the 
assay buffer containing 21% t-BuOH so that the final concentration of t-BuOH in the 
reaction was 20%. The reaction was performed for 14–18 h in a plate incubator shaker 
set at 30 °C with agitation speed of 300 rpm. 100 PL of the reactions were quenched 
with 50% MeOH. The products in the quenched reaction were monitored using liquid 
chromatography-mass spectrophotometry (LCMS). The peak areas of product 
glucuronides were determined using M/Z value of 546.30 (CMO-DHEA glucuronide) 
or 463.20 (testosterone glucuronide). The peak area of each well relative to the average 
peak areas of the positive controls (glucuronylsynthase parent) was then computed to 
isolate potential hits.  
 
 
2.9. Translational misincorporation study: E-GUS assay to 
investigate effects of expression condition 
 
The plasmid pJ401/syn was e-transformed into BW25142 e-competent cells and 
propagated on M9K50 agar plates. Colonies were grown at 37 °C for 16 h. Single 
colonies were picked and inoculated into 10 mL of LBK50. Starter culture was grown at 
37 °C for 16 h, shaking at 200 rpm. 100 PL of starter cultures were subcultured in 50 
mL of 2xYTK50 in sterile 150 mL Erlenmeyer flasks for 3 h at 37 °C until the OD600 
reached ~ 0.6–0.8. 0.5 mM IPTG was then added to induce the cells at 18 °C, 30 °C and 
37 °C for a period of 4 h, 8 h and 16 h with agitation at 200 rpm on orbital shakers. 
Cells were then harvested and the cell pellets were frozen at -80°C.  
 
Cell pellets were resuspended in 1 mL of 50 mM NaPi, pH 7.4. BugBuster® 
10× Protein Extraction Reagent (Merck, EMD) was diluted with 62.5 mM NaPi, pH 7.4 
to obtain 2× BugBusterTM. 2× BugBusterTM was added to the cell resuspension in a 
volume ratio of 1:1. Lysis was performed at room temperature on orbital shakers by 
gentle shaking at speed ~ 50 rpm.  
 
E-GUS activity of the crude lysate samples was measured using 150 PL of crude 
lysate from the 4 h expression trial and 150 PL of 1/10 diluted crude lysate samples 
from the 8 h and overnight expression trials. Reactions were initiated with 100 PL of 
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2 mM pNPGlcA. The progress of the reaction was followed at wavelength 405 nm on 
SpectraMax® M2e microplate reader over a period of three days at 25 °C.    
 
Bovie Serum Albumin (BSA) standard curve was made using 0.0625–2.5 g/L of 
BSA in buffer. 5 PL of prepared BSA solution was added into 100 PL of mQH2O and 
100 µL of 20% Bradford reagent (Appendix C). The components were mixed 
thoroughly and left to stand at room temperature for ~ 5 min. Endpoint absorbance was 
taken at 595 nm on the SpectraMax® M2e microplate reader. Crude enzyme lysate was 
diluted in mQH2O and the amount of crude enzymes was determined in the same way as 
the BSA standard curve determination. Diluted crude enzyme lysates (10–20 PL) were 
also analyzed on SDS-PAGE according to the procedures in Section 2.10.6.  
 
 
2.10. Protein expression and purification 
 
This section describes the protein expression and purification method used to 
purify enzymes for kinetics and biophysical characterization. The growth and 
expression method for the E-GUS recombinants and glucuronylsynthase recombinants 
are first described in separate sections. This is followed by a description of the lysis 
procedure. Two purification methods are described- Nickel affinity purification using 
5 mL HisTrap FF columns and size exclusion chromatography (Superdex S-200).  
 
2.10.1. Growth and protein overexpression for E-GUS recombinants 
 
Plasmid DNAs of E-GUS parent or E-GUS variants were e-transformed into 
BW25142 e-competent cells and propagated on M9K50 agar plates. Colonies were 
grown at 37 °C for 16 h. Single colony was picked and inoculated into 10 mL of LBK50. 
Starter culture was then grown at 37°C for 16 h, shaking at 200 rpm. 1.6 mL of starter 
culture was inoculated into 500 mL of 2xYTK50 in 2 L sterile baffled flasks. Subculture 
was grown for 3 h until it reached OD600 of ~ 0.6–0.8. Subculture was then induced with 
0.5 mM IPTG and left to continue shaking at 30 °C, 200 rpm for 16 h in water bath 
orbital shakers.  
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2.10.2. Growth and protein overexpression for glucuronylsynthase recombinants 
 
Plasmid DNAs of glucuronylsynthase (Syn) parent or glucuronylsynthase variants 
were e-transformed into BW25142 e-competent cells and propagated on M9K50 agar 
plates supplemented with 8 mg/100 mL of X-gluc. Colonies were grown at 37 °C for 
16 h. Singles colonies were picked and inoculated into 10 mL of LBK50. Starter culture 
was grown at 37 °C for 16 h, shaking at 200 rpm. Subculture was prepared by 
inoculating 3.2 mL starter culture into 1 L of 2xYTK50 in 2 L sterile baffled flasks and 
allowing the subculture to grow for 3 h until it reached a confluence of ~ 0.6-0.8 OD600. 
Subculture was then induced with 0.5 mM IPTG and left to continue shaking at 28 °C, 
200 rpm for 16 h in water bath orbital shakers.  
 
2.10.3. Protein extraction for protein purification 
 
Induced cultures were harvested at 4 °C by centrifugation at 5, 000 rpm for 
20 min in a VWR R9A rotor. Supernatants were discarded and the cells pellets were 
washed with cold 200 mL of 50 mM NaPi, pH 7.4 buffer. Resuspended cells was 
pelleted at 4 °C by centrifugation at 4, 000 rpm for 30 min and transferred into 50 mL 
conical tubes for storage at -80 °C.  
 
Cell pellets were resuspended in 30 mL of HisTrap column binding buffer 
supplemented by 1 mM of AEBSF to minimize proteolysis. The column binding buffer 
was 50 mM NaPi, pH 7.4 containing 500 mM sodium chloride (NaCl). Cell suspensions 
were pre-treated with 60 PL of 40 mg/mL hen egg-white lysozyme prepared in the same 
binding buffer per gram of cell pellet. Pre-treated samples were incubated with gentle 
agitation on orbital shakers at 4 °C for 15 min. Samples were then lysed using Omni 
Sonic Ruptor® equipped with OT-T-375 probe from Omni Sonic. This was performed at 
RT with the samples kept cold in ice bath. Cells were disrupted at 50% power and 50% 
pulse length for 2 min. This was repeated four times. In between each sonication repeat, 
the sonication probe was rinsed with cold water to keep it from warming up to minimize 
protein denaturation. Cell lysates were clarified by centrifugation at 14, 000 rpm in a 
VWR R20A2 rotor kept at 4 °C for 40 min. Clarified cell lysates were then applied to 
purification columns using a peristaltic pump or a syringe.       
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2.10.4. Metal affinity purification  
 
5 mL FF HisTrap® columns charged with Ni2+ were used for 6×HisTag enzyme 
samples. Purification was performed using AKTATM FPLC System at 4 qC or by 
manual bench-top purification at room temperature. Columns were equilibrated with 50 
mM NaPi, pH 7.4 containing 500 mM NaCl (binding buffer, buffer A).  
 
For purification using FPLC, unbound fractions were washed out of the column 
with 5 column volumes (CV) of buffer A. Weakly bound fractions were then washed 
out of the column by 3 CV of 10% elution buffer. The elution buffer was 50 mM NaPi, 
pH 7.4 containing 500 mM NaCl and 500 mM imidazole (buffer B). Samples were 
eluted using a linear gradient of 10% to 100% B over 10–20 CV. Fractions 
corresponding to the highest peak on the FPLC chromatogram were analyzed on SDS-
polyacrylamide gel electrophoresis in 12% polyacrylamide gels to check their purity. 
Fractions that were > 95% pure were pooled and dialyzed overnight against 
50 mM NaPi, pH 7.4 buffer. Alternatively, the fractions were concentrated to 1 mL 
using Amicon® ultra centrifugal filters with 30 kDa molecular weight cutoff cellulose 
membrane by centrifugation at 4, 000 rpm at 4–8 °C. This was then applied to a 5 mL 
HiTrap® desalting column pre-equilibrated with 50 mM NaPi buffer, pH 7.4. Samples 
were then eluted using the same buffer. Eluted samples were collected in 0.5 mL 
fractions. Fractions that had the enzyme were pooled and concentrated again to 500 PL. 
10 mL of phosphate buffer was added gently to the concentrated sample to further dilute 
any trace amount of residual salt that might have been retained after the desalting 
column. Samples were concentrated again to 250 PL and stored in -20 °C as 25% 
glycerol stocks. 
 
For purifications using manual bench-top method, washing buffers A1 and A2 
were prepared by mixing buffer A and buffer B in volume ratio of 1:9 (A1) and 4:6 
(A2). Columns were equilibrated with 5 CV of A1 containing 5 mM of imidazole prior 
to cell lysates loading. Unbound and weakly bound fractions were washed out of the 
column with 4 CV of A2. Samples were then eluted with 20 mL of buffer B. Eluted 
samples were collected in fractions of 2.5 mL, 2.5 mL and 5 mL thereafter. Buffers 
were kept as cold as possible and were passed through the column either using 
peristaltic pump or syringe. This method was sometimes used for purification of E-GUS 
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variants and all the time used for purification of glucuronylsynthase variants. Eluates 
were analyzed, concentrated and stored as described for the FPLC purification.     
 
2.10.5. Size-exclusion purification  
 
1 mL of concentrated sample from HisTrap purification was loaded onto 
Superdex S-200 column (bed dimension 16 (d) x 600 mm (l), bed volume of 120 mL) 
and purified at a flow rate of 0.5 mL/min using the FPLC system. The column was first 
equilibrated with 120 mL (1 CV) of 50 mM NaPi, pH 7.4 before loading the samples. 
Sample was eluted over 1 CV in 50 mM NaPi, pH 7.4. Fractions were collected in 
0.5 mL fractions and analyzed on SDS-PAGE. Size-exclusion purification was 
performed on E-GUS for kinetics characterization in Chapter 3 and for an isothermal 
titration calorimetry (ITC) experiment that was set-up to investigate the binding 
between E-GUS and E-D-glucuronic acid (1GlcA) (data not presented in this thesis).  
 
2.10.6. Protein visualization and quantification 
 
Enzyme samples were visualized using Laemmli SDS-PAGE system27. A 
two-component SDS-PAGE gel consisting a 5% (w/v) stacking gel at pH 6.8 and a 15% 
(w/v) resolving gel at pH 8.8 was used. 10 lane gels were prepared using combs with 
well widths of 5 mm. The two components of the gel were prepared as in Table 2-7. 
 
Table 2-7: Components of SDS-PAGE gel. 
 15% (w/v) Resolving gel 5% (w/v) Stacking gel 
Acryl/Bis 37.5: 1, 40% (w/v) 3000 PL 375 PL 
0.5 M Tris, pH 6.8 - 833 PL 
1.5 M Tris, pH 8.8 2000 PL - 
10% (w/v) SDS 80 PL 33.3 PL 
dH2O 2850 PL 2069 PL 
TEMED 10 PL 3 PL 
10% (w/v) APS 60 PL 20 PL 
Total volume 8000 PL 3333.3 PL 
 
Low range SDS-PAGE molecular weight standard was used as a standard. The 
marker contains six proteins with molecular weights ranging between 14.4 kDa and 
97.4 kDa. The marker was purchased as a 20× stock from BioRad, and is diluted 20-
fold with E-mercaptoethanol and stock sample buffer as recommended by the supplier’s 
protocol. The protein standard was heated for five minutes at 95 °C and stored 
at -20 °C.  
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Enzyme samples were mixed with SDS-reducing sample buffer (Appendix A) at a 
ratio of 1:2 and heat-treated at 95 °C for 5 min. Incubated samples were left to cool to 
room temperature for 5 min prior to loading and 10–20 PL of the enzyme samples were 
loaded per well. Electrophoresis was performed using the SDS running buffer system 
described in Appendix A. A constant current of 30 mA per gel and variable voltage was 
used. Running water was passed through the system to keep it cool. Separation was run 
for 35–45 min until the dye front migrated to the end of the gel.  
 
Protein gels were stained using BioRad Coomasie G-250 dye. Prior to staining, 
SDS was removed by boiling the gel three times in water, changing the water in 
between each treatment, and then washing it with cold water. Gels were stained for 
40 min if a fresh staining solution was used, or at least 6 hours if a recycled staining 
solution was used. The gels were then de-stained in water overnight. Images of the gel 
were scanned. The amount of protein was estimated using ImageJ (NIH). 
 
Enzyme concentration was determined by NanoDrop® by measuring the 
absorbance at 280 nm. 2 PL of enzyme sample was used for each measurement. Three 
measurements were taken for each sample and averaged. Measurements were repeated 
if the standard deviation of the replicate measurements was more than 5%. The protein 
concentration was calculated form the A280 values using the Beer-Lambert 28 equation 
A = Hcl; where A is the absorbance, l is the cell path length (cm) and H is the molar 
absorption coefficient (M-1cm-1) estimated by ProtParam tool 
(http://web.expasy.org/protparam/). 
 
 
2.11. Enzyme characterization using activity assays 
 
The purified enzymes of E-GUS and glucuronylsynthase variants were 
characterized using activity assay. This section describes the procedures used to 
determine their kinetic parameters. 
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2.11.1. Enzyme kinetics of E-GUS and variants 
 
HisTrap purified enzymes ranging between 20–50 nM were reacted with 50 PM 
to 16 mM  pNPGlcA or pNPGlc in 50 mM NaPi, pH 7.4 buffer. The liberation of pNP 
product from pNPGlcA in a reaction volume of 240 PL was followed for 20 min on 
SpectraMax® M2e microplate reader at a wavelength of 405 nm at 25 °C. The liberation 
of pNP product from pNPGlc in a reaction volume of 240 PL was followed for 60 min 
on SpectraMax® M2e microplate reader at a wavelength of 405 nm. The extinction 
coefficient of pNP was determined to be 7625 M-1cm-1 in 50 mM NaPi, pH 7.4 (Figure 
A2-1, Appendix 2-1). Kinetic parameters of the wild-type and mutant enzymes were 
obtained by fitting the turnover rates to the Michaelis-Menten equation using 
Kaleidagraph 4.5 (Synergy Software, Reading, PA). 
 
2.11.2. Enzyme kinetics of E-GUS in t-BuOH 
 
HisTrap purified enzyme samples (20–50 nM) were pre-incubated in 90 PL 50 
mM NaPi, pH 7.4 assay buffer containing 20% t-BuOH for 20 min at 30 °C, in a total 
volume of 120 PL. Pre-incubated enzyme mixtures were then reacted with pNPGlcA at 
concentrations ranging from 10–50 PM in 50 mM NaPi, pH 7.4 buffer containing 20% 
t-BuOH. Hydrolysis of pNPGlcA in a reaction volume of 240 PL was followed for 20 
min on SpectraMax® M2e microplate reader at a wavelength of 405 nm at 25 °C. The 
extinction coefficient of pNP was determined to be 8259 M-1cm-1 in the assay buffer 
with 20% t-BuOH  E-GUS kinetics (Figure A2-2, Appendix 2-1). Kinetic parameters of 
the wild-type and mutant enzymes were obtained by fitting the initial velocities to the 
Michaelis-Menten equation.  
 
2.11.3. Solvent stability study for E-GUS recombinants 
 
HisTrap purified enzymes (50–100 nM) were pre-incubated in 80 PL of 50 mM 
NaPi, pH 7.4 containing solvents at a v/v ratio of 1:4 and total volume of 100 PL for 20 
min at 30 °C. A control reaction mixture was also performed by incubating 20 PL of 
50–100 nM of purified enzyme with 80 PL of 50 mM NaPi, pH7.4 20 min at 25 °C. The 
pre-incubated mixture was then added into 80 PL of 50 mM NaPi pH 7.4 (assay buffer) 
at a v/v ratio of 1:2. The reaction was initiated by adding 120 PL of 2 mM pNPGlcA 
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prepared in the assay buffer. Hydrolysis of pNPGlcA in a reaction volume of 240 PL 
was followed for 20 min on SpectraMax® M2e microplate reader at a wavelength of 405 
nm at 28 °C. Residual activity was obtained by dividing the activity of solvent pre-
incubated sample with the activity of the control sample. The residual activity was then 
plotted as a function of the solvent concentration to generate a sigmoidal curve. The 
curve was fitted to a Boltzmann function (Equation  2-3) using sigmoidal curve-fitting 
function on Kaleidagraph. The solvent concentration at which the enzyme loses half its 
activity, [solvent]50, was obtained from the inflection point per Equation 2-3. 
y	= ymin+ y
max- ymin
1+e
(S-S50)
λ
                                                (2-3) 
 
where ymin and ymax are the values of the minimum and maximum activity, S is the 
concentration of solvents, S50 is the [solvent]50, and λ denotes the slope of the transition 
between active and inactive enzyme.  
 
2.11.4. Enzyme kinetics of glucuronylsynthase variants 
 
HisTrap purified enzymes of concentrations ranging between 0.1–0.4 PM were 
reacted with 1.75 mM D-D-glucuronyl fluoride and CMO-DHEA at concentrations 
ranging from 0 PM to 12 mM in 50 mM NaPi, pH 7.4 reaction buffer containing 20% t-
BuOH at 30 °C. Reactions of total volume 1.2 mL were performed in 1.5 mL HPLC 
vials with resealable lids. Reaction mixtures were left in the LCMS sample 
compartment maintained at 30 °C. Reaction progress was monitored by quantifying 
CMO-DHEA glucuronide in real time via automated sampling of 10 PL reaction every 
4 h. A C-18 Poroshell 120 column with dimensions 2.1 x 30 mm or 50 mm and 2.7 Pm 
pore size was used to resolve the glucuronide produce and acceptor substrate peaks. The 
method development for the LCMS analytical method will be described in Chapter 4. 
 
2.11.5. t-BuOH stability study for glucuronylsynthase recombinants 
 
HisTrap purified enzymes of a concentration 4 PM were pre-treated with 100 PL 
of 50 mM NaPi pH 7.4 containing 0–65% t-BuOH for 20 min at 30 °C in a final volume 
of 125 PL. A control reaction mixture was also performed by incubating the same 
amount of enzyme with 160 PL 50 mM NaPi, pH7.4 for 20 min at 30 °C. Pre-incubated 
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samples were diluted 10 times in reaction mixtures containing 1.75 mM of D-D-
glucuronyl fluoride and 2 mM CMO-DHEA 50 mM NaPi pH 7.4. Their activities were 
determined using the same method for glucuronylsynthase enzyme kinetics in Section 
2.11.3. Residual activities and [t-BuOH]50, the concentration of t-BuOH at which 50% 
of an enzyme sample was inactivated, were determined as in Section 2.11.4.  
 
2.11.6. Half-lives of glucuronylsynthase variants in t-BuOH 
 
HisTrap purified enzymes of a concentration 1 mM were pre-treated at 30 °C with 
160 PL 50 mM NaPi, pH 7.4 containing 10% t-BuOH either in the absence of presence 
of 1 mM D-D-glucuronyl fluoride, in a final volume of 200 PL. At various time points 
between 30 min and 4 h, 5 PL samples were diluted 10 times in 50 mM NaPi buffer, pH 
7.4. Diluted samples were kept at 4 °C temporarily prior to being used for the reaction 
assay. A control reaction was also performed by incubating the same amount of enzyme 
sample with 160 PL of 50 mM NaPi, pH 7.4 for 20 min at 28 °C. Incubated samples 
were diluted 10 times with 50 mM NaPi pH 7.4. The residual activity was determined 
as in Section 2.11.5. The [t-BuOH]50 was determined as in Section 2.11.4. The residual 
activity was then plotted as a function of the incubation time and fitted to a Boltzmann 
function (Equation 2-4) using sigmoidal curve fitting on Kaleidagraph. The time point 
at which the enzyme lose half its activity, half-life t1/2 , was obtained from the inflection 
point. 
y = ymin+ y
max- ymin
1+e
(t-t1/2)
λ
                                           (2-4)	
where ymin and ymax are the values of the minimum and maximum activity, t is the 
incubation time, t1/2 is the half-life, and λ denotes the slope of the transition between  
active and inactive enzyme.  
 
2.12. Biophysical and biochemical properties of enzymes 
 
Thermal shift assay (differential scanning fluorimetry), intrinsic fluorescence 
assay, and circular dichroism were used to probe the biophysical properties of the 
enzyme. The ligand binding affinity of the glucuronylsynthase and its variants were 
determined using isothermal titration calorimetry.  This section describes the procedures 
used in these experiments. 
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2.12.1. Thermal shift assay 
 
Thermal shift assay was used to determine the temperature denaturation profiles 
of the enzyme. The method utilizes a fluorescent dye, Sypro Orange®, which binds non-
specifically to hydrophobic surfaces and is quenched by water. As the protein denatures, 
the hydrophobic core becomes solvent exposed. The fluorescence of the dye increases 
as they bind to the exposed hydrophobic surface.  
Reaction mixtures of 20 PL containing 5 PM of purified enzyme samples (final 
concentration) and 5× Sypro Orange® diluted in 25 mM NaCl (final concentrations) 
were set-up. The thermal effect on enzyme unfolding was observed for every 0.1 °C 
between 20 °C and  95 °C at a rate of 1 °C min-1 in a 7900HT Fast Real-Time PCR 
machine at the BRF (JCSMR, ANU) equipped with 488 nm argon-ion laser excitation 
source. Emission fluorescence was monitored using continuous wavelength (O) 
detection from 500-660 nm. The fluorescence at 605 nm was recorded and plotted as a 
function of temperature. The protein unfolding transition between the lower limit and 
the upper limit of the denaturation profile in response to increasing temperature was 
fitted to the Boltzmann function using the sigmoidal curve-fitting function of 
Kaleidagraph as in Equation 2-4. The term t1/2 was replaced by Tm, the temperature 
midpoint between protein transition. 	
 
2.12.2. Intrinsic fluorescence assay 
 
The E-GUS enzyme contains 13 tryptophan and tyrosines, which enabled the 
monitoring of its intrinsic fluorescence. Intrinsic fluorescence was used to follow the 
unfolding of enzyme in the presence of chemical denaturant29,30 (urea and t-BuOH). 
Purified enzyme solutions of 10 mg/mL in 50 mM NaPi, pH7.4 buffer were incubated 
in different concentration of solvents (0–8 M of urea) at a volume ratio of 1:5 
(enzyme:solvent). Incubations were done at room temperature for 30 min. Incubated 
samples were then diluted 7–8 times to 4 PM with 50 mM NaPi, pH 7.4. Fluorescence 
of 4 PM enzyme solutions was monitored using Oexcitation = 274 nm and 280 nm, and 
continuous Oemission between 310 nm and 500 nm were recorded. Protein unfolding 
transition was observed from the decrease in fluorescence intensity and from a red shift 
from 325 nm to 345 nm. The natural logarithmic function of the fluorescence intensity 
ratios at 325 nm and 345 nm were plotted against solvent concentration. A sigmoidal 
curve with two-state transition was generated. The [solvent]50 was obtained by curve-
fitting the transition profile to the Boltzmann function as in Section 2.11.4. 
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2.12.3. Circular dichroism (CD) spectroscopy 
 
Circular dichroism (CD) spectroscopy was used to monitor the secondary 
structure perturbation31,32 of  enzyme solutions incubated with 20% t-BuOH in the 
presence or absence of a ligand (D-D-glucuronyl fluoride). Enzyme solutions enzyme 
solutions with concentrations ranging between 0.25–0.5 mg/mL were incubated at room 
temperature in 10 mM NaPi buffer, pH7.4 containing 0% or 20% t-BuOH. To monitor 
unfolding in the presence of ligand, 1 mM of D-D-glucuronyl fluoride was added to the 
incubation mixture. At different time-points between 0 h and 8 h, the incubated samples 
were transferred into a UV-transparent quartz cuvette with a pathlength of 0.1 cm. CD 
spectra were recorded at room temperature (25 °C) using Chirascan set with a time 
constant of 100 ms. Data (in millidegrees) was collected for wavelengths between 190 
and 260 nm31, at intervals of 0.5 nm, 0.5 s per point. A blank spectra of the buffer in 
20% t-BuOH was collected for blank subtraction. At least two scans were performed for 
each spectrum and averaged. Collected measurements were converted to the mean 
residue ellipticity [T]MRE (deg cm2 dmol-1) by normalizing the raw elliptical data to the 
pathlength (in cm) and amount of protein (in dmol) used.  
  
2.12.4. Isothermal calorimetry titration (ITC) 
 
Isothermal titration calorimetry (ITC) experiments were performed to study the 
ligand affinity33,34 of the glucuronylsynthase enzyme with glucuronyl donor, D-D-
glucuronyl fluoride. Experiments were performed on ITC2000 (TA Instruments, Texas, 
USA). Purified enzyme sample of 100 PM concentration and 4–5 mM of the ligand 
were used to conduct the experiment. Purified enzyme and ligand solutions were 
degassed prior to the experiment for 10 min to avoid bubble formation in the 
calorimeter cell. A stable baseline was achieved prior to ligand injection. Experiments 
were performed at 25 °C with a stirring rate of 300 rpm to equilibrate the titration 
mixtures. Equilibration time between each injection was set as 150 s. The data obtained 
was corrected for dilution heat by subtracting excess heat at high molar ratio of ligand 
to protein. The thermodynamics parameters – enthalpy (∆H°), binding affinity (K) and 
entropy (∆S°) – were interpreted using the NanoAnalyze® software provided by TA 
instruments. The association (Ka) and dissociation (Kd) constants were determined using 
an independent (1:1) model. The binding standard molar Gibbs energy change (∆G°) 
and standard molar entropy contribution (T∆S°) were calculated according to the 
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thermodynamics relationships ∆G° = -RT ln Ka  and ∆G° = H° - T∆S°, where T is 
298 K and R is the gas constant in kJ mol-1K-1.  
 
 
2.13. Computational tools 
 
DNA sequences were analysed using Sequencher 4.10.1.  Multiple sequence 
alignmnents of DNA and protein sequences were performed using Clustal-Omega35 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). Pymol 1.3 (DeLano Scientific) was used to 
visualize protein structures and to generate the figures of the structures. SWISS-
MODEL36–38 (http://swissmodel.expasy.org/) was used to generate models of E-GUS 
and glucuronylsynthase, and their variants using E-GUS WT as template. Evolutionary 
conservation of amino acids and phylogenetic relationship were calculated using the 
ConSurf-DB server37,38 (http://bental.tau.ac.il/new_ConSurfDB/). Enzyme-solvent 
interactions were predicted using FTMap41,42 (http://ftmap.bu.edu/). CUPSAT43,44 was 
used to predict destabilization ∆∆G of single-site mutations (http://cupsat.tu-bs.de/). 
Molecular docking of pNPGlcA and 1GlcA in Chapter 6 was performed using the 
pair-fit command in Pymol 1.3. Heat map was generated using open source server 
Plotly (https://plot.ly/). All curve fitting was performed using Kaleidagraph 4.5 
(Synergy Software, Reading, PA). 
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3. Directed evolution of E-glucuronidase (E-GUS)  
 
 Preamble 
 
The main aim of this thesis is to improve the glucuronylsynthase system 
developed by the McLeod group1. We had intended to do this in two steps as outlined in 
Section 1.4. This chapter describes the evolution of E-GUS. Our hypothesis was that a 
E-GUS variant with higher activity in the presence of high substrate concentration   
(10–20 times Km) could be converted into a glucuronylsynthase (Syn) that is more 
suitable for synthetic application.  
 
During the course of evolution, it was noted that the McLeod group observed 
improvement in the process chemistry for the glucuronylsynthase reactions when 
t-BuOH was added. However, the amount of t-BuOH that could be added to the system 
was only 10% due to enzyme stability issues. We envisioned that a E-GUS variant with 
enhanced performance in the presence of t-BuOH would also be converted to an 
improved glucuronylsynthase variant. Hence, we added t-BuOH to the screening assay 
in the latter evolutionary rounds, while maintaining the substrate concentration at 
20-times the E-GUS Km. 
 
To differentiate the evolutionary rounds conducted under different conditions, we 
classified those performed without t-BuOH as Stage I E-GUS evolution. Stage II E-GUS 
evolution continues from Stage I, with the presence of t-BuOH. We will describe the 
screening strategies that were employed for the two-stages of evolution and the outcome 
of the evolution attempt.  
 
 
 Library size considerations 
 
One of our earlier concerns in evolving the E-GUS was the sheer size of the 
enzyme. It is a multi-domain homo-tetramer with more than 600 amino acids per chain. 
Compared to the other enzymes that are investigated in this laboratory, evolving this 
enzyme will involve larger screening effort (Appendix 3-1, Table A3-1). To reduce the 
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library size, we considered an evolution strategy where segments of the gene were 
evolved separately. We used the crystal structure of the E. coli E-GUS obtained by 
Wallace et al.2  in 2010 to choose our target regions (Figure 3-1).  
 
The identified fragments were located in the TIM-barrel domain that contained 
the active site.  The largest of these fragments consists of residues K286–T503 (Lp2 
libraries). A shorter peptide fragment within Lp2 that focused on residues 429 to 503 
was also engineered (Lp4). These residues are proximal to the catalytic residues, E413 
and E504 (Figure 3-1, inset). Hence, targeting this region may yield a variant that has 
altered binding and kinetic properties. Q547–S580 is a long loop consisting 40 amino 
acid residues that overhangs the active site. This loop (Lp6) may facilitate substrate 
entrapment and product release. Hence, this loop was also targeted. 
 
(b)  |-----------------------Domain III (TIM-barrel)----------------------| 
 Domain I Domain II Lp2 Lp6 
  N-terminal 
{ 
Lp4 
(part of Lp2) } 
C-terminal
 
Figure 3-1: Peptide fragments and protein feature view of the targeted fragments chosen for random 
mutagenesis. (a) Peptide fragments chosen for targeted random mutagenesis. Inset on the right shows Lp4 
in green. (b) Protein feature view of E-GUS shows the relative positions of the three domains and targeted 
loops.  
(a) 
E504 
E413 
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 Results 
	
3.3.1. Optimization and validation of screening methodology 
 
The procedures for library growth and expression for E-GUS evolution was 
described in Chapter 2.7. We had applied the pooling strategy3 described in Section 
2.7.1.2 to increase screening efficiency. However, to apply this strategy, two important 
aspects had to be considered. The first was the number of colonies to be pooled in each 
well. The second was the setting of appropriate criteria to select wells for secondary 
screens. We chose to dilute four colonies per well (4 cfu/well) based on deductions that 
were derived from estimates of screening errors (inter-plate variation) and the expected 
activity distribution of a library.  
 
Experiments were set-up to establish the basis for assuming the choice of diluting 
4 cfu/well. We first determined from six plates containing only wild-type, that the 
inter-plate variation (% CV) that would arise from screening would be around 20% 
(Figure 3-2a), with the lowest variation at 12% and the highest at 23%. We also 
determined that a library with a mutation rate of one amino acid per gene would have 
median activity of 0.8-fold (Figure 3-2b). Approximately 25% of the library appeared to 
be inactive. Based on these numbers, we assumed the following. In most of the wells, 
one of the four clones pooled would likely be inactive while the other three clones 
would have ~ 0.8x control activity. These wells would display around 0.6-fold the 
control activity. By contrast, a well with one 2-fold improved variant and one inactive 
variant would display 0.9-fold control activity (Figure 3-3). This would be significantly 
higher than the rest of the plate. Thus, we would be able to single out wells that contain 
potential hits i.e. at least 2-fold improved for secondary screening. We compared this to 
pooling 3 cfu/well, which is used by the others in the laboratory. There was no 
significant difference when the number of colonies in a well was reduced to three. 
Hence, we decided that pooling 4 cfu/well would allow maximum screening efficiency. 
Figure 3-3 describes four types of wells (A–D) that will most likely be encountered in 
the screening plates when we pool 3 cfu/well or 4 cfu/well. 
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Figure 3-2: Investigating the inter-plate variation. (a) The expected inter-plate variation (% CV) caused 
by systematic and random errors during screening. Red wells and blue wells are positions that are 
susceptible to being picked as false negative (blue) or false positive (red). (b) The activity distribution in a 
library with mutation rate of 1 amino acid per gene. 
	
(a) 
(b) 
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Figure 3-3: Discrimination of wells containing 2-fold improved hits over the expected average activity in 
a plate when pooling 3 or 4 cfu/well. 
	
3.3.2. Stages of E-GUS evolution  
 
Two stages of evolution were performed on E-GUS. The first stage was 
performed without solvent, and the second stage was performed with t-BuOH. Libraries 
for the two stages of evolution were created using error-prone PCR (ePCR) and 
StEP-ePCR as described in Chapter 2. Table 3-1 summarizes the libraries that were 
created and the screening method that was employed to screen them. The mutation rates 
and coverage of the library size are also listed in the table. Appendix 3-2 (Table A3-2) 
summarizes the mutations that were found in the two stages of evolution. 
 
3.3.2.1. Stage 1 of E-GUS evolution   
 
Libraries for three different fragments (Lp2, Lp4 and Lp6) were screened in the 
first stage evolution. The locations of these fragments were pointed out in Figure 3-1. 
No improved clones were detected in Lp6 library and this library was left for 
revisitation in a latter section. Lp4, which was meant to search part of Lp2 region more 
thoroughly, also did not yield any improved clones. Hence, we did not pursue this 
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region further. However, we continued the evolution done on Lp2 where we made 
several observations. 
In the first round, two different types of Lp2 libraries were screened. One of these 
had an average mutation rate of 1.2 amino acid change per gene. The other library had 
an average mutation rate of 2.2 amino acid change per gene. Although we did not find 
any clones that were significantly improved, we managed to isolate several neutral 
mutations. These were subsequently recombined using StEP-ePCR.  
 
Table 3-1: Libraries that were generated for the directed evolution of E-GUS.  The libraries that were 
screened in the presence of t-BuOH (Stage-2) are highlighted in blue. The level of recombination was 
estimated by counting the number of recombination events observed in randomly selected sequences. 
 
 
Two different recombinant libraries (2aLp2 and 2bLp2) were screened because 
our first attempt generated a library that had very low recombination frequency. The 
second library, 2bLp2, showed more recombined sequences compared to our first 
attempt. Nevertheless, we screened both libraries and after screening nearly 5000 clones 
from both libraries, we did not find any recombined mutations that were better than the 
wild-type. Some of the mutations from the first round disappeared. However, seven of 
the fourteen mutations that were found in the first round libraries (1LowLp2 and 
1HighLp2) were retained. Interestingly, with the exception of mutation K495R, none of 
the other mutations from 1HighLp2 library were retained. The other two mutations that 
had appeared together with K495R also disappeared, but K495R reappeared in the final 
Lp2 library as a single mutant variant.  
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Mutants that appeared in the final round were subjected to tertiary screen to 
reconfirm their activity (Figure 3-4a). This was done by re-transforming the variants 
and expressing them in 1 mL scale. The activities were determined using the same assay 
used in primary and secondary screen and then normalized based on the cell density. 
The best clone (A426S) and a mediocre clone (S376G) were purified. Their activities 
were compared with the wild-type (Figure 3-4b). A426S showed very marginal 
improvement over wild-type, but this was within the error range. Nonetheless, this 
mutation was added to the pool of templates for the subsequent library, where t-BuOH 
was introduced.  
Figure 3-4: Confirmation of potential hits from Stage I evolution. (a) Relative activity of clones from 
Stage I library compared to wild-type in tertiary screen. (b) The activities of purified enzymes - A426S 
and S376G – compared to the wild-type. 
 
3.3.2.2. Second-stage of E-GUS evolution  
 
Round 3 marked the start of the second-stage evolution of E-GUS. Solvent 
t-BuOH was added to the screening assays so that we could isolate a variant that 
performed better in t-BuOH4. Before we commenced screening, a quick investigation 
was conducted to determine the concentration of t-BuOH that should be used for the 
screens. Purified E-GUS enzyme was incubated in 5–60% t-BuOH for 20 min. The 
incubated samples were then assayed using 1 mM of pNPGlcA substrate. The enzyme 
lost most of its activity but it was not completely inactivated in the presence of 20% 
t-BuOH (Figure 3-5a). We decided to use this amount of t-BuOH in the screening assay.   
 
(a) (b) 
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Three additional rounds of evolution with incremental t-BuOH (20–25%) were 
conducted using this assay. Variants from both 2aLp2 and 2bLp2 were used as 
templates for ePCR-StEP to generate the library for Round 3. At this stage, we also 
expanded the mutagenesis region to encompass the entire TIM-barrel domain (Lp2+6). 
Mutagenesis was subsequently extended to include the entire protein in the final round. 
Figure 3-5b summarizes the evolutionary route that was taken.  
 
 
 
Figure 3-5: The second stage of E-GUS evolution. (a) Deactivation curve of E-GUS (wild-type) in the 
presence of t-BuOH to determine amount of t-BuOH for screening assay. (b) Evolutionary route taken in 
Stage II. 4GUS1 and 4GUS12 are triple mutants consisting mutations H313L/K495R/L561S and 
K277Q/A431V/L561S respectively.  
 
Following the expansion of the mutagenesis region to include the entire TIM-
barrel, several new mutations were found in the C-terminal region (Lp6 region). One of 
these was L561S, which was conserved through to the final round. Most of the 
mutations from Stage I disappeared but, mutations K277Q, H313L and K495R were 
retained. Mutation A426S from Stage I was not retained. Of these three conserved 
mutations, H313L and K495R were retained in the final variant, along with L561S.  
 
The final round was created using triple mutant H313L/K495R/L561S (4GUS1) 
as the template for random mutagenesis. This variant had more than two-times the 
activity of wild-type in the presence of t-BuOH (Appendix 3-2, Table A3-3) and was 
chosen rather than 4GUS12 as the single mutation A431V appeared to be 
non-beneficial. Screening the final round library led to the final variant (5GUS12) 
consisting of eight mutations (Figure 3-6 (a)), and that had nearly two-times the activity 
of the parent triple mutant 4GUS1 (Figure 3-6 (b)). Interestingly, the four random 
mutations that were introduced in this round were found in the first domain and no new 
mutations were introduced in the catalytic domain. 
(a) (b) 
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Figure 3-6: Variants from Round 5 evolution. (a) Fold improvement over 4GUS1 (H313L/K495R/L561S) 
template. Standard deviations for 5GUS5 and 5GUS13 was obtained from several wells that had the same 
genotype. (b) 5GUS12 is the final evolution variant, constituting mutations from 4GUS1 and D31Y, 
R71C, F74S, D196G and H452R. 
	
3.3.3. Library Lp6 revisited 
 
The Lp6 segment consists of a mobile region made up of 20 amino acids        
(AA550–578) and remained interesting because the flexibility of this region may be 
useful for tailoring enzymatic activity. Ensuing from the positive selection of the 
mutation L561S after introducing 20% t-BuOH, we decided to revisit this region using 
the library that was created for Stage I even though we could not identify any hits 
during the first stage evolution. Two screening assays were performed – with and 
without t-BuOH – so that we could compare the activities under different solvent 
conditions and compute the t-BuOH stability. Table 3-2 lists some of the mutations that 
were found in this library. The full diversity can be found in Appendix 3-3 (Table 
A3-4).  
 
As was the case for Stage I-II evolution, we did not find any mutations that were 
more active than the wild-type in the absence of t-BuOH. In the presence of t-BuOH, 
mutation L561S appeared again among Lp6 diversity and showed higher activity and 
residual activity. There were several outliers that showed high relative residual acitivity, 
but their activities were relatively poor. As a result, these appeared to be more stable. 
However, deeper analysis of the data revealed that this was an artifact caused by low 
initial activities in buffer. As we preferred to maintain as much native activity (activity 
in buffer) as possible, we removed them from further consideration.    
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Table 3-2: Diversity of Lp6 potential hits from round 1 t-BuOH screen. Marked in red are artifacts, which 
showed high relative residual activities because their initial activities in buffer were low. Rel Act (bfe): 
activity relative to wild-type in 50 mM NaPi, pH 7.4 buffer; Rel Act (t-BuOH): activity relative to wild-
type in 20% t-BuOH, Rel residual: Residual activity in the presence of 20% t-BuOH relative to wild-type.  
Full list from Lp6 evolution can be found in Appendix 3-3 and 3-4. (False-R: considered as false and 
removed, NR: not removed). Mutations were recombined to generate second generation library (2Lp6). 
	
 
Variants that retained more than 20% wild-type (WT) activity in native condition, 
and that were 2-times more stable than wild-type in the presence of t-BuOH (variants 
that have > 2-times relative residual activity with t-BuOH) were recombined using 
StEP. A library of 104 clones was generated. We checked the library quality by 
determining the number of new unique sequences (sequences that showed shuffling or 
recombination events) out of 12 randomly picked clones. From 12 sequences, four of 
these were new and unique. We screened approximately 10% (800 clones) of the library 
in the presence of 25% t-BuOH. Clones that had more than 3-times WT activity were 
sequenced. The diversity we found in this round (round 2Lp6) was significantly 
reduced. Mutation L561S was found in all the recombinants. Appendix 3-4 lists the full 
diversity from the second generation library of Lp6 t-BuOH evolution (2Lp6). 
Recombinants that contained neighbouring mutations (I560T/L561S) and mutations that 
frequently appeared (F593S and K596R) were selected for characterization and 
reassigned as in Table A3-5 (Appendix 3-4). We also selected double mutant 
S557L/L561S because substitution at S557 had been reported in the literature5 to 
accommodate other glycosyl rings. In addition, we were surprised over the absence of 
mutation T509A in our evolution program. This mutation had been prevalent in 
literatures and had been reported to be beneficial for activity on other E-glycosides5–9 
and for thermostability6,10. It was not clear to us why this mutation did not turn up in 
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both the earlier evolution (Stage I-II) and in this targeted Lp6 evolution. Hence, we 
made the variant T509A site specifically for characterization. 
 
3.3.4. Kinetic parameters of mutants  
 
Kinetic parameters of the variants from Round 3–5 in Stage II and the selected 
mutants from Lp6 were obtained. Table 3-3 lists the mutations of the variants that were 
characterized. It also summarizes some of the observations for the more interesting 
variants. Table 3-4 summarizes the kinetic parameters of the variants in buffer and in 
the presence of 20% t-BuOH. The t-BuOH tolerance was determined by determining the 
% t-BuOH where the enzymes lost half their activity [t-BuOH]50. The turnover rate with 
and without t-BuOH, and the stability in [t-BuOH]50 are compared in Figure 3-7.  
 
Table 3-3: Variants that were selected for kinetics characterization and the mutations that they harbour. A 
summary of their activities relative to wild-type in the screening experiments are given where possible; 
ND: not determined, NA: not available. 
  
Source Variants 
Mutations                   
Native 
activity 
t-BuOH 
activity 
Residual activity 
in the presence of 
20 - 25% t-BuOH D
31
 
R
71
 
F7
4 
D
19
6 
H
31
3 
K
49
5 
T5
09
 
S
55
7 
I5
60
 
L5
61
 
F5
93
 
K
59
6 
Q
59
8 
β-GUS Native              1 1 1 
Stage I-II 
evolution 
L561S          S    0.51 4.35 ND 4GUS1     L R    S    ND 3.31 ND 5GUS12 Y C S G L R    S    ND 5.60 7.15 
Lp6 revisit 
7GUS7         T S  R  0.54 3.89 7.15 7GUS10        L  S    0.83 3.58 4.30 
7GUS13         T S    0.62 3.45 5.56 7GUS14          S S   0.56 3.52 6.25 7GUS24          S  R  0.34 2.41 6.88 Rational 
design T509             A             NA NA NA 
 
	
	
Table 3-4: Kinetic parameters in the presence of 20% t-BuOH and in 50 mM NaPi, pH 7.4 buffer (reflects 
physiological conditions). 
	
WT 5.24 ± 0.56 0.14 ± 0.0017 38.25 ± 4.114 76.57 ± 2.46 0.14 ± 0.019 530.9 ± 71.9
L561S 41.52 ± 1.71 0.52 ± 0.084 80.34 ± 13.398 40.05 ± 1.00 0.14 ± 0.015 279.7 ± 29.4
4GUS1 18.56 ± 5.31 0.22 ± 0.012 82.35 ± 18.810 4.31 ± 0.16 0.031 ± 0.007 140.6 ± 32.9
5GUS12 35.65 ± 1.75 0.40 ± 0.081 89.44 ± 18.691 67.38 ± 3.12 0.17 ± 0.030 402.3 ± 74.5
7GUS7 19.96 ± 0.5 0.57 ± 0.049 35.14 ± 3.176 16.69 ± 0.74 0.051 ± 0.012 329.8 ± 78.4
7GUS10 14.95 ± 0.76 0.46 ± 0.094 32.21 ± 6.733 6.54 ± 0.18 0.047 ± 0.007 138.9 ± 20.6
7GUS13 15.31 ± 0.66 0.43 ± 0.068 35.26 ± 5.759 41.09 ± 0.72 0.14 ± 0.010 299.0 ± 21.8
7GUS14 34.17 ± 1.247 0.60 ± 0.076 56.53 ± 7.358 37.70 ± 0.40 0.10 ± 0.005 364.2 ± 17.2
7GUS24 23.67 ± 1.203 0.47 ± 0.086 50.01 ± 9.477 26.80 ± 0.23 0.067 ± 0.003 401.8 ± 17.2
T509A 6.76 ± 0.214 0.31 ± 0.034 21.75 ± 2.445 46.25 ± 2.04 0.10 ± 0.019 486.0 ± 100.6
Variants
20% t-BuOH NaPi, pH 7.4
k cat  (s-1) K m  (mM) k ca t/Km (mM-1 s-1) k cat  (s-1) K m  (mM) k ca t/Km (mM-1 s-1)
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The kinetic behavior of the wild-type enzyme in 50 mM phosphate buffer (NaPi), 
pH 7.4 is consistent with the values reported in various literature5,7,9. In buffer only, 
none of the variants were better than wild-type. In t-BuOH, all the variants chosen from 
library screening were better than wild-type. However, rational design variant, T509A, 
was not better than wild-type in t-BuOH. This would explain its absence in our 
evolution program.  
 
 
Figure 3-7: The relative activities of the variants. Top: Comparison of the activity of variants under 
physiological condition and in 20% t-BuOH. Bottom: Comparison of the t-BuOH stability of the variants 
as determined by the midpoint of a melting curve, [t-BuOH]50 and their activities under physiological 
condition. 
 
The final variant (5GUS12) carries eight mutations and it was the most 
catalytically efficient variant. Amongst these mutations, the mutation L561S carried the 
dominant effect. The presence of single mutation L561S conferred 8-fold improvement 
in its turnover rate (kcat) value when compared to WT (Figure 3-8) in t-BuOH.  
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Consistent with our selection criteria during screening, this improvement was sacrificed 
slightly for better t-BuOH stability in 4GUS1. The final variant 5GUS12 recovered 
most of the activity that was lost by the addition of t-BuOH and had a higher catalytic 
efficiency compared to L561S and 4GUS1. Although the kcat improved by 
approximately 8-fold in the presence of t-BuOH when L561S was introduced, the 
catalytic efficiency (kcat/Km) in the presence of t-BuOH only doubled (Figure 3-8). This 
was sustained by variants obtained in subsequent generations, which was interesting 
because we did not expect 4GUS1 to be as efficient as L561S due to its lower kcat. This 
may be explained by the reduced Km in 4GUS1 and can be rationalized from its 
structure. The substitution in K495R would decrease the distance between residue K495 
and the CD backbone of D454 that interacts with the catalytic residue E413. 
Consequently, this would lead to increased rigidity of the network formed (Figure 3-8, 
insets) and alter the binding behavior in the active site. The increased rigidity may also 
explain the higher thermal stability of the variant (Figure 3-9). However, the mutations 
that were added in the subsequent round reversed the stability effect. 5GUS12 was the 
least thermostable compared to L561S and 4GUS1, but the mutations in 5GUS12 had 
benefitted its catalytic activity in both conditions- presence and absence of t-BuOH. The 
observations above showed that it was difficult to co-evolve for improved catalytic 
properties in different conditions – absence and presence of t-BuOH – and increased 
stability simultaneously. 
 
Figure 3-8: The trend in evolutionary progress of β-GUS activity in 20 % t-BuOH. Insets show the 
interactions of K495(WT) and R495 (mutant) with D454 and the network of 495-454-416 that may 
modulate the position of base catalyst residue, E413. 
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Most of the variants that had improved activity in t-BuOH also had improved 
stability. This was with the exception of the variant 7GUS7 (I560T/L561S), 7GUS13 
(I560T/L561S/K596R), and the most efficient variant 5GUS12. These had reduced 
thermostability compared to the wild-type. Hence, it may appear that the mutations at 
Lp6 with the exception of I560T appeared to be beneficial for thermostability even 
though they only conferred slight improvement in activity in the presence of t-BuOH. 
Lower thermostability in 5GUS12 may have been due to the other mutations from the 
other regions. Notably, 7GUS10 (S557L/L561S) was 7	°C more stable than the wild-
type even though it was only three times faster than the wild-type. However, there was 
an exception – the double mutant I560T/L561S. The neighbouring mutations may have 
interacted negatively to cause a reduction in thermostability. Some of the stability was 
recovered by K596R. When the mutation I560T was removed from the triple mutation 
combination I560T/L561S/K596R, the lost stability in double mutant I560T/L561S was 
recovered. 
 
 
Figure 3-9: Thermal stability values of E-GUS variants. Most mutations at Lp6 (L561S, S557L, F593S 
and K596R) improved the thermostability of E-GUS; the exception was I560T, that appeared detrimental 
as a double mutant (I560T/L561S). The additional mutations accumulated in the final round of Lp2 
evolution (5GUS12) reduced the thermostability of E-GUS.  
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3.3.5. Stability study in various denaturants 
 
The use of organic solvents are sometimes needed in chemoenzymatic  
reactions11–14 and in some cases have been shown to be able to improve enzyme 
performance15. We compared the activity of the variants towards t-BuOH and two 
alcoholic solvents (isopropyl alcohol and ethanol) that are often used in the industry. 
We also determined their resistance towards glutaraldehyde that is used in the industry 
as a cross-linker to stabilize enzymes in industrial process16. Mutations that confer 
greater solvent tolerance to E-GUS may be advantageous for biocatalysis by the 
glucuronylsynthase. A greater resistance towards glutaraldehyde also offers the 
possibility of obtaining cross-linked enzyme crystals that can be used for structural 
studies or in the enzymatic reactions. In addition, E-GUS is a common reporter 
enzyme17,18 but suffers from function loss during tissue fixation due to poor stability, 
particularly in glutaraldehdye or formaldehyde19. Hence, it would be interesting to know 
if greater t-BuOH stability also translated to greater stability in other solvents that may 
be useful for other E-GUS applications.  
 
The tolerance in different solvents was determined using a residual activity assay. 
The concentrations at which the enzymes were 50% inactivated, [solvent]50 were 
determined. Relative stabilities of the variants compared to the wild-type E-GUS were 
visualized in a heat map generated using the online analytics tool Plotly (Montreal, 
Quebec). The heat map allowed for direct comparisons of all the data in a two-
dimensional matrix where lighter colors represented lower solvent stabilities and darker 
colors represented higher solvent stabilities (Figure 3-10).  
 
Generally, variants that were more tolerant of t-BuOH were also more tolerant of 
other alcoholic solvents compared to E-GUS. However, in the other alcoholic solvents, 
the enhancement seen was less impressive than in t-BuOH. The most interesting variant 
was the 7GUS14 (L561/F593S) that had higher resistance towards both t-BuOH and 
glutaraldehyde. It displayed the most consistency in stability across all solvents. When 
compared to the parameters obtained in the previous section, this variant also showed 
good thermostability and was nearly as efficient as L561S. Therefore, this variant was 
taken as an enzyme with the most enhanced biophysical properties, while the L561S 
variant offers the greatest benefits in turnover rate. 
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Figure 3-10: Heat map depicting the degree of enhancement conferred by mutations relative to wild-type. 
The colour scale ranges from 0-3, where 0 = no tolerance, 1 = same tolerance as wild-type towards the 
respective solvent, and 3 = 3-times more tolerant than wild-type towards the respective solvent. 7GUS14 
has the highest tolerance towards t-BuOH and glutaraldehyde. 
 
 
 Discussion 
 
3.4.1. Structural rationalization of L561S and other variants 
 
The change from leucine to serine at residue 561 is the key mutation in the 
evolution towards increased activity in the presence of t-BuOH organic solvent. The 
fact that it was found in two parallel evolutions, Lp2 and then Lp6, establishes the 
pivotal role of this mutation. We attempted to rationalize the structural basis for the 
enhancement conferred by L561S. In the crystal structure obtained by Wallace et al., 
the residue L561 is found on a subunit interface (Figure 3-11a). The Leu-Leu distance is 
around 3.3	Å, which allows weak non-polar interaction between the Leu from adjacent 
subunits. LeuÆSer substitution increases this distance to 7.5	Å, which is not possible 
for molecular interaction. However, this creates a space for solvent molecules to 
potentially dock. We investigated this possibility by subjecting the wild-type and L561S 
variant to docking analysis using FTMap20 (Figure 3-11 (b)-(d)). FTMap is a server that 
identifies hot spots on macromolecules that bind small organic molecules or probes. 
ND* 
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Locations where the probes are predicted to dock are known as solvent clusters. One of 
the solvent clusters predicted was on the Leu-Leu interface in the wild-type (Figure 3-
11b). However, mutation to Ser at this position removes this potential docking site 
(Figure 3-11c). 
 
 
Figure 3-11: Positions of the mutations in the crystal structure 3K4D. (a) Positions of the active site, the 
disordered loop and the L561 residues on two subunits. L561 is at the interface of the subunit but is 
unlikely to interact. It may interact with the disordered loop to partially obstruct the active site entrance. 
(b) L561 dimeric interface with solvent clusters (dots) generated by FTMap. (c) FTMap revealed that the 
mutation to serine displaces the solvent cluster (d) Mutations that conferred stability were generally found 
at solvent-exposed loops.  
 
Hence, from structural examination, we deduce that the mutation LeuÆSer 
reduced subunit interactions by disrupting the interaction between the 561 residues of 
adjacent subunits. This increases the flexibility of the loop harbouring residue 561 
(Lp6).  This loop and the N-terminal portion of the disordered loop (residue 361-362), 
which can also interact with the leaving group of the substrate, are within accessible 
distance of each other. The two loops can partially obstruct the entrance to the active 
site (Figure 3-11a). This inevitably affects the dynamics involved in substrate binding 
and product release. Substitution to the smaller amino acid (LeuÆSer) opens up the 
aperture and consequently facilitates these events. Therefore, the pivotal mutation 
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L561S affects turnover rates more than stability. This is supported by the characteristics 
of the other Lp6 variants, which saw additional mutations to the L561S single mutant 
increase the thermostability while sacrificing some of the gain in kcat by the single 
mutation L561S. In most cases, the mutations (K596R and F593S) occurred on solvent 
exposed positions, but they are not implicated in any loop motion that is likely to 
benefit activity (Figure 3-11d). The trend in activity-stability sacrifice seen with L561S 
is congruent with observations from other directed evolution experiments21,22.  
	
	
3.4.2. Implications of screening and evolutionary strategies that were adopted 
 
In the first round of experiments, the activity of the native enzyme was high and 
the screening method failed to identify mutants with improved activity. There may have 
been mutants with enhanced activity, but the change in activity would have been within 
the systemic errors inherent in library screening. This made it difficult to identify any 
clones with improved activity. In the second set of experiments, the t-BuOH greatly 
reduced the activity of the native enzyme. In this case, the screening method could 
identify mutants that had increased activity because the increment was above the error 
levels of the screens. Therefore, it appears that it is easier to identify mutants with 
enhanced activity when starting with a template that has low activity.   
 
Although the pooling method is a powerful screening approach, it may not have 
been appropriate for the first stage evolution. Even though we had taken into account 
the various factors that would affect the discrimination of a well containing better 
clones compared to the rest of the screening plate, our reasoning had failed because we 
overestimated the improvement that we expected to see. We had chosen to pool four 
cfu/well based on accounts from the literature that proposed that pooling ten colonies 
could increase chances of detecting super-mutants (clones with five-fold 
improvement)3,23,24. We reduced the number of colonies pooled according to our 
expectation that we were unlikely to detect any super-mutants, but we had assumed that 
we would see a mutant that was at least two-fold better.  
 
The assumption that we had adopted in the pooling strategy may have been valid 
if we were screening to enhance a different function e.g. to increase one of its 
promiscuous activity such as the E-glucosidase activity. However, our aim was to 
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increase its native activity in the presence of excessive native substrate. This was with 
the hope that we could isolate a variant that has a more rapid turnover at high substrate 
load, while concomitantly raising its Km (Figure 3-12). This evolutionary pressure was 
very subtle and was almost akin to enhancing the E-GUS native activity. As such, a 
more reasonable expectation should have been 1.1–1.2 fold improvement that would 
have been well within our screening error range. In this case, even without pooling, 
discriminating these hits over the noise level of library screening would have been 
difficult. Employing the pooling strategy regardless of the number of colonies pooled 
had simply made matter worse. All these suggest that the first approach may not be as 
easy as it had seemed.  
 
We had attempted evolution by region to increase screening efficiency. This had 
worked to a certain extent because we could search a sequence space very thoroughly. 
This enabled the identification of single mutations that have pivotal roles, in this case 
L561S. This was isolated in parallel evolution – the Stage I-II evolution – and revisited 
Lp6 evolution. However, not many mutations that added benefits to L561S were found 
in these regions subsequently. The prevailing proof for this was in the fifth round, 
where most mutations were accumulated outside of the TIM-barrel region (Lp2 and Lp6 
targeted prior to the fifth round). This suggests that too many mutations introduced 
simultaneously into the active site or catalytic domain (Lp2 and Lp6) would be 
detrimental to the enzyme. A better strategy may be to screen a few regions in parallel 
and select the best progenitor from one of the regions as a template for a subsequent 
round which targets a different region. This concept would be similar to the iterative 
saturation mutagenesis (ISM) that was developed in the Reetz’s laboratory25. The 
  
 
 
	
	
	
	
	
	
 
 
Figure 3-12: Desired 
kinetic profiles from our 
hypothesis.	
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difference is that this involves the recombination of fragments rather than single sites. 
This approach had worked in the final round, where we isolated 5GUS12, which had 
regained the catalytic efficiency that was sacrificed in the previous round. This variant 
also outperformed L561S in its catalytic efficiency in physiological condition, making it 
a variant that can function well under both conditions. 
 
 
 Concluding remarks 
 
As part of the two-step strategy towards an improved glucuronylsynthase, this 
step yielded three potential candidates for the second step of the evolution – L561S, 
5GUS12 and L561S/F593S – where the mutation E504G could be introduced 
site-specifically. The mutation L561S had dominated the evolution program when 
t-BuOH was added and was determined to be important for improving turnover rate in 
t-BuOH. Hence, we took the L561S as the first variant to test in the two-step approach. 
This will be elaborated on in the next chapter. 
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4. Engineering the glucuronylsynthase  
 
4.1. Preamble 
 
In Chapter 3, we identified a mutation, L561S, which was more stable and 
performed better than E-GUS in the presence of 20% t-BuOH. We hypothesized that 
this enhancement would be translated to higher glucuronidation activity when we 
introduce EÆG mutation into the variant at residue 504 to produce the 
glucuronylsynthase (Syn) variant. Thus, we introduced this mutation into L561S using 
site directed mutagenesis. Glucuronylsynthase (Syn) and recombinant Syn L561S were 
then purified as described in Section 2.10. Purified enzymes were tested by the McLeod 
group in synthetic reactions using testosterone as the acceptor substrate. Reaction 
mixtures were incubated at 30 °C for three days and the products were analysed using 
NMR. However, we could not detect the testosterone glucuronide product for the Syn 
L561S reaction even though Syn showed approximately 65% conversion for the 
glucuronidation of testosterone (data not presented). Hence, we decided to reprioritize 
our approach and attempted instead to engineer the glucuronylsynthase (Syn)1 using the 
linear approach (Figure 4-1, right side).  
 
 
Figure 4-1: Two engineering approaches used in attempts to improve the Syn system. The two-part 
(indirect) approach was the original strategy that involves E-GUS evolution first before incorporating 
E504G mutation. This chapter deals with the direct approach. In this approach, a recombinant that already 
has E504G mutation incorporated was directly engineered instead. 
 
Before commencing the one-step approach, we devoted some effort to the 
development and optimization of a library screening method as we lacked a suitable 
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assay for Syn library screening. We also had to consider better library design – smaller 
but more effective library – because the assays that would potentially be applied for Syn 
library screening would be more demanding than the E-GUS assay. To proceed with 
assay development, we first had to contemplate the selection pressure for the screens. 
We will be describing these in this chapter.  
 
 
4.2. Setting the selection parameters for library screens 
 
There were three parameters that had to be set for the engineering endeavor: 
choice of acceptor substrate, co-solvent and glycosyl donor:acceptor ratio. All of these 
will create the selection pressure for the evolution effort.  
 
(A) Substrates 
 
Like its parent glycosidase (E-GUS), the glucuronylsynthase is specific for the 
glycosyl moiety but is expected to show a wide range of activity for different steroids. 
As our aim was to develop a variant that would be more efficient in synthesizing 
glucuronides of drug components that contain steroid acceptors, we narrowed our 
substrate selection to steroid based substrates. We were presented with three choices of 
steroid acceptor substrates: CMO-DHEA, DHEA and testosterone. They contain steroid 
scaffolds and are mostly hydrophobic. However, CMO-DHEA has an oxime group that 
aids solubility. The activity of Syn with CMO-DHEA was the most understood as this 
was used in most of the process development work in the synthetic laboratory. Hence, 
we chose CMO-DHEA as the substrate for most of our evolution work.  
 
(B) Co-solvent 
 
The addition of t-BuOH would be necessary because the acceptor substrates have 
poor solubilities2,3. In the optimization process by the McLeod group, 10% of t-BuOH 
was found to be optimal for their Syn chemoenzymatic reactions, due predominantly to 
increased steroid (acceptor substrate) solubility. Furthermore, the use of t-BuOH 
(between 5–20%) does not form t-butyl glycoside, and thus would not pose as a 
competing reaction. From these past observations, we expected that the addition of 
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more t-BuOH could improve the catalytic activity of the glucuronylsynthase. To induce 
sufficient pressure for the evolution, we doubled the amount of t-BuOH to 20%. This 
was with the hope that we would be able to isolate a more efficient and more stable 
variant compared to Syn.  
 
(C) Glycosyl donor (1FGlcA): Acceptor ratio 
 
In previous investigations, it was found that a reaction using 1:1 molar equivalent 
of 1FGlcA halted after 14 h4. This was caused by decreased availability of the 1FGlcA 
substrate over the entire course of the reaction (36 h). Hence, a higher molar 
equivalence of 1FGlcA (5:1) was used to achieve near-complete conversion rates. This 
also reduced product inhibition. We would use a ratio of 3:1 (donor:acceptor) in our 
screening procedure. 
 
 
4.3. Method Development 
 
4.3.1. General materials and methods 
 
 
All buffers were prepared as described in Chapter 2. Oligonucleotide primers for 
the incorporation of E504G and library randomization were purchased from Integrated 
DNA Technologies (IDT, Coralville, USA). The sequences of the primers are listed in 
Appendix D. The host and expression system used were BW25142 (Chapter 2.3) and 
pJ401 (Chapter 2.4). Purified enzyme solutions were obtained using manual HisTrap 
purification as described in Section 2.10.4. D-D-glucuronyl fluoride (1FGlcA), CMO-
DHEA and testosterone were prepared by the McLeod research group (Research School 
of Chemistry, ANU). Buffers and indicators that were used for the development of an 
indicator displacement assay were also prepared by the McLeod group. Mobile phases 
were prepared using chromatography-grade MeOH and Milli-Q water filtered through 
0.22 Pm filters. Chromatography-grade MeOH was purchased from Merck. Milli-Q 
water (mQH2O) was collected from Millipore water purification system. The same 
solvent system was used to quench the reactions for library screening.  
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4.3.2. Tailoring the reaction time and amount of crude lysates for screening 
 
The workflow for growth and expression was similar to the procedures described 
in Section 2.7.1.1 with one subtle difference. The volume for growth and expression 
was increased to 500 PL so that we could maximize the amount of crude lysates that 
could be obtain from growth and expression in 96-well plates. We anticipated that this 
volume would yield approximately 0.025–0.05 mg/mL of overexpressed enzyme, which 
would be enough for the library screening assays. This was based on the following 
observations. First, based on Bradford assay of crude lysate, 5 mL of 
pJ401/Syn/BW25142 grown overnight can yield 70 mg of the protein per L of cell 
culture. Second, SDS-PAGE analysis typically showed that Syn made up 50% of the 
total protein expressed. Therefore, 500 PL culture would give us approximately 
0.035 mg/mL of glucuronylsynthase enzymes. Third, in typical synthetic reactions 
using 1–2 mg/mL of purified Syn, a three-day reaction course would yield ~ 95% 
conversion of CMO-DHEA.  Hence, allowing the screening reaction to run overnight 
(12–24 h) should yield approximately 9–10% conversion of CMO-DHEA, which 
should yield sufficient CMO-DHEA glucuronide product to be detected and to 
differentiate between improved variants and Syn like variants.  
 
We set up the assays for library screening using 500 PL of overnight expressed 
cultures induced by 0.5 mM IPTG at 30 °C. Cells were clarified by centrifugation and 
resuspended in 150 PL of 50 mM NH4OAc buffer. Lysis was done at room temperature 
by adding 50 PL of 4 U/PL of rLysozymeTM and agitating the mixture at high-speed for 
15 min. Lysates were then cleared by centrifuging at 3, 700 rpm for 15 min. 150 PL of 
cleared lysate was used in 400 PL of reaction containing 2 mM (~ 0.6 mg/mL) of 
CMO-DHEA and 6 mM 1FGlcA (1:3). Reactions were incubated at 30 °C overnight for      
12–16 h. 120 PL overnight reaction was then quenched by addition of MeOH to a final 
concentration of 50% (v/v) MeOH and assayed. 
 
4.3.3. Assay designs for glucuronylsynthase screens  
 
The major challenge for Syn engineering was the development of a suitable assay 
for library screening. The most reliable and straightforward assay for detecting hits 
would be by monitoring glucuronidated products using HPLC or LCMS. However, to 
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use either method for screening an instrument with 96-well plates automation capability 
would be required. We did not have this facility at the start of the program. Instead, we 
attempted to optimize an indicator displacement assay that would allow us to monitor 
the amount of fluoride liberated.  
 
4.3.3.1. Fluoride-selective indicator displacement assay  
 
As glycosynthetic reactions generally use an D-sugar fluoride donor, the 
displacement of fluoride F- is a common feature across all glycosynthetic reactions.  
Therefore, a F- indicator displacement assay can be applied to a wide range of 
glycosynthases, including the glucuronylsynthase system. Using this method, we would 
be able to assay libraries of 103-104 clones.  
 
The F- indicator displacement assay utilizes a tetravalent zirconium (IV)-EDTA 
complex and a 2’-sulfoflavanol5. Mixing the two compounds generates a Zr-EDTA-
flavanol complex in situ and emits blue fluorescence (Oem = 460 nm). In the presence of 
free F-, 2’-sulfoflavanol is displaced and fluorescence will be quenched (Figure 4-2). 
The reduction in fluorescence intensity corresponds to the amount of F- present that can 
be used to monitor the extent of the glycosynthase reaction.  
 
 
Figure 4-2: The reaction involved in an indicator displacement assay. The F- ions generated during the 
glucuronylsynthase reaction displaces the 2’-sulfoflavanol from the Zr-EDTA-sulfoflavanol complex  
 
We tested the limit of detection of this screening assay using 0–100 PM of sodium 
fluoride, NaF. This was done by plotting the response factor, F/Fr  against variable NaF 
concentrations, where  Fr = response for 0 PM NaF and F = response at different NaF 
concentrations. The value at 0 PM of NaF solution would be an indication of the noise 
level in this assay and the F/Fr, would account for the signal-to-noise level of this 
CHAPTER 4 
	
 — 92 —
system. Using this system, we could discriminate down to 5 PM F- (Figure 4-3a). 
However, when we tested the system with crude cell lysates and 1× BugBuster™ to 
simulate the conditions of library screening, the discrimination power decreased to 
50 PM (Figure 4-3b).  
 
 
 
 Figure 4-3: Quantifying the limit of detection in the fluorescence indicator displacement assay. (a) The 
sensitivity of the assay in the abscence of cell matrices in library screens can reach as low as 5 PM. Inset 
shows the response factors at [NaF] lower than 20 PM. (b) The sensitivity of the assay is compromised in 
the presence of cell matrices. There was no discriminatory power when the [NaF] was lower than 50 PM. 
 
Two reasons may account for the reduced performance in the library screening 
simulation. First, low-levels of non-enzymatic hydrolysis of the D-D-glucuronyl 
fluoride donor could have interfered with the assay at lower F- concentrations. Second, 
the additional components that would be present under screening conditions could have 
caused the interference.  
 
We found that the presence of cell lysate raised the pH of the reaction by nearly 
one unit (Figure 4-4). The ligand-exchange reaction is known to be sensitive to pH with 
an optimal around 5.85. If the presence of other cell components causes such differences 
to the pH, then this assay is unsuitable for high-throughput screening of the 
glucuronylsynthase libraries as the increase in pH would reduce the sensitivity of the 
assay. Furthermore, the use of t-BuOH in the reactions might complicate the situation 
further. Hence, this method would be limiting and another assay was needed. 
  
4.3.3.2. Developing the LCMS method for library screening 
 
Most of the problems faced in the previous section could be circumvented with an 
LCMS fitted with auto plate screening capability. The LCMS method would be more 
(a) (b) 
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straightforward and would be capable of detecting glucuronide drugs in derivatized 
urine samples at concentrations below 10 nM6,7. When the plate LCMS became 
available, we developed two analytical procedures: one for the analysis of enzyme 
kinetics and another for rapid analysis of libraries. 
To resolve the peaks, we used an Agilent Poroshell C-18 column of 30 mm length 
and 1.8 mm diameter packed with 2.7 Pm beads attached to a 5 mm guard column. 
Temperature of the column was maintained at 30 qC. The mobile phase system 
consisted of 10% MeOH/90% 10 mM NH4OAc (mobile phase A) and 90% MeOH/10% 
10 mM NH4OAc (mobile phase B), and the flow rate was set at 0.2 mL/min.  
 
A mock reaction solution containing 6 mM 1FGlcA, 2 mM CMO-DHEA, and 
0.8 mM of CMO-DHEA glucuronide was prepared. This was then diluted two-fold in 
neat MeOH and further diluted 20-fold in MeOH/water (50:50). The signal strength for 
the glucuronide was relatively weak. Hence, the fragmentation power and capillary 
voltage (Vcap) were optimized to increase the signal to noise ratio for CMO-DHEA 
glucuronide. Table 4-1 lists the different conditions tried, with the final condition 
underlined. Using the fixed parameter, different ratios of the mobile phase solvents A 
and B were tested to optimize the separation of CMO-DHEA and CMO-DHEA 
glucuronide (Table 4-2). We also made further modifications to the method in order to 
achieve shorter analysis time without losing the resolution of the two peaks. This was 
achieved using 50:50 ratio of A/B. A calibration curve (Figure 4-5) was then obtained 
for CMO-DHEA glucuronide. The LCMS chromatograms are shown in Appendix 4-1 
(Figure A4-1). 
 
Figure 4-4: The pH values of indicator displacement assays before and after the addition of lysis buffer. 
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The optimized analytical method was then used to test enzymatic reactions with 
crude lysates. Overnight glucuronylsynthase reaction assays were then set up to 
exemplify screening conditions described in Section 4.3.2. We simulated a reaction that 
would mimic a potential hit with two times the activity of Syn by doubling the amount 
of crude lysate used in the reaction. Four 400 PL reactions for each Syn and 
hypothetical “hit” were set up. Peak areas for the hypothetical hits’s reactions were two 
times higher than the Syn (Table 4-3). This meant that we were able to discriminate 
improved variants with at least 2-fold improvement. The experiment validated the 
screening process and the analytical method.   
 
Table 4-1: The different detector parameters 
optimized. Bolded and underlined are the finalized 
parameters. 
Table 4-2: Optimization of the mobile phase to 
resolve the peaks of glucuronide and free steroid 
(CMO-DHEA). 
 
Capillary 
voltage 
(Vcap) 
Fragmentation voltage  
Mobile phase 
A:B 
Retention time (min) 
Glucuronide Free steroid 
2500 100, 175, 200, 225, 250, 275  60:40 0.91 1.31 
3000 80, 100, 175, 200, 225, 250  50:50 0.93 1.52 
3500 80, 100, 175, 200, 225, 250  35:65 0.92 1.53 
4000 80, 100, 175, 200, 225, 250  25:75 0.95 1.94 
 
To further reduce the analysis time, we performed the chromatography using only 
a 5 mm guard column. Both analytes (steroid substrate and glucuronide product) eluted 
about 0.5 minutes quicker. We lost some resolution between the peaks but the 
discrimination of the peak areas between the Syn and the hypothetical hit was not 
compromised. Hence, we proceeded with this method for library screening as we could 
decrease the analysis time to less than 0.9 minutes per sample (Appendix 4-2, 
Figure A4-2).  
 
In summary, we have developed, optimized and validated an analytical method 
that would allow us to screen the synthase libraries. We have also optimized an 
analytical method that would be suitable for kinetic characterization of the screening 
hits. The method developed for screening allowed us to detect Syn hits with two-fold 
improved catalytic rate. Approximately 400 clones were screened per night using this 
method. 
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Figure 4-5: Calibration curve of 
CMO-DHEA glucuronide for the 
quantification and validation of the 
analytical method. Inset is the linear 
response between 0 and 6 PM 
CMO-DHEA glucuronide. The final 
conditions and parameters used for 
the analytical method were 50:50 
mobile phase ratio A/B, 3000 V 
capillary voltage, 100 and 200 V of 
fragmentation voltage for the 
detection of free CMO-DHEA and 
CMO-DHEA glucuronide respective
-ly, using a 30 mm C-18 column 
appended with a guard column. 
 
Table 4-3: Validation for LCMS analytical method using Syn and hypothetical hit (2x Syn). Hypothetical 
hits (wells with two times lysate load) could be discriminated from Syn because they showed two times 
relative activity compared to 1x load of Syn. Syn sample mixtures contain CMO-DHEA, Negative 
control (neg ctrl) is a mixture containing steroid.  
 
 
 
4.4. Results and Discussion 
 
4.4.1. Glucuronylsynthase rational engineering 
 
Directed evolution represents an elegant way of engineering enzyme, but the 
success of an evolution project depends on the size and the quality of the library. The 
larger the screening capacity, the higher the chances of isolating improved variants. 
tr (min) Peak A tr (min) Peak A
Pos Ctrl 
Average 1x
Syn1 (1x) 0.931 1.50E+04 1.538 4.90E+05 3.03 0.939
Syn2 (1x) 0.931 1.60E+04 1.537 4.70E+05 3.4 1.053
Syn3 (1x) 0.928 1.50E+04 1.536 4.90E+05 3.04 0.942
Syn4 (1x) 0.933 1.70E+04 1.539 4.70E+05 3.44 1.066
Syn1 (2x) 0.931 3.10E+04 1.539 4.50E+05 6.46 2.002
Syn2 (2x) 0.922 3.50E+04 1.524 5.80E+05 5.63 1.744
Syn3 (2x) 0.923 3.00E+04 1.524 6.00E+05 4.74 1.469
Syn4 (2x) 0.931 3.00E+04 1.538 4.80E+05 5.98 1.853
Neg ctrl 0.859 307.1 1.524 638896 0.05 0
NA
Sample St-gluc St % conversion Rel act over Pos Ctrl 1x
0.93 3.00E+04 1.523 6.20E+05 3.23
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This poses a challenge for directed evolution experiments that are performed without 
the convenience of high-throughput screening facilities. This challenge can be 
overcome using directed evolution approaches that engineer enzymes based on 
structure-guided knowledge (semi-rational engineering). Structure-guided evolution 
approaches aim to create smarter libraries, i.e. small but effective libraries, and involve 
screening libraries targeted at a specific site (site-saturation libraries) or at a particular 
region. We employed semi-rational design for directed evolution of the Syn so that the 
throughput of the libraries could be managed.  
 
Targets for semi-rational engineering were chosen based on the consideration that 
the substrate system of the parent β-GUS and the E-GUS/E504G variant, Syn, is 
different. The β-GUS binds glucuronide, while the Syn binds glucuronyl fluoride of a 
different anomeric configuration and releases glucuronide. Therefore, the substrate 
system of the glucuronylsynthase is different from its parent. This may contribute to 
suboptimal binding of the glucuronylsynthase substrate and result in modest 
performance. Furthermore, the E504G mutation prevents the enzyme from forming a 
glycosyl-enzyme covalent bond, the reaction intermediate. This prevents the formation 
of the intermediate state that in the parent enzyme is highly stabilizing8,9. In several 
studies, it was found that the intermediate in E-glucosidase offers a transition state 
stabilization up to 10 kcal/mol through substrate-enzyme interaction at the glycosyl C2 
position8,10. In one directed evolution experiment of a glycosynthase, it was postulated 
that the mutations accumulated in the improved glycosynthase mutant was imparted by 
conformational changes that resulted in the restoration of the transition state interactions 
at C211. Based on this, we rationalize that choosing sites that are on the flexible loops 
close to the Syn substrate binding pocket may yield useful mutations that would favour 
the new substrate system and subsequently lead to enhanced glucuronylsynthase 
activity. Following this rationale, we chose eight different sites for single-site saturation 
mutagenesis and performed random mutagenesis on a disordered loop in the active site 
region. Each of the experiment is discussed separately in the following sections. 
 
4.4.1.1. Site saturation mutagenesis (SSM) 
 
Our targeted sites for site saturation mutagenesis study (SSM) were: (i) 160, 162, 
and 164, which we refer to as the Domain 1 cluster, (ii) 361 and 362, which will be 
referred to as the disordered loop sites and  (iii) N412, M447, and D508. These sites are 
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not directly involved in substrate binding but they reside on flexible loops that harbor 
other residues that are involved in substrate interaction (Figure 4-6). As such, they may 
alter the active site plasticity to accommodate a two-substrate system or stabilize the 
active site conformation in favour of the glucuronylsynthase substrates.  
 
We used degenerate NNK codons to randomize each site separately (where 
N=a/c/g/t and K=g/t). This would encode all 20 amino acids with a degeneracy of 32 
codons per 20 amino acids. The library size for NNK randomization was calculated 
according to the algorithm used in CASter12,13 (Appendix 4-3). We screened 84 clones 
in each library using 2 mM of CMO-DHEA and 3 molar equivalent of D-glucuronyl-
fluoride (1FGlcA) donor. Using the algorithm described in Appendix 4-3, this would 
achieve approximately 85% coverage of the libraries. Table 4-4 summarizes the quality 
of the library, the quality of the screens and the activity distribution in each library. 
 
  
 
	
	
	
	
	
Figure 4-6: Sites (turquoise and blue) 
targeted for single-site saturation 
mutagenesis are labeled. Active site 
residue E413 and a glucaro-G-lactam 
inhibitor in the crystal structure (PDB 
ID:  3K4D) are shown with carbons in 
white. The inactivated nucleophilic 
residue (E504G) is shown as dots and 
labeled as G504. 
 
The coefficient of variation (% CV) was higher than the ideal 20%14. This was 
because we had less control over the evaporation of t-BuOH co-solvent from 96-well 
plates during the course of a 12–16 h reaction. As a result, the problem of edge 
effects15,16 was more pronounced than what we encountered in the previous chapter. We 
attempted to minimize this effect by using higher volumes of reaction volume (400 PL 
as opposed to the typical 200 PL reaction volume used in previous chapter) and by 
double sealing the assay plates. This reduced the % CV, but still did not eliminate the 
risks of false-positives and false-negatives. To minimize our chances of missing 
potential hits, it was thus necessary to conduct a secondary screen.  
D508 
GDL 
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Table 4-4: Summary of Syn SSM library screening. % of wells that were at least half as active as  Syn 
(> 0.5x) and % of wells that had less than 20% glucuronylsynthase activity compared to Syn. Sites 160, 
162, 164, 361 and 362 are less susceptible to mutations compared to sites 412, 447 and 508. % CV and 
mutation frequency are the indicators of the screening quality and library quality. 
Sites 
Assay Statistics Library quality 
> 0.5x Syn 
activity (% well) 
< 0.2x Syn 
activity (% well) 
Inter-plate 
% CV 
Mutation frequency 
(%) 
160 100 0.00 26.0 64 
162 84.4 2.08 28.0 60 
164 100 0.00 33.0 50 
361 85.4 2.08 16.0 60 
362 89.6 4.17 16.0 60 
412 36.5 61.5 33.0 65 
447 26.0 39.6 35.0 66 
508 27.1 61.5 32.0 62 
 
 
Secondary screen was conducted on the top 10% wells from libraries that were 
neutral. Some of the clones isolated in the primary screening were identified as false 
positives as they did not perform as well as they did in the primary screens. Clones that 
showed as much glucuronylated product as Syn in the secondary screen were also 
sequenced. A few false positive clones from library 361 were also picked for 
sequencing. These were identified as L361A and L361V. Table 4-5 lists the relative 
activities of the variants in the secondary screen. The clones that were confirmed by the 
secondary screen to have the best improvement in their respective libraries, Y160G and 
H162Q, were purified and characterized. Their kinetic properties will be discussed in 
Section 4.4.2.  
 
Table 4-5: Relative improvement of various mutants in secondary screen. Mutants were confirmed as 
false or true hits in the secondary screen. Standard deviations were taken from three replicates. 
Mutants Relative improvement over SynWT (Average) Description 
Syn 1.00 ± 0.07 Parent (Control)  
Syn Y160G 1.59 ± 0.24 Potential positive hit  
Syn Y160V 0.84 ± 0.19 Neutral mutation  
Syn H162A 1.50 ± 0.09 Potential positive hit  
Syn H162F 1.44 ± 0.21 Potential positive hit  
Syn H162P 1.06 ± 0.08 Neutral mutation  
Syn H162Q 1.77 ± 0.21 Potential positive hit  
Syn H162R 1.14 ± 0.12 Neutral mutation  
Syn L361A 0.42 ± 0.01 False positive  
Syn L361V 0.92 ± 0.12 False positive  
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4.4.1.2. Disordered loop targeted random mutagenesis 
 
We targeted a disordered loop (360-370) for random mutagenesis. A random 
library focused on residues 286–420 was generated such that it included the disordered 
loop, an N-terminal flanking region of 73 residues and a C-terminal flanking region of 
50 residues. This region is also approximately half of the TIM-barrel (active site 
domain) and is positioned spatially opposite the inactivated nucleophilic residue E504G 
(Figure 4-7a). Engineering of this region may lead to the alteration of active site 
preference to accommodate the Syn substrates. 
 
Ten clones were randomly picked to determine the average mutation rate (µ). The 
P determined was 1.0 amino acid change per gene (standard deviation, V = 0.67). The 
standard deviation differed slightly from the theoretical standard deviation 
(Vtheoretical = 1.0) for the calculated P assuming Poisson distribution. The difference 
reflected a deviation from the Poisson distribution that could have been caused by the 
small sampling size used in the P determination. Approximately 550 clones in six 96-
well plates were screened. Based on the empirically determined P, the screening size 
covered about 15% of the theoretical library size (150C1 x 20 possible amino acids in 
each position, where the number of residues randomized = 150). 40% of the library was 
nearly as active as Syn, and indicated the neutrality of the region towards mutations 
(Figure 4-7b).  
 
 
 
Figure 4-7: Screening of the targeted random mutagenesis library. (a) The region that was subjected to 
random mutagenesis (blue). This region encompasses the disordered loop (red) and makes up the part of the 
TIM-barrel that is opposite the E504G (shown as dots). (b) Distribution of the synthase library relative 
activities (ranked in order) in six plates. Inset shows the inter-plate variation in each plate. 
(a) 
(b)
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Several clones appeared to be better than the Syn. However, when eight of these 
were sequenced, six of them were confirmed as Syn. False identification was caused by 
a slightly higher inter-plate variation in one of the plates (~ 35%). When we closely 
examined the distribution of activity within the library (Figure 4-7), even though the 
sequenced mutants appeared to have more than 1.5-fold improvement in activity, there 
were other control wells (red bars in Figure 4-7) that had as high as 2-fold 
improvement. Consequently, this plate was more susceptible to false positives. Of the 
eight clones that were sequenced, the other two contained single mutations P371T and 
K372E respectively. These were purified and characterized to confirm their catalytic 
properties.  
 
4.4.2. Kinetic properties of glucuronylsynthase and its variants  
 
Kinetic parameters for glucuronylsynthase variants H162Q, Y160G, P371T and 
K372E in the presence of 20% t-BuOH were measured. We also recombined the two 
mutations P371T and K372E with H162Q and characterized them. Table 4-6 lists the 
variants that were characterized and the mutations that they harbor.  
 
Table 4-6: Mutations in the variants that were kinetically characterized. Kinetic parameters for Syn and 
six Syn variants were obtained. 
Variants Mutations 
Syn E504G 
Syn Y160G E504G + Y160G 
Syn H162Q E504G + H162Q 
R2V1 E504G + P371T 
R2V2 E504G + K372E 
R3V1 E504G + H162Q + P371T 
R4V2 E504G + H162Q + P371T + K372E 
 
Kinetic characterization was first performed using CMO-DHEA concentrations 
between 0 mM and 4 mM, but when we attempted to fit the data to the 
Michaelis-Menten (MM) model, these concentrations appeared to be significantly lower 
than the Km. We repeated some the experiment with higher concentrations of 
CMO-DHEA i.e. 8, 10 and 12.5 mM. However, even at these concentrations, the Vmax 
was not approaching saturation (Figure 4-8) and signifies that we were still operating at 
concentrations below the Km value for the CMO-DHEA acceptor substrate. 
Consequently, the parametric values kcat and Km determined from these plots may still 
CHAPTER 4 
	
 — 101 —
be inaccurate. Therefore, we determined the kcat/Km by extrapolating the linear slope at 
low substrate concentrations in the rate plot (Figure 4-8, dotted lines).  
 
At low substrate concentrations i.e. concentrations lower than the Km (Km << [S]), 
the MM equation can be simplified to vo = Vmax[S]/ Km as the [S] term in the 
denominator of the MM equation approaches zero17. Hence, at low substrate 
concentrations, vo exhibits linear dependence with [S], and the Vmax/Km (i.e. kcat/Km) can 
be determined from the linear slope extrapolated from the low [S] concentrations in the 
rate plot17. This would give a more accurate estimate of the enzyme’s catalytic 
efficiency than from using the kcat and Km parameters obtained from the MM curve-fit 
obtained under non-saturating substrate concentrations, as is the case for the 
glucuronylsynthase and its variants.  
 
 
 
Figure 4-8: Plots of initial rates versus increasing CMO-DHEA concentration for Syn (blue) and Syn 
H162Q (black) and the curve-fit parameters from applying the Michaelis-Menten model. Data was taken 
from three measurements, n = 3. Saturation could not be obtained even though the regression values 
indicated a good fit of data. Curve-fit parameters may be inaccurate. The kcat/Km parameters were 
determined from the extrapolated slope (dotted lines) of the plot.  
	
To compare the improvement in catalytic activity, we compared the turnover rate 
of the variants at sub-saturating CMO-DHEA concentration (4 mM). Under this 
condition, single mutant Syn H162Q was the most efficient with a rate of 0.80 x 10-2 s-1, 
followed by Syn Y160G that has a turnover rate of 0.25 x 10-2 s-1 (Figure 4-9a).  Hence, 
the single mutant, Syn H162Q catalyzed the synthetic reaction by approximately 4-
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times quicker than Syn, while Syn Y160G only improved the glucuronylation activity 
by 1.5-times with 4 mM CMO-DHEA. Values of kcat/Km (obtained from initial vo) also 
point towards the variant Syn H162Q to be approximately 4-times more efficient than 
Syn (Figure 4-9b).  Hence the mutations Y160G and H162Q improve both the turnover 
rate and enzyme efficiency simulataneously by 2 and 4-times respectively.  	
 
 
Figure 4-9: Kinetic characterization of Syn and Syn variants. (a) The initial vo of enzymes using 4 mM of 
CMO-DHEA acceptor substrate. The standard deviations were taken from at least three independent 
replicates, n = 3. (b) The trends of CMO-DHEA kcat/Km for Syn and the variants determined from the slope 
of vo against [S]. Error bars indicate the standard deviation from three data sets,  n = 3. 
 
We recombined Syn H162Q with P371T and K372E. In the absence of H162Q 
mutation, the mutations P371T and K372E were worse than the Syn. This trend is 
different from the screening data where both mutants were identified as potential hits 
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with at least two-times the activity of Syn. The kinetics experiment here therefore 
confirm that these were also false positives. Nevertheless, when the mutations were 
recombined with H162Q, the variants R3V1 and R4V2 appeared to be 2-times more 
efficient than Syn. Nonetheless, both recombined variants were not as good as single 
mutant Syn H162Q. The observations provide confirmation that the H162Q mutation is 
indeed advantageous, but both P371T and K372E mutations are in fact slightly 
deleterious. The mutations H162Q, P371T and K372E also appeared to be interacting in 
an additive manner i.e. the effects of the mutations combine additively.  
 
The difficulty in reaching kinetic saturation that we faced was also reported by 
Wilkinson et al.2, and is a reflection of the high Km for the acceptor substrate. This is 
expected since the wild-type (E-GUS) from which Syn was derived is known to be 
glycosyl specific, but a generalist for the acceptor moiety. This feature is advantageous 
to us for the purpose of developing a system that can be applied to a broad range of 
acceptor substrates. To investigate the potential broad range applicability of the Syn 
variants, we compared the relative performance of Syn, Syn Y160G and Syn H162Q in 
the presence of sub-saturating levels of acceptor substrates – 4 mM testosterone and 4 
mM CMO-DHEA (Figure 4-10). Both mutations conferred similar enhancement in 
glucuronylation activity for both steroidal substrates. This suggested that the variants 
would be capable of faster glucuronylation with a broad range of acceptor substrates. 
 
 
Figure 4-10: Investigating the relative performance of Syn variants with different steroid acceptor 
substrates. The steroid acceptor substrates tested were: (a) CMO-DHEA, and (b) testosterone. (c) The 
relative performace of Syn variants tested against the two acceptor substrates at a fixed substrate 
concentration of 4 mM. 
(a) 
(b) 
(c) 
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4.4.3. Stability of glucuronylsynthase and its variants 
 
4.4.3.1. Half-lives in t-BuOH and thermostability 
 
Acceptor substrates of the glucuronylsynthase system that will be of practical 
interest are typically hydrophobic. Examples include codeine and steroidal compounds, 
such as CMO-DHEA and testosterone. The use of t-BuOH as a solvent overcomes the 
solubility issues of hydrophobic acceptor substrates and improves the reaction rate2,3. 
This necessitates the addition of t-BuOH in the glucuronylsynthase reaction but its 
stability in solvents had not been determined. Furthermore, the duration to achieve full 
conversion of CMO-DHEA is considerably long (2–3 days)1–3. It would be interesting 
to know if the Syn and its variants remain active throughout the course of the reaction. 
Hence, we measured the half-lives of the Syn and single mutants (Syn H162Q and Syn 
Y160G) in 20% t-BuOH. Enzyme solutions were incubated with 20% t-BuOH at 30 ºC 
between 0 h and 12 h. Incubated solutions were sampled at 1, 2, 4, 7 and 12 h. The 
residual activities of the enzymes sampled at different time points were plotted as a 
function of incubated time. The half-lives (Table 4-7) were then determined from the 
sigmoidal function described in Section 2.11.6.  
 
  We observed half-lives (t1/2) 
of less than 2 h for Syn and less 
than 30 min for the 
glucuronylsynthase variants 
(Table 4-7). These values were 
considerably shorter than the usual 
reaction duration of 24–36 h, and 
were incompatible with our observation from monitoring glucuronide production during 
the synthetic reactions. The glucuronide peak area continued to increase even after 12 
hours. This discrepancy could be reconciled with the fact that we had performed the 
incubation for stability study without a ligand or substrate18. We suspected that the 
presence of 1FGlcA substrate stabilized the glucuronylsynthase enzyme in the reactions. 
To verify this, we monitored the unfolding of the enzyme in the presence and absence 
of 1FGlcA (Figure 4-11) using circular dichroism (CD)19,20. Without 1FGlcA, alteration 
to the secondary structure of the enzyme was observed within the day (Figure 4-11(a–
b)). However, in the presence of 1FGlcA, the secondary structures of mutant enzymes 
Table 4-7: Half-lives of Syn, Syn Y160G and Syn H162Q 
in 20% t-BuOH from three replicates (n=3).
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remained unchanged (as determined by CD) after overnight incubation in t-BuOH 
(Figure 4-11(c–d)).  
 
The stabilization effect of 1FGlcA was also observed in a thermal shift assay 
experiment. We obtained the Tm of the enzymes using the procedures described in 
Section 2.12.1 and observed that the Tm of the enzymes increased significantly with the 
addition of 1FGlcA (Figure 4-12). This observation is similar to other experiments that 
have described the stabilizating effects of substrates and ligands18. We also compared 
the degree of stabilization by 1FGlcA on the variants by estimating the percentage 
difference in the Tm with 1FGlcA and without 1FGlcA (Figure 4-12a). Thus, the larger 
 
Figure 4-11: Alteration in the secondary structures of Syn and Syn H162Q monitored by circular 
dichroism (CD). (a) Changes in the secondary structure of Syn without 1FGlcA (b) Changes in the 
secondary structure of SynH162Q without 1FGlcA (c) Changes in the secondary structure of Synwith 
1FGlcA (d) Changes in the secondary structure of Syn H162Q with 1 mM of 1FGlcA. The variants lose 
structural integrity rapidly in the absence of 1FGlcA but remains unchanged overnight when 1FGlcA was 
present. 
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the percentage difference, the larger is the ligand stabilization effect. The increase in the 
Tm induced by the presence of 1FGlcA was the most significant for Syn H162Q, 
suggesting that the variant is more stabilized by the substrate than the parent Syn. 
Increased ligand stabilization effect by the mutation H162Q can be explained by the 
inter-domain interaction between the loop in Domain 1 and the active site  
(Figure 4-12b).  
 
 
 
Figure 4-12: Effects of 1FGlcA on Tm. (a) The stabilization afforded by 1FGlcA for each variant. The 
values of Tm with and without 1FGlcA for the three variants are listed in the inset table below the plot. (b) 
The inter-domain interaction between Domain I and the active site in the crystal structure with a glucaro-
δ-lactam (GDL) inhibitor. D163 is a substrate-binding site approximately 3.2 Å away from the 
carboxylate group of GDL. (c) Thermal dissociation curves with and without 1FGlcA for (i) Syn, (ii) 
Syn Y160G (iii) Syn H162Q. Syn appears to be more thermostable compared to the variants.  
 
In addition, we also observed a shoulder during dissociation (in black) in the 
thermal denaturation profiles of enzymes incubated with 1FGlcA (Figure 4-12c). This is 
comparable to the biphasic transition that was observed in the endotherms of other 
enzymatic systems at subsaturating ligand concentration21,22. Our observations can be 
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accounted for by considering the simplest model for the denaturation of an enzyme: 
Folded (F) ↔	Unfolded (U). During denaturation, the two forms are in equilibrium and 
at Tm they exist in 1:1 molar ratio. In the presence of ligand, the folded form binds a 
ligand molecule that upon unfolding, is released. At subsaturating ligand concentration 
level, the released ligand can be taken up by a transient intact enzyme molecule21,22. 
Consequently, this gives rise to the biphasic transition that is seen during denaturation 
of enzymes with subsaturating ligand concentration. In our case, the presence of the 
shoulder in the thermal dissociation curves suggests that the event of 1FGlcA exchange 
between the unfolded and folded forms occurs during denaturation of the Syn variants 
when 1FGlcA is present as a ligand.  
 
The different degree of ligand stabilization afforded by the presence of 1FGlcA 
for the three variants suggests that the interaction between Domain I and the active site 
has changed and this may have affected the substrate affinity of this loop. The loop that 
harbours residue H162 is involved in ligand and substrate binding through the 
neighbouring residue D163 (Figure 4-12b). When the ligand 1FGlcA is bound in the 
active site, the interaction between this residue and the ligand locks the loop in place, 
thereby increasing the rigidity of the enzyme and hence, the stability. The mutation 
H162Q may change the affinity of this loop for the 1FGlcA ligand and thus, result in 
higher degree of 1FGlcA stabilization for the Syn H162Q variant.  
 
4.4.3.2. Inactivation of glucuronylsynthase in the presence of t-BuOH and urea 
 
 
The activities of Syn and variants, Syn Y160G and Syn H162Q, at different 
t-BuOH concentrations were determined. Enzyme solutions were incubated in different 
t-BuOH concentrations for two hours at 30 ºC. Their activities after incubation were 
determined using reaction assays containing 4 mM of steroid CMO-DHEA and 3 mM 
glycosyl fluoride. Residual activity was calculated using the activity of the samples 
incubated with 0% t-BuOH as the reference. To monitor urea-induced denaturation, 
enzyme solutions were incubated in urea for 30 min at 30 °C. Urea induced 
denaturation was observed using intrinsic fluorescence as described in Section 2.12.2. 
Unfolding was monitored in the presence of 2–8 M urea. The concentrations of t-BuOH, 
([t-BuOH]50) and urea ([Urea]50) at which the enzymes lost 50% of their initial activity 
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or are 50% unfolded (Table 4-8) were determined from sigmoidal curve fit values 
(Figure 4-13). 
 
Table 4-8:  The concentration of t-BuOH at which 50% of the activity is lost for Syn and the variants and 
the concentration of urea at which 50% of the enzyme samples were unfolded. 
 
 
 
Urea (M) t-BuOH (%) 
Syn  4.62 (± 0.088) 21.8 (± 0.66) 
Syn Y160G 2.38 (± 0.020) 15.7 (± 1.50) 
Syn H162Q 2.04 (± 0.032) 19.5 (± 0.83) 
 
Unfolding of the enzymes in urea was observed with a red-shift in fluorescence. 
The wild-type glucuronylsynthase could tolerate higher concentrations of urea before it 
was fully unfolded. This and the earlier data on thermostability indicate that the variants 
have traded-off some biophysical properties in exchange for improved catalytic activity. 
This trade-off effect23–25, is a common occurrence in evolution when attempting to 
evolve for enhanced catalytic property because activity and stability are governed by 
different features. It is widely believed that stability benefits from an increase in 
structural rigidity while some degree of structural flexibility is required to modulate the 
activity. We would not have been able to increase both rigidity and flexibility at the 
Figure 4-13: Inactivation of the enzyme solutions in t-BuOH and urea. (a) Residual activities of the 
enzymes as measured using reactions containing 3 mM donor substrate and 4 mM acceptor substrate. (b) 
Unfolding of the enzymes in urea was monitored using intrinsic fluorescence and by comparing the 
ellipticity measurements at 325 nm and 345 nm. 
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
0 10 20 30 40 50 60 70
Stability in t-BuOH
(Syn and R1)
Syn H162Q Syn Syn Y160G
R
el
at
iv
e 
ac
tiv
ity
[t-BuOH] %
-0.02
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
-2 0 2 4 6 8
E J O
In
tr
in
si
c 
Fl
uo
re
sc
en
ce
 
ln
 (3
25
/3
45
nm
)
[Urea] M
Intrinsic F
E=H162Q, J=Syn, O=Y160G(a) (b) 
CHAPTER 4 
	
 — 109 — 
same time with only a single mutation (Y160G or H162Q). This would have caused the 
trade-off that was seen in our case.  
 
Intriguingly, although we had evolved Syn H162Q and Syn Y160G to have higher 
catalytic activity in the presence of 20% t-BuOH, we have not managed to increase its 
[t-BuOH]50, its t-BuOH tolerance. When this result was compared alongside the 
thermostability profiles and the half-lives without 1FGlcA obtained in the earlier 
section, Syn consistently showed higher stability compared to its variants. All the 
results taken together indicate that we have increased the dependence of the variants on 
the 1FGlcA to stabilize them. 
 
Overall, although we have increased the synthetic activity of the 
glucuronylsynthase variants, Syn Y160G and Syn H162Q, we have made small 
sacrifices in their biophysical properties. We have likely increased their dependence on 
1FGlcA to stabilize the enzymes. This corroborates earlier discussions that suggested 
that the intrusion of the loop from Domain I into the active site in Domain III plays a 
significant role in substrate binding and that the role of this loop in substrate binding is 
also an important factor for the stabilization of the glucuronylsynthase active site.  
 
4.4.4. The trend in glycosyl binding properties of Syn and variants 
 
Isothermal calorimetry titration (ITC)26 experiments are used to determine binding 
parameters by measuring the heat absorbed or heat liberated during the binding event. 
ITC does not establish kinetic parameters but its thermodynamic parameter (Ka or Kd) is 
often taken as an approximation of an enzyme’s Km values27,28. ITC can therefore be 
used to estimate the binding affinities of the three variants for the 1FGlcA substrate. 
The disadvantage of using this method to quantify the binding affinity of the 
glucuronylsynthase with the 1FGlcA is that, measurements may be complicated by 
background hydrolysis of 1FGlcA. However, analysis of the binding isotherm 
(Appendix 4-4, Figure A4-4) did not indicate the presence of background hydrolysis, or 
the background hydrolysis is not significant enough to completely swamp the heat 
liberated from the binding event. In addition, 1FGlcA is used as a substrate in 
enzymatic reactions that were run over 3–5 days, which implies that the background 
hydrolysis, if present, should be on a longer timescale than the ITC experiment that 
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takes approximately two hours. The results from ITC can therefore give an 
approximation of the trends in the binding affinity among the different variants. 
 
The ITC experiments were carried out as detailed in Section 2.12.4. Independent 
measurements (n = 2) to estimate the dissociation constant (Kd) were performed using 
100 µM of freshly prepared enzyme and 4–5 mM of freshly prepared ligand. The ligand 
used was 1FGlcA prepared in 50 mM phosphate (NaPi) buffer, pH 7.4. We titrated 
1.25 PL of 1FGlcA into the enzyme, with an equilibration time of 300 s between each 
injection. A non-linear regression global curve fit was used to calculate the binding 
parameters. The binding was exothermic (∆H < 0) and a best fit with stoichiometry 
n	= 1 was obtained from an independent model using the curve-fitting function on 
NanoAnalyze (TA Instruments). The affinities of the glucuronylsynthase variants for 
1FGlcA were significantly higher than Syn. Dissociation constants (Kd) for Syn, 
Syn Y160G and Syn H162Q were determined to be in the order of 10-4 M (Syn), 10-5 M 
(Syn Y160G) and 10-6 M (Syn H162Q) (Figure 4-14). Representative binding isotherms 
for the three samples are shown in Appendix 4-4.   
 
 
 The standard deviations for replicates of ITC measurements on Syn were large 
and mirrors previous attempts in the McLeod group where their binding parameters 
were also estimated with large standard errors4. Although this indicated some degree of 
inaccuracy in the determination, it also served as an indication of its weak affinity for 
 
Figure 4-14:  The dissociation constants (Kd) for Syn, Syn Y160G and Syn H162Q. Inset is a magnified 
view of Syn Y160G and Syn H162Q. Syn H162Q appears to have increased affinity for the substrate. 
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1FGlcA. In both instances, the suboptimal binding of Syn with 1FGlcA would cause 
low values of the critical parameter, c, which determines the shape of its binding 
isotherm. This is determined by the equation26,29: c = Et x Ka , where Et = total enzyme 
concentration, Ka = determined association constant. The critical parameter, c, is related 
to the steepness and the resolution of the titration curve. A lower c-value indicates that 
the binding is too poor and the titration curve is too shallow for accurate determination 
of the Ka parameter. For accurate determination of the binding constant, the value of c 
should fall between 10 and 10029. Since the binding of Syn with 1FGlcA is weak, the 
c parameter would have been too small for its Ka to be determined with high accuracy 
(Table 4-9). However, the measurements for Syn Y160G and Syn H162Q were more 
accurate as the requisite in the c parameter was easier to satisfy because they both had 
better affinity for 1FGlcA than the Syn.  
 
Table 4-9: The values of the c-parameter in Syn and the variants. The enzyme concentration used was 100 
µM. The required total enzyme (Et) to achieve c-parameter of at least 10 is given in the last column. For 
Syn H162Q, the required Et is less than what was used. Using 100 µM of the enzyme solutions, we 
achieved the required 10<c<100 for SynH162Q. 
  Et used c-parameter Required Et* 
Syn 100 µM 0.28 3601 
SynY160G 100 µM 7.24 138 
SynH162Q 100 µM 14.1 70.7 
 
 
To summarize, the glycosyl substrate binding affinities of Syn and the two 
variants can be ranked as such: Syn H162Q > Syn Y160G > Syn. The Kd determined for 
Syn with 1FGlcA (355 PM) also agrees well with the Km of the Syn with 1FGlcA 
(200 PM) that was determined by Wilkinson et al.2 When we compared the Kd values 
with the kinetic parameter kcat/Km, the trend reflects a correlation between increased 
affinity for 1FGlcA of the variants, Syn Y160G and Syn H162Q, and their catalytic 
efficiencies (Figure 4-15). This also agrees with our earlier experiment in the thermal 
shift assay in which Syn H162Q and Syn Y160G both saw larger stabilization effects by 
the 1FGlcA substrate and that suggests that the loop conformation change induced by 
the mutations increased substrate affinity. 
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Figure 4-15: Trends in Kd and kcat/Km of the Syn variants. Improvement in catalytic efficiency seemed to 
be correlated with higher affinity.  
 
	
4.5. Structural deduction of mutations Y160G and H162Q 
 
The consequence of Y160G mutation can be rationalized from the crystal 
structure of E-GUS (PDB ID: 3K4D)30. Y160 forms a H-bond with S557 (Figure 4-16) 
that will be disrupted when tyrosine is replaced by glycine. Consequently, the mobility 
of both loops increases. In the case of residue 160, an increase in the dynamics of this 
loop changed the substrate binding property, thus changing its glycosyl affinity. 
However, disruption to the Y160-S557 bond also caused the flexible loop harbouring 
S557 to be less rigid. Since the S557 loop is involved in subunit interactions, decreasing 
its rigidity would result in lower stability. As a result, Syn Y160G exhibited increased 
activity but lower stability. 
 
Figure 4-16: Interaction between Y160 
and S557. 
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The mutation H162Q does not appear to be directly involved in glycosyl binding.  
In the crystal structure, the side chain of H162 points away from the active site 
(Figure 4-16). The only possible interaction that a glutamine at position 162 may have 
is a hydrogen bond between its carbonyl group on the side chain with its backbone 
amino group. HisÆGln mutation may rigidify the loop to facilitate better interactions 
between its neighboring residue, D163 with the non-native D-glucuronyl substrate 
(1FGlcA). The large % change in Tm observed upon the addition of 1FGlcA suggests a 
high degree of stabilization by the presence of the ligand, which supports this line of 
reasoning.  The new loop conformation induced by Q162 may restore some of the 
stabilizing effects of the transition state in the native hydrolytic enzyme that would have 
been lost with the substitution at the nucleophilic residue. As proposed in the work by 
Kim et al., restoration of the glycosyl C2-hydroxyl group interaction with the enzyme 
was one main reason that accounted for the improvement brought about by their 
mutations11. Along a similar line, we postulate that the mutation H162Q changes the 
dynamics of the loop that alters the interaction of its neighbor, D163, with the active site 
pocket. Consequently, this adjusts the active site conformation to favour the 
glucuronylsynthase donor substrate of an inverted anomeric configuration.  
 
 
Figure 4-17: Position and spatial orientation of residue 162 and 163 in the crystal structure. His Æ Gln 
mutation at position 162 was performed using the mutagenesis function on PyMol with an RMS value 
0.027. The side chain of residue 162 points away from the active site and does not interact with the GDL 
inhibitor (substrate analogue), but is capable of hydrogen bond interaction with its backbone amino 
group. Altering this residue may have changed the position of the loop so that the binding affinity 
between D163 and the inhibitor (GDL) also changed. 
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4.6. Conclusion and future directions 
 
Our experiment shows that targeting sites that can modulate loops that affect 
glycosyl binding has been a reasonable strategy for engineering a faster 
glucuronylsynthase. Glucuronylsynthase single site-saturation libraries Y160 and H162 
each produced a variant (Syn Y160G and Syn H162Q) that were two and four-times 
more efficient than Syn. Our thermal shift assay experiment suggests that there may be 
a causal relationship between 1FGlcA binding affinity and the stabilization of the active 
site pocket through better substrate-enzyme interaction. X-ray crystal structures of the 
glucuronylsynthase soaked with a 2’deoxy-2,2-difluoro-D-glucuronyl fluoride as a 
substrate analogue may provide structural evidence to support this. In addition, since 
both mutations appear to reduce the stability of the enzyme, it may be worthwhile to 
consider an evolution for increased stability before recombining the mutations.  
 
Surprisingly, random mutagenesis of the disordered loop that is located in the 
active site space did not yield any beneficial mutants. This loop is poised for loop 
reconfiguration that can affect glycosyl-enzyme interactions. The best mutations 
identified (P371T and K372E) from screening this library were confirmed to be slightly 
deleterious when combined with the Syn or with Syn H162Q. It seems that targeting 
this region is disadvantageous for improving the glucuronylsynthase activity. 
Nevertheless, it must be noted that the library was generated with low mutation rate (P 
= 1), which could produce a neutral library. Furthermore, the screening data for this 
library was associated with large errors. Consequently, there may be minute 
improvements or neutral mutations that were not detected. Since the accumulation of 
neutral mutations can act synergistically to produce an overall improvement, evolution 
of this loop and nearby regions may warrant a second investigation.  
 
The outcome from incorporating E504G into L561S showed that our initial 
strategy was not effective. We thought that this was due to increased competing 
hydrolytic activity (Figure 4-16). However, we were not sure how this could have 
arisen. We made two inferences. First, the serine mutation (L561S) reactivated the 
hydrolytic activity. This would be possible if the introduction of mutation E504G has 
not completely abolished the parental activity.  In the seminal work on glycosynthases 
done by the Withers group31, they quantified that their glycosynthase retained 
CHAPTER 4 
	
 — 115 — 
(8  x  10-6)% of the glycosidase activity. This is very low but it suggests the possibility 
that a variant with improved glycosidase activity could have higher background 
hydrolysis when E504G is incorporated. 
 
Second, there was wild-type contamination. Since the glucuronylsynthase activity 
is very low and the E-GUS activity is very high, slight contamination of the E-GUS 
species may reverse the accumulation of glucuronide product from the 
glucuronylsynthase reaction, thus inhibiting the synthetic reaction. However, we could 
not pinpoint the source for E-GUS contamination. It could be caused by human error or 
from using the wrong expression system. Yet, a third possible contamination source 
may have been translational misincorporation. This had been quoted in the literature32, 
but had never been systematically investigated. We will describe this in the next 
chapter.   
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5. E-GUS contaminant and translational misincorporation in the glucuronylsynthase system 
 
5.1. Introduction 
 
In Chapter 4, we attributed the absence of glucuronylsynthase activity in Syn 
L561S to wild-type contamination. We suggested several possibilities of contaminating 
sources. One of these was translational misincorporation. In this chapter, we will show 
that wild-type contamination from translational misincorporation can give rise to wild-
type contamination that can affect the performance of the glucuronylsynthase system.  
 
Translational misincorporation is a biological event that arises from errors during 
protein synthesis. This can be caused by inaccurate base transcription or codon 
translation. Resulting from this is the introduction of trace amounts of contaminating 
species, which can reduce the quality and yield of desired protein. The rate of 
translational misincorporation varies depending on the protein and the expression 
system that is used. Production of recombinant protein under unnatural environment and 
high metabolic burden can increase the rate of misincorporation. Nevertheless, the rates 
of misincorporation are typically quoted as 1:106-8 for base transcription1 in E. coli, and 
1:103-4 for codon translation2–4 in E. coli and mammalian expression systems.  
 
Generally, the rates of misincorporation are too low for it to be detected or for it 
to cause adverse effects. However, occasionally, misincorporation may lead to 
observable altered function5,6 or protein misfolding7. As such, translational 
misincorporation can have far-reaching consequences for protein structure and function 
studies. It also represents a niche issue for the preparation of therapeutic proteins as 
minor contaminants can induce immunogenic responses8,9. However, its occurrence 
barely has significant consequences in biocatalysis6, including that for glycosynthases10, 
but the protein purity for a pharmaceutical company marketing a recombinant protein 
may be of utmost concern and knowing the factors that affect translational 
misincorporation may be extremely useful. Unfortunately, the techniques that have been 
used to detect misincorportaion are not ideal for rapid and easy detection under 
numerous conditions.  
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There are several ways to detect translational misincorporation. This includes 
studies using isoelectric focusing11, Edman sequencing12, two-dimensional gels13 and 
mass spectrometry coupled with peptide mapping analysis9,14–16., Alternatively, we can 
deduce the effects of translational misincorporation by investigating altered properties, 
for example reduced activity5,17,18 or misfolding7,19 of a protein. We will explore the 
translational misincorporation in glucuronylsynthase by monitoring the reacquisition of 
the native (hydrolytic) activity in the wild-type, E-GUS.  
 
The investigation on wild-type contamination and translational misincorporation 
will be pursued in three parts. First, we will we will investigate the catalytic action of 
nucleophilic catalyst E504G. Then, we will systematically eliminate exogenous sources 
of wild-type contamination. Lastly, we will observe the effects of translational 
misincorporation using codon usage, expression conditions and different glycoside 
substrates. The hydrolytic activity of the E-GUS is extremely high so that reversions of 
E504G to the wild-type (E504) can be easily detected with an activity assay that can be 
monitored with crude lysates. Hence, some idea of the factors that affect 
misincorporation can also be easily detected over a variety of conditions. 
 
 
5.2. Results 
 
5.2.1. The catalytic nucleophile of E. coli E-GUS E504 
 
The role of residue E504 in the E. coli E-GUS has been reported previously20. 
When sequence alignment was performed with other sequences that are related to 
E. coli E-GUS (human E-GUS, mouse E-GUS, and E. coli E-GAL), the position E504 is 
fully conserved and aligns with the nucleophilic residues in the human E-GUS (E540)21 
and E. coli E-GAL (E537)22 (Figure 5-1a). In addition, we studied the effects of small 
nucleophilic molecule formate on the Syn hydrolytic activity, where we titrated 0 M, 
2 M and 4 M formate into a reaction containing pNPGlcA and Syn. Formate acts as a 
small nucleophilic molecule that occupies the space created by the EÆG substitution in 
the active site pocket of Syn, thereby reactivating the hydrolytic activity23,24. 
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We observed a 30-fold recovery in hydrolytic activity (Figure 5-1b) when formate 
was present. Doubling the concentration of the activator molecule also doubled the 
recovered activity. The reaction progress curves also revealed a lag time that became 
more pronounced with increasing formate concentration. This may be an indication of 
slow equilibration of the formate, which took the place of the glutamate as the 
nucleophile, in the active site. We did not characterise the D-glucuronyl formate product 
but the formation of the yellow product that was monitored under UV/Vis absorbance of 
405 nm indicated the liberation of pNP (Figure 5-1c). Hence, all observations thus far is 
compatible with the assignment of the E504 as the nucleophilic residue20,25–28. The 
reacquisition of hydrolytic activity in the presence of small nucleophilic molecules is 
also in line with the other glycosynthases23,24,29–32 and indicates that the mechanism of 
glucuronylsynthase is likely to be similar to the proposed mechanisms for other 
glycosynthases.   
 
 
5.2.2. Eliminating E-GUS contamination 
 
Several experiments were set-up to ascertain that we had not introduced E-GUS 
contamination through the growth and expression system, or through the media 
components that were used. First, we created a double knocked-out mutant by 
substituting glutamate with glycine and alanine at the second catalytic residue, E413 
that is responsible for base hydrolysis. If there were wild-type species contamination 
from external or internal factors, then cultures of glucuronylsynthase and the double 
knocked-out variant would exhibit similar background activities. The hydrolytic 
activities of both Syn E413A (E413A/E504G) and Syn E413G (E413G/E504G), and 
Syn (E504G) crude lysates, were observed qualitatively over a period of one week using 
1 mM of pNPGlcA as substrate. The growth of BW25142 strain, used as the host cell 
for this experiment, and the overexpression of arylsulfatase (AtaS) were used as 
negative controls. The AtaS sulfatase catalyzes the hydrolysis of sulfate esters and does 
not hydrolyse glucuronides. It is also nearly the same size (60 kDa) as the E-GUS 
(69  kDa). Thus, it is a good negative control to establish that the overexpression of an 
enzyme in BW25142 host does not induce the synthesis of contaminating E-GUS. The 
overexpression of wild-type E-GUS served as the positive control. Whole cell lysates  
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Figure 5-1:  Confirming E504G as the nucleophilic residue. (a) Sequence alignment of four glycosyl 
hydrolases at position E413 and E504 (E. coli E-GUS). (b) Recovery of hydrolytic activity in the presence 
of small nucleophile is indicated by the relative activity of reaction mixtures with formate compared with 
reaction mixtures without formate. 2 M and 4 M HCOONa were titrated into the enzyme incubation 
buffer containing 50 PM of Synthase enzyme. Turnover rate, kcat, of the hydrolytic rate in 0 M formate 
was obtained from H = 7625 M-1cm-1. (c) Schematic diagram of the chemical rescue reaction. 
 
 
were obtained from 10 mL of overnight cell cultures and lysed using rLysozyme™ 
(50 kU/g of cell mass). Overexpression of gene products was visualised on SDS-PAGE.  
 
There was no E-GUS activity (Figure 5-2a) detected in the negative controls, 
BW25142 (empty cell line) and AtaS. In the SDS-PAGE analyses (Figure 5-2b), the 
overexpressed gene products for AtaS corresponded with the size of the sulfatase used, 
and no overexpression of gene products was detected for the empty cell line BW25142. 
The positive control, E-GUS turned over the pNPGlcA almost instantaneously (within a 
minute). The glucuronylsynthase exhibited low but noticeable E-glucuronidase activity. 
(a) 
(b) 
(c) 
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It turned over the pNPGlcA overnight. However, the reaction assay containing double 
mutants of E504G recombined with E413A or E413G remained colourless even after 
one week. This indicated that the presence of hydrolytic activity by the double mutants 
was too low to be observed and was thus considered negligible.  
 
The above results inferred two points. Firstly, the drastic loss of hydrolytic 
activity caused by mutating E413 implied that the glucuronylsynthase with a stand-
alone E413 was capable of hydrolysis, albeit slowly and inefficiently. Secondly, the 
presence of contaminating wild-type that gave rise to observable E-GUS activity was 
unlikely to have arisen from the constituents of the growth media or from the expression 
system used. Hence, it could only be caused by an intrinsic factor such as inaccurate 
transcriptional and translational events during the course of growth and expression.  
 
 
Figure 5-2: Eliminating external sources as potential contaminant. (a) Qualitative analysis of hydrolytic 
activities. The intensity of the yellow colour gives a crude indication of the rate of pNP liberation  (b) 
Expression profiles of triplicate expressions of Syn (E504G) and Syn variants (E413A/E504G and 
E413G/E504G), host cell BW25142 and negative control represented by AtaS, and wild-type E-GUS 
used in this study.   
 
 
5.2.3. Codon usage of mutation E504G affects the extent of hydrolytic by 
glucuronylsynthase  
 
The genetic code is degenerate and leads to redundancy of codon usage. This 
gives rise to bias in codon usage that results in a particular set of codons being favored 
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by an organism for optimal translational process31. Favored codons occur more 
frequently in an organism and are called common codons. We utilized this bias to 
investigate inaccurate translational events.  
 
The misincorporation of glycine to glutamate in the E. coli system was observed 
using mass spectrometry by Huang et al.15 recently. Drawing on this finding, we 
incorporated two sets of glycine codon at residue E504. Misincorporation at this residue 
from GÆE would therefore introduce the revertant G504E that is essentially the wild-
type (E-GUS). Hence, the extent of mistranslational events could be monitored through 
a simple E-GUS activity assay i.e. the hydrolysis of pNPGlcA. The four degenerate 
codons that encode glycine are ggt (2.8), ggc (3.0), gga (0.7) and ggg (0.9) * . We 
encoded “ggt” and “gga” to produce the common and the rare E504G mutants. If the 
effects of inaccurate translational events are small, they both should have comparable 
hydrolytic (E-GUS) and synthetic (glucuronylsynthase, Syn) activities. 
 
Using His-Trap enzymes purified from His-Trap columns dedicated to each 
glucuronylsynthase (Syn) variants that were expressed from the two codon sets, we 
measured their hydrolytic activity with pNPGlcA. Their activities were measured from 
three replicates and averaged (Figure 5-3a).  The hydrolytic activity of the Syn encoded 
with rare codons was approximately 103 fold higher than the Syn encoded with common 
codons (Figure 5-3b). However, there was only a slight difference between the Km 
values of both the glucuronylsynthases compared to the wild-type (Figure 5-3b). From 
an unpaired t-test analysis, the difference was insignificant (p > 0.05), t(4) = -1.32, 
p = 0.25 for rare Syn, and t(4) = 1.59, p = 0.20 for the common Syn, and was likely due 
to systematic errors, as reflected in the large standard deviations of the Km values of the 
glucuronylsynthases. Given that the Km values are similar, we infer that the hydrolytic 
activity that were observed in the glucuronylsynthase samples were caused by the same 
species and the contaminant was most likely contaminating wild-type.  
 
Both versions of the glucuronylsynthase were also tested for their synthetic 
activity in glucuronylsynthase enzymatic reactions. We detected glucuronylated 
products (CMO-DHEA glucuronide) in the reactions performed using Syn encoded by 
common codon but could not do so with the Syn encoded by rare codon. Comparison of 
																																																							
*	Values in parentheses denote the average frequency of the codon per 100 codons in E. coli.	
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the synthetic activity kcat against the hydrolytic kcat revealed that the synthetic rate of the 
Syn encoded with common E504G was 102-fold faster than the rate of its hydrolytic 
activity (Table 5-1). Thus, this would still result in a net production of E-glucuronide 
products. By contrast, the Syn encoded with rare E504G had a hydrolytic kcat value 
103-fold higher than the hydrolytic kcat value of the common E504G Syn. Although we 
were not able to quantify the CMO-DHEA glucuronide production by the rare E504G 
Syn, we expected both versions of the Syn to have the same synthetic ability. Therefore, 
based on this assumption and the comparisons of the hydrolytic kcat values of both 
mutants, the hydrolysis rate of the rare E504G Syn will outpace its production of 
E-glucuronide. Consequently, this would result in no net production of glucuronylated 
products (Figure 5-4).     
 
 
Figure 5-3: Kinetics of the hydrolytic activity exhibited by glucuronylsynthase encoded with rare and 
common codons. (a) Michaelis-Menten curve-fit of the E-GUS activity in enzymatic assays containing 
E504G encoded by rare codon (red) and common codon (black), where rare codon = gga and common 
codon = ggt. Curve-fit was done using the average of three replicates obtained from two different batches 
of expressed enzymes. (b) The relative activities of WT, Syn (rare) and Syn (common) in logarithmic 
values. The activity exhibited by Syn (rare) is 1000-fold higher than Syn (common). WT activity is more 
than 105 higher than the Syn (common). Embedded table compares the kinetic parameters of the 
E-glucuronidase activity obtained for wild type and the two versions of glucuronylsynthase. 
 
Table 5-1: The turnover rates kcat of purified E-GUS and glucuronylsynthase activities by wild-type, Syn 
(rare) and Syn (common). (a) could not be determined because no products could be detected. (b) synthetic 
activity determined using 4 mM CMO-DHEA and 6 mM glucuronyl fluoride as in Chapter 4. 
    WT   Syn (rare)   Syn (common) 
kcat (s-1) 
{hydrolytic} 
76.0 
 
0.460 
 
5.26 x 10-4 
(± 2.6)   (± 0.26)   (± 0.35 x 10-4) 
kcat (s-1) 
{synthetic} 
ND (a) 
 
ND(a) 
 
1.67 x 10-2 (b) 
   
 
  (± 3.2 x 10-3) 
(a) (b) 
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Overall, the results showed that the choice of codon affects the amount of E-GUS 
contaminants, which is an indication of different levels of mistranslational events. The 
choice of codon appears to have a real and observable effect on the efficiency of the 
glucuronylsynthase system.	
 
 
5.2.4. Minimizing hydrolysis using different expression conditions 
 
 
Overexpression is one of the factors that can increase translational inaccuracy that 
leads to translational misincorporation. Overexpression subjects the host organism to an 
unnatural environment that increases metabolic stress6, which in turn increases error 
rates that can introduce impurities. The level of metabolic stress that is induced upon the 
cells depends on different overexpression conditions and this can subsequently affect 
the rate of translational inaccuracy. 
 
In the glucuronylsynthase system, we can investigate the effects of different 
overexpression conditions by monitoring the GÆE reversion at residue 504. We set up 
an experiment for this purpose. This experiment served two purposes. First, it served to 
provide additional support that translational inaccuracy events were accountable for the 
E-GUS activity seen. Second, through this experiment we would be able to determine 
conditions that can minimize the effects of translational inaccuracy.  
 
 
 
 
 
 
 
 
Figure 5-4: Competing hydrolysis 
by glucuronylsynthase encoded by 
rare codon (E504G rare) or 
common codon (E504G 
common). Lengths of arrows 
represent the rate of reactions (not 
to scale). The hydrolytic reaction 
needs to be significantly slower 
than the synthetic activity in order 
for the product to accumulate. 
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We overexpressed glucuronylsynthase in BW25142 host cell for different lengths 
of time at three temperatures (18, 30 and 37 	°C). Whole cells were lysed using a 
detergent based lysis method (BugBusterTM). The overexpressed products were then 
visualized on SDS-PAGE (Appendix 5-1, Figure A5-1) and the total amount of crude 
lysates were determined using Bradford assay. Their activities were then measured 
using pNPGlcA assay and standardized according to the amount of total lysate. 
Standardized activities of the crude lysates were then normalized relative to the average 
activity observed from samples grown and expressed at 18	°C for 4 h (Figure 5-5). 
 
Figure 5-5: Comparing the effects of different induction duration and temperatures on the E-GUS activity 
by glucuronylsynthase. Four different expression replicates from two different days (two replicates per 
day) were compared. Bradford assay and SDS-PAGE gels were used to quantify the amounts of enzyme 
present to obtain the relative activities. Data represents average from four different expression replicates. 
Inset: Enlarged views for 18 ° C expression at various time and 4 hours expression at various 
temperatures. 
 
Regardless of expression time, the samples expressed at 18	°C exhibited very low 
levels of E-GUS activity (0.022 – 0.020 nM/min/mg total enzyme) (Appendix 5-2, 
Table A5-1). Comparing this to the kcat value obtained in Table 5-1, this is 
approximately 0.020% of wild-type activity. The level of E-glucuronidase activity 
determined from samples expressed for 4 h doubled when the induction temperature 
was increased from 18	°C to 30	°C, and from 30	°C to 37	°C. The trend was different for 
samples obtained from 8 h and overnight expression. In these cases, the increase in the 
level of E-glucuronidase activity observed was larger when the induction temperature 
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was increased from 18	°C to 30 °C compared to when the induction temperature was 
raised from 30 	°C to 37 	°C. In the case of overnight expression, the increase in 
E-glucuronidase activity was nearly 20-fold when the induction temperature was 
increased from 18	°C to 30	°C but only doubled when the induction temperature was 
raised from 30 to 37 °C. At 30	°C and 37	°C, we also observed an exponential increase 
in the E-glucuronidase activity after 8 h induction. In addition, it may be worth noting 
that the errors in the overnight expression sample at 37 	° C was caused by large 
differences between duplicates on different days, and was likely caused by a difference 
in the incubation period (~ 20 h on Day 1 and ~ 16 h on Day 2). Using available data on 
the growth curve of BW25142 cell line harbouring constitutive expression systems 
(pJWL1030/gusA/BW25142) and of an inducible system harbouring the GUS gene 
(pET28a/GUS/GMS407) in GMS407 (DE3) cell line, the samples on Day 1 may have 
already entered the stationary phase, resulting in higher levels of misincorporation. Both 
growth curves showed two stages of growth phase where the growth slowed down after 
4 hours, and enters into the stationary phase after 20 hours (Appendix 5-3, Figure 
A5-2).  
 
From all the data, we infer that the rate of misincorporation increases 
exponentially as it transitions to a different growth phase but remains largely consistent 
during a particular phase. Prolonged induction at 30 °C and 37	°C increases the levels of 
misincorporation significantly, thus introducing more E-GUS contaminants. Altogether, 
the data suggests that starvation of the cells at the latter stages of overnight growth and 
expression is a major contributing factor of translational misincorporation of the 
glucuronylsynthase. This data also points towards the nature of the occurrence of E-
GUS activity as one being related to an intrinsic factor of growth and expression rather 
than an external factor.  
 
5.2.5. Hydrolytic activity of the glucuronylsynthase on other glycosides 
 
Next, we tested the glucuronylsynthase system for glycosidase activity using 
purified glucuronylsynthase and purified wild-type on three glycoside substrates: 
E-glucuronide (native), E-glucoside and E-galactoside (Figure 5-6). E-glucoside is very 
similar to native E-glucuronide. It only differs at the C5 position, where the –COOH 
group is replaced by a CH2OH. By contrast, E-galactoside is comparatively different 
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from the native E-glucuronide with C4 bearing a different configuration, and C5 a 
different functional group.  
 
E-GUS exhibits promiscuous activity with E-glucoside and E-galactoside. The 
E504 residue is involved in substrate binding through the formation of a glycosyl-
enzyme covalent bond. Thus, mutation here will change the glycosyl specificity. If the 
E504G mutant (glucuronylsynthase) exhibits basal levels of hydrolysis, then it may 
show different substrate specificity than the wild-type. Therefore, observable changes in 
the Km for different glycosyl substrates would indicate the presence of genuine 
hydrolysis by the glucuronylsynthase. Conversely, the Km with the glycoside substrates 
will be the same for both purified wild-type and glucuronylsynthase if the hydrolytic 
activity by the glucuronylsynthase is due to the presence of contaminating wild-type in 
purified enzyme sample. 
 
   
E-D-glucupyranuronic acid 
(E-glucuronide) 
E-D-glucopyranose 
(E-glucoside) 
E-D-galactopyranose 
(E-galactoside) 
Figure 5-6: The glycosyl rings of the three glycoside substrates studied. In parentheses are the substrates 
that harbour the glycosyl rings. E-D-glucupyranuronic acid is the native glycosyl ring of E-GUS native 
substrate, E-glucuronide. 
	
The kcat values for the glucuronylsynthase were very low, approximately five 
orders of magnitude lower than the wild-type, for each of the glycosides (Figure 5-7). 
This might reduce the accuracy of the hydrolytic kinetics parameter that was determined 
for the glucuronylsynthase, but still serve as a good estimate. The substrate preferences 
of the parent E-GUS and glucuronylsynthase for the E-glucuronide and E-glucoside 
substrates were similar (Figure 5-7). However, there was a pronounced difference in the 
Km values exhibited by Syn and the wild-type for the E-galactopyranose substrate. The 
mutant displayed a lower binding affinity. This suggested that the E-galactosidase 
activity observed in the glucuronylsynthase was not caused solely by E-GUS 
contamination and may reflect the mutant’s catalytic aptitude with this substrate. This 
also suggests that the E413 is capable of low levels of base catalysis that gives rise to 
detectable water-assisted hydrolysis.  
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Water-assisted hydrolysis is extremely inefficient. Wang et al. reported an overall 
kcat of 10-6 s-1 for their glycosynthase and 10-7 s-1 as the true value for its parent 
glycosidase activity23. This meant that 10% of the glycosidase activity seen in their 
synthase could be attributed to genuine hydrolysis caused by glucuronylsynthase. If we 
assume the same case, then genuine basal hydrolysis caused by the rare E504G 
contributes insignificantly to the hydrolysis, and in the case of common E504G would 
have been infinitesimal. Unfortunately, such low level of activity would neither be 
useful as a starting point for evolving the galactosidase activity nor for 
glucuronylsynthase evolution. Hence, it would be better to tailor growth and expression 
factors to reduce the misincorporation rates. 
 
 
Figure 5-7: Hydrolytic kinetic parameters of the glucuronylsynthase and the wild type with different 
glycosides. The trend in Km values of purified Syn and E-GUS with E-glucuronide, E-glucoside and E-
galactoside substrates. Inset: Enlarged view for E-glucuronide substrates. The turnover rates of purified 
E-GUS and Syn with three glycoside substrates. 
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5.3. Discussion 
 
The use of glucuronylsynthase system to detect translational misincorporation is a 
chance event  
 
Our observations on misincorporation events came under unusual circumstance. 
In many cases, translational misincorporation is probed by monitoring its detrimental 
effects on the function, specificity and stability of a protein. By contrast, our study 
involved monitoring the reacquisition of the native activity (E-GUS) in a knocked out 
system (glucuronylsynthase) whose function is reversed of its parent. Essentially, we 
were monitoring the effect of amino acid reversion at a catalytic residue that is critical 
for function. This was only possible because the wild-type activity was considerably 
higher than the mutant E504G’s activity. This meant that the slightest incidence of the 
reversion (~ 0.001%) was observable. Consequentially, this provided a useful 
alternative for us to estimate the misincorporation events.  
 
Deducing translational misincorporation 
 
When we first noticed that the glucuronylsynthase had higher than expected 
E-glucuronidase activity, we instinctively assumed that this was caused by wild-type E-
GUS contamination due to an oversight in the experimental design. We thought this 
could be abolished through extra precautions. When this had failed to overcome the 
contamination issue problem, only two other explanations could have accounted for the 
presence of hydrolytic activity in the glucuronylsynthase system. The first was 
associated with the catalytic function of E504 and the mechanism of the 
glucuronylsynthase. We were opposed to this idea because the role of E504G is well 
established and our chemical rescue experiment supported this. Even though the stand-
alone E413 may be capable of low levels of hydrolysis through water-assisted catalysis, 
this would be very inefficient and cannot account for the relatively rapid turnover of 
pNPGlcA. Secondly, intrinsic factors related to the growth and expression machinery in 
bacteria6 introduced a contaminating wild-type species through the misincorporation of 
GÆE. 
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Bacterial cell replication and gene expression involve multitude biological 
components, which act together to create a seamless operation34. However, each step in 
the process is prone to very low levels of errors either during transcription (10-5-(-6))35, 
translation (10-3-(-4))36 or DNA replication (10-7-(-8))1,37. Although all three types of errors 
are intricately tied in that one can affect the other two, the errors arising from translation 
inaccuracy is known to be more frequent. Translation errors can be caused by ribosome 
errors during mRNA decoding (10-4), amino misacylation (10-5), and amino acid 
misrecognition by tRNA (10-5)35. Our experiments with codon usage and expression 
conditions provided strong circumstantial evidence that these erroneous events were 
likely the main contributors of the presence of impurities that gave rise to 
E-glucuronidase activity in the glucuronylsynthase system. In addition, this theory is 
supported by a recent novel observation of the GÆE misincorporation15 in a 
recombinant peptide in E. coli, which suggests that this amino acid misincorporation is 
possibly a prevalent occurrence in E. coli. 
 
It is known that overexpression conditions can significantly affect the 
misincorporation rate34. Its occurrence is more prevalent in high-yield expression 
systems due to metabolic stress11. When stressed, the frequency of ribosome errors and 
amino acid misacylations increase, causing codon mistranslation. We have found that 
overexpressing the glucuronylsynthase system under high metabolic stress, which 
E. coli. is not optimized for affected the levels of E-GUS activity. Even though stronger 
overexpression conditions i.e. higher temperature and prolonged expression period for 
the glucuronylsynthase system yielded more enzymes, this also increased the incidence 
of translational errors. This gave rise to a higher proportion of mistranslated G504E 
products, which are essentially wild-type (E-GUS) impurities.  
 
The proof for translational misincorporation was further strengthened by 
experiments with different codons. The genetic code is redundant, whereby the 20 
canonical amino acids can be encoded by 61 codon sets. The usage of these codon sets 
is optimized differently in different in organisms according to their cellular tRNA 
makeup38. This had been optimized so that translational inaccuracy can be 
minimized33,39, causing the display of codon usage bias40. In E. coli, its preferred codon 
sets for glycine are the ggt and ggc, while gga is a rare codon. Using the rare codon gga 
to encode the glycine mutation at E504 would have caused sub-optimal codon usage 
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due to lower abundance of the rare codon cellular tRNA and result in higher rates of 
misincorporation40,41,42.  
 
The high native hydrolytic rate seen for E-GUS also extended to the promiscuous 
hydrolytic activities. This had allowed us to characterize these activities in the 
glucuronylsynthase system and confirmed that inefficient base catalysis can occur. 
Unfortunately we could not quantify this, as we did not use an analytical method such 
as the mass spectrophotometry (MS) or gel electrophoresis to quantify the amounts of 
misincorporated product. Even if we had attempted to use this, we might not have been 
able to quantify such low levels of misincorporated products since the application of 
analytical methods to detect misincorporated products that are orders of magnitude less 
than the error-free species is often challenging34. Furthermore, this is subjected to the 
availability of a sensitive and reliable MS instrument. Hence, detecting 
misincorporation events through crucial active sites, particularly in a fragile system 
such as the glucuronylsynthase, can be a useful alternative for translational fidelity 
studies when an analytical method is unavailable.  Nonetheless, this method is subject 
to limitations as it requires that there is an available detection method sensitive enough 
to detect the activity of the mistranslated product.  
 
Implications of translational misincorporation on the glucuronylsynthase system 
and biocatalyst engineering 
 
The presence of hydrolytic activity in the glucuronylsynthase system can 
undermine its performance because of the nature of this system. Nevertheless, if the 
hydrolysis occurs at a rate that is much slower than the synthetic rate, this is not a 
problem.  
 
We have determined that two factors contribute to hydrolytic activity in the 
glucuronylsynthase system. The first is the basal hydrolytic activity caused by the base 
catalyst E413. In the scheme of things, this is of little consequence to the 
glucuronylsynthase system. In comparison, changes in codon usage and expression 
conditions together can reduce the rates of misincorporation by factors up to 103. This 
recovery rate is actually higher than what we achieved in the chemical rescue and 
illustrates the importance of optimal expression systems. 
CHAPTER 5 
	
 — 133 —
A stronger expression system or overexpression condition is often deemed helpful 
for enzyme and protein production, but as we have shown in this exercise, it may not 
always be the case. High expression levels increase the amount of the products, which 
gives the appearance of a more productive manufacturing process. However, this 
increases the metabolic burden on the expression system and promotes translational 
inaccuracy. In the case of glucuronylsynthase, the cost of using strong expression 
systems or conditions to increase the yields of the enzyme can be significant. Hence, the 
cost-benefit of using high-yield expression systems or conditions should be carefully 
weighed. Whilst we have not conducted a study using different expression systems, our 
study suggests that it might be worthwhile to consider codon optimization and 
bioprocessing optimization, which are often regarded as trivial, to reduce translational 
misincorporation while engineering biocatalysts.  
 
	
5.4. Conclusion 
 
For biocatalyst production, translational misincorporation can cause reduced 
activity or substrate specificity and result in undesired side activity. However, to our 
knowledge, this has not been known to inhibit the reaction in which the biocatalyst is 
used such as what we saw with the synthetic activity of the glucuronylsynthase encoded 
with rare codon. Our case was unique, and it brought to light the significance of 
ensuring high translational accuracy in the production of biocatalysts. Although we are 
unlikely to abolish E-GUS contamination, we can reduce the incidence of 
misincorporation by tailoring the expression systems and conditions. More importantly, 
our observation in this chapter stresses upon the need to evolve a faster 
glucuronylsynthase enzyme.  
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6. Mutational tolerance of the Escherichia coli E-GUS  
 
6.1. Introduction 
 
Mutations, generally classified as deleterious, neutral and beneficial, create 
diversity in the genetic pool. They are the driving force behind evolution because they 
can alter protein structure1,2, properties3,4 and function5. These changes result in 
variation to their traits or phenotypes, which is also known as phenotype variation. 
Examples of phenotype variation include the inactivation of protein function, the 
improvement of a promiscuous activity (adaptation), or the acquisition of a different 
biophysical property6.  
 
Mutational tolerance describes the ability of a protein in resisting changes to its 
traits when subjected to random mutations. At the molecular level, mutational tolerance 
involves looking at the properties of a molecule as a function of mutation rate. One can 
generate large libraries of mutated genes and then examine the activity, or some other 
property such as the stability of the variants. If the gene encodes a protein that is 
essential for the survival of the organism, then one can look at the survival rates as a 
function of mutation rate to gain some idea of mutational tolerance7–11. These 
experiments generate a distribution of fitness data that is then used to compute 
mutational tolerance. Mutational tolerance can be computed by plotting the distribution 
of fitness against mutation rate9 or by calculating a library’s inactivation probability 
based on the fitness data7,8,10,11,12. An enzyme that has higher mutational tolerance is 
able to withstand higher mutation rate.  
 
There appears to be many ways to quantify mutational tolerance. For example, 
studies by Guo et al. in Loeb’s group includes the development of a substitutability 
index, the x-factor, to quantify the mutational tolerance of the AAG10, and the DNA 
Pol I11. In other their studies, the parameters D and E that were developed by 
Charlesworth13 were used to quantify mutational tolerance and negative epistasis9,14, 
and the D/E ratio was used to describe the degree of epistasis9.  
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It had been shown that mutational tolerance can facilitate adaptation15,16. Hence, 
better understanding of the factors that impact mutational tolerance may lead to better 
understanding of the driving forces of evolution or adaptation that may benefit 
laboratory evolution experiments. There are various ways to study mutational tolerance. 
Structure-function analyses through experiments that investigate mutation effects can 
provide useful insights into what drives mutational tolerance. In studies involving the 
DNA repair enzyme 3’-methyladenine DNA glycosylase (AAG)10 and DNA 
Polymerase I (DNA Pol I)11  performed in Loeb’s group, the group has demonstrated 
that there is a relationship between the mutational tolerance of the residues in the 
enzymes and their evolutionary conservation score, structural motifs and solvent 
accessibility.  
 
Other factors that affect mutational tolerance are the population size8,17 and 
thermostability7,9,18. In one experiment, Bloom et al. subjected a P450 variant to three 
parallel evolution experiments such that each experiment would have a different rate of 
accumulation in diversity8. They found that high diversity yielded a population that has 
higher mutational tolerance and better thermostability due to a surplus of stabilizing 
mutations that are present in diverse population. It has also been shown in various 
experiments that evolution is caused by adaptive mutations that also tend to be 
destabilizing19,20,21. As a result, proteins tend to accumulate mutations with 
compensatory roles with improved biophysical properties22 that can compensate for 
these destabilizing effects of adaptive mutations. As such, there is a strong association 
between stability and mutational tolerance, which also promotes the ability of a protein 
to evolve for new function (evolvability)23,24,25.  
 
Analyses such as those described above leads to better understanding of 
mutational tolerance that can facilitate the development of small and smart directed 
evolution libraries through structure-based library design. However, when multiple 
mutations are involved, each mutation may change the network of interactions in a 
macromolecule. Consequently, the net effects of mutations may not always be equal to 
the sum of their individual influence and this complicates structure-function analysis or 
library design. This effect, also called epistasis, is caused by non-additive interactions 
between mutations and can impact the mutational tolerance of an enzyme. When an 
epistastic mutation arises, the mutational tolerance of an enzyme, which is expected to 
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fall off in a linear manner, may decrease in an exponential manner as the effects of the 
mutation can overshadow the effects of other mutations. One study that was performed 
through computational modelling predicted that epistasis can enhance mutational 
tolerance. This was later verified in an experimental study by Bershtein et al.9 that 
concluded that lower mutational tolerance was associated with weaker epistasis and that 
the apparent robustness of an enzyme increases with the presence of thermostable 
mutations. The study not only provides experimental evidence on the impact of epistasis 
on mutational tolerance, but it also provides additional insights into how enzyme 
stability can affect mutational tolerance.  
 
In this chapter, we will first study the mutational tolerance of the E. coli E-GUS. 
This enzyme is a multimer that consists of multiple domains. These features are 
expected to result in increased structural complexity, which is likely to cause the 
enzyme to exhibit a different mutational tolerance from structurally simpler forms of 
enzyme. One simple monomeric enzyme that have had its mutational tolerance study 
comprehensively is the TEM-1 by Bershtein et al.9 Their study, aimed at providing 
insights into the effects of epistasis caused by the accumulation of deleterious mutations 
on the protein’s ability to tolerate mutations, had computed various D-values of the 
TEM-1 for quantifying the mutational tolerance of TEM-1 under different selection 
pressures. The D parameter of the TEM-1 can therefore serve as a primary reference to 
facilitate direct comparisons of the E-GUS mutational tolerance against an enzyme that 
is structurally less complicated. Secondly, we will investigate the mutational tolerance 
of eight individual active site residues. Some of these residues are implicated in 
substrate binding and interacts with the glycosyl C6 position. The libraries will be 
screened against two different substrates that differ at the C6 position- the native 
substrate, E-glucuronide (pNPGlcA) and a promiscuous substrate, E-glucoside 
(pNPGlc). We will associate the mutational tolerance of the amino acids with their 
evolvability. From these experiments, we aim to understand the factors that govern the 
mutational tolerance of E-GUS. Insights gained from the experiments can be useful for 
understanding its evolvability and for guiding future designs of laboratory evolution, 
particularly for the E-GUS enzyme. 
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6.2. Results 
 
6.2.1 Random mutagenesis on whole gene and selected regions in enzyme 
 
We subjected the whole length of gusA gene to random mutagenesis with six MnCl2 
concentrations. This created six sub-libraries of gusA random libraries, each with 
different mutation rate (P). Appendix 6-1 describes the method used to determine the 
accuracy of the P determination. Mutation rates were determined by randomly 
sequencing eight colonies from each sub-library (Appendix 6-1, Table A6-1 and 
Figure  A6-1). The sub-libraries were screened using the X-gluc blue-white screening 
method described in Section 2.7.2 and the pNPGlcA solution based assay described in 
Section 2.7.3. The percentage of active mutants in a sub-library was taken as the 
measure of the sub-library’s fitness, Wn.  
 
Wn was determined by taking the percentage of a library screened against 
pNPGlcA that retained 99% of the activity (activity cut-off 1%) or by enumerating the 
fraction of colonies that turned blue after overnight incubation on a colony agar plate 
consisting  0.8 mg/mL X-gluc. We plotted this against the mutation rate and found that 
the sub-library’s fitness declined exponentially with the mutation rate. This fitness 
decline was taken as a measure of the mutational tolerance of E-GUS. Since our 
experiment is analogous to a random mutational drift experiment in the absence of 
purifying selection, the exponential function that describes our fitness decline can be 
written in the form shown in Equation 6-1:   
Wn = K exp (-DP)                                             (6-1) 
where Wn is the fitness of the sub-libraries, P is the mutation rates or the mutational 
burden and D is the rate of fitness decline. 
 
Higher values of D indicate that a library is less tolerant of high mutation rates and 
imply that it is less tolerant. K is a constant that should be 100 (100% activity when 
P = 0) in an ideal case. Since the value of K represents an ideal case, the experimentally 
determined value of K also gives an indication of how accurate the assessment is. The 
rate of inactivation (D) for E-GUS is 0.46 with a K value of 104 (Figure 6-1).  
 
  CHAPTER 6 
	
	 — 141 —
 
 
 
Figure 6-1: Rate of fitness decline in 
response to increasing mutation rate P 
for E-GUS follows an exponential 
function defined by Wn = K exp(-Dµ). 
The mutation rate is the expected 
number of amino acid changes in the 
gene. Standard deviation for fitness is 
taken from multiple screens where 
each screen consisted of 100–200 
clones. The fitness decline rate D for 
E-GUS is 0.46 with a K value of 104. 
 
 
We compared the D-value of E-GUS to the one that was obtained for TEM-19 
under random mutational drift as this selection pressure is the one that closely reflects 
our experimental design. We also compared their solvent accessibility surface areas 
(Table 6-1). The average SASA value was calculated from the Solvent Accessibility 
Surface Areas (SASA) function in PyMol and then averaged by the number of residues. 
The D-value that was used for comparison from the TEM-1 study was the one obtained 
from the library that was allowed to drift under highest fitness level  (Lib0)9. The 
E-GUS appears to be slightly less tolerant than the TEM-1 with D-value 0.46. In 
addition, the SASA of E-GUS is approximately 10 Å2 less than the TEM-1.  This is 
unsurprising since we expect the functional quarternary structure of the macromolecule 
assembly to be roughly globular, and for globular shapes, the surface:volume ratio 
decreases with increasing size. The decrease in average SASA calculated for the E-GUS 
as its oligomeric number increases also suggests that there are more buried residues in 
the E-GUS.  
 
6.2.2 Tolerance of active site residues towards mutation  
 
We extended our study to focus on the mutation tolerance at several active sites. 
The active site residues chosen are listed in Table 6-2. The table also includes the key 
feature associated with each residue. The residues that were chosen can be classified 
into four distinct category: (i) glycosyl binding residues (ii) non-binding residues (iii) 
leaving group and (iv) catalytic loop flip residues. The crystal structure of glucaro-G-
lactam (GDL) bound E-GUS obtained by Wallace et al.27 (PDB ID: 3K4D) was used to  
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Table 6-1: Solvent accessibility areas. The total solvent accessibility area (SASA) and average SASA per 
residue of a reference enzyme (TEM-1) and the different structural compositions in E-GUS.(a) Only the 
monomer was considered for TEM-1 because it is a monomeric protein26, (b) the two subunits in the 
crystal structure of E-GUS had slightly different solvent accessibility areas (c) the references for D-value 
and crystal structure of TEM-1. 
Enzyme Structural assembly 
No. of 
AA Total SASA 
Average 
SASA α 
TEM-1 
(reference)c Monomer
 (a) 263 11984.71 45.57 0.37 
           
       
β-GUS 
Monomer A (b) 603 24246.36 40.21 
0.46 
Monomer B (b) 603 24647.54 40.87 
Dimer 1206 45738.56 37.93 
Tetramer 2412 85096.22 35.28 
 
 
shortlist glycosyl and non-glycosyl binding residues (Figure 6-2a). Substrate pNPGlcA 
was docked into the active site by pair-fitting pNPGlcA with the inhibitor GDL. The 
pair-fit RMSD value was 0.19 (Figure 6-2b).  
 
Of the shortlisted glycosyl binding residues, we identified D163, Y472 and R562 
as targets for single-site saturation mutagenesis. These are within 4 Å of the carboxylate 
group at the C6 position in pNPGlcA and would interact with the glycosyl group of 
pNPGlcA at this position. We chose these residues so that we could compare the 
mutational tolerance when screened using pNPGlcA against the mutational tolerance 
when screened with pNPGlc. The pNPGlc is a promiscuous substrate of E-GUS and 
bears a different C6 functionality i.e. a –CH2OH group at C6 in pNPGlc (a E-glucoside) 
in contrast to a –COOH in pNPGlcA (a E-glucuronide) (Figure 6-2c). We would use the 
comparison between the two screening data sets to investigate the relationship between 
mutational tolerance and evolvability.  
 
Four other residues N412, M447, Y469 and T509 that are not implicated in 
glycosyl binding were also investigated as these were in locations that may modulate 
the catalytic residues (E413 and E504) and the glycosyl binding residues. Amino acid 
N412 is a fully conserved residue that does not interact directly with the substrate, but 
interacts with the E413 catalytic residue via a bridging water molecule (Figure 6-3a). It 
is interesting that this residue is fully conserved and we were interested to know if  
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Table 6-2: The sites chosen for randomization and their roles. The sites are classified according to the 
classification column. The sites are listed according to the order in which they were investigated.  
Sites Comments Classification 
D163 Glycosyl C6 interaction Glycosyl binding residue 
R562 Glycosyl C6 interaction Glycosyl binding residue 
N412 
Conserved uncharged residue adjacent to catalytic 
glutamate E413 that participates in general acid/base 
hydrolysis 
Non-binding residue 
M447 Leaving group interaction Aglycone binding residue 
T509 Important site based on literature not involved in binding Non-binding residue 
Y468 Flipped residue resulting from loop conformation change Catalytic loop flip residues 
Y469 Flipped residue resulting from loop conformation change Catalytic loop flip residues 
Y472 Glycosyl C6 interaction upon loop conformation change 
Catalytic loop flip 
residues/Glycosyl binding 
residue 
 
 
Figure 6-2: Interaction between substrate-binding residues and pNPGlcA. (a) Key interactions between E. 
coli E-GUS and docked substrate pNPGlcA. pNPGlcA was pair-fitted to the inhibitor glucaro-G-lactam 
(GDL) in the inhibitor bound E-GUS crystal structure obtained by Wallace and co-workers. Interaction 
distances were derived from the superimposed pNPG substrate and the residues. (b) The superimposition 
of pNPGlcA (white sticks) over GDL (represented as blue lines) in the crystal structure. (c) Glycosyl 
rings of E-glucoside (top) and E-glucuronide (bottom). 
 
 
randomizing this amino acid would also yield interesting changes in enzyme acitivity. 
M447 was also interesting because it does not interact directly with the glycosyl ring, 
but interacts with the p-nitrophenolate (pNP) leaving group. This residue is also found 
to occlude the cleft of the active-site (Figure 6-3b) and may control product release. 
M447 also interacts with Y469 in a sulfur-π-ring interaction (Appendix 6-2, Figure A6-
2a). The Y469 residue is involved in a loop conformation change involving itself, Y468 
and Y472 (Appendix 6-2, Fig A6-2) that happens upon substrate binding. This 
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conformational change appears to be important for substrate interaction as Y472 flips 
into the active site to interact with the glycosyl ring. Hence, these residues were also 
investigated. 
 
 
Figure 6-3: Interactions of several active site residues in E-GUS. (a) Interaction between E413 and N412 
in the active site of E-GUS with a GDL inhibitor is mediated by a bridging water molecule (white dot). 
(b) The loop that bears M447, Y468 and Y469 (represented as surface in cyan) can occlude the exit of 
hydrolysis products. Docked active sites is pNPGlcA (yellow) using the pair-fitting function that is 
available in PyMol.  
 
 
6.2.3.  Developing a statistical approach to study the mutational tolerance of single- 
site saturation mutagenesis libraries  
 
The mutational tolerance of an amino acid residue can be denoted by the fraction 
of the library that appears active. However, for the solution-based assays such as the 
pNPGlcA assay, an inactivity threshold has to be assigned to classify inactive variants. 
For example, in a library whose threshold value is designated 10%, any variant 
exhibiting less than 10% activity will be considered inactive. The fraction of the library 
that remains active above this value is taken as a statistical representation of the fitness. 
However, this can be ambiguous because the threshold value is a subjective value. It is 
also less suitable for single site-saturation mutagenesis libraries because it does not 
account for the bias that is imparted by the presence of wild-type. The mutation 
frequency of site-saturation libraries is the percentage of variants in the library that has 
been successfully mutated. This depends on the efficiency of the randomization at a 
particular site. The typical mutation frequency achieved by the NNK codon 
randomization method lies between 60 and 95% (values taken from literature28,29 and 
our experience). A library with lower efficiency randomization rate has more wild-type 
encoded clones that will lead to overestimation of its mutational tolerance.   
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We designed a method based on the activity distribution of an individual library to 
derive a measure for the mutational tolerance of our site-saturation libraries. The 
mutants in a site-saturation library will display a range of activities. When ranked in 
order, the activity distribution fits a sigmoidal function. The gradient that describes the 
rate at which activity is lost in the library is then taken as the statistical measure of the 
mutational tolerance at each site. This is represented by m3, the inflection point of the 
sigmoid curve that fits Equation 6-3. Figure 6-4 illustrates the method using three 
hypothetical libraries.  
y = ymin+ 
ymax- ymin
1+(
x
x1/2
)
S                                            (6-3) 
where ymax (m1) and ymin (m2) are the asymptotes of the sigmoidal curve, S1/2 = slope at 
x1/2 and x1/2 = inflection point of the sigmoidal curve. A more negative S1/2 corresponds 
to higher inactivation rate and hence, reflects lower mutational tolerance. This number 
is independent of the screening size (Appendix 6-3, Figure A6-3) or the mutation 
frequency, and is not affected by the ambiguity in assigning a threshold value. 
	
6.2.4. Quantifying the mutational tolerance of the single-site saturation 
mutagenesis libraries 
 
Figure 6-5 summarizes the mutational tolerance of the eight single-site saturation 
mutagenesis libraries. The mutational tolerance of each site towards the substrates 
pNPGlcA and pNPGlc was compared. For each site, two independent screening 
experiments for both substrates were performed. We found that the non-glycosyl 
binding residue M447 was the most tolerant followed by T509 and N412. The M447 
library also appears to have similar mutational tolerance with both substrates, 
suggesting that it is not evolvable. T509 appeared to be most evolvable with several 
screening data points that was above 1.0 (improved activity). It also appeared to have a 
lowest inactivation factor (most tolerant) with the non-native substrate, again indicating 
better evolvability.  
 
We randomly picked clones in the screened libraries to sequence. When the 
activity distribution curves (Appendix 6-4, Figure A6-4) and sequencing data 
(Appendix 6-4, Table A6-2) were analysed, we found that there were various mutants in  
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Figure 6-4: Simulation of activity distribution profile following data sorting of activity levels relative to 
wild-type in a library (hypothetical). Figures (a)–(c) each represent an intolerant library, moderately 
tolerant library and tolerant library with clones that are more active than wild-type. In each of the curves, 
the sigmoidal curve-fit parameters are listed and their residual errors, where m1 = maximum asymptote, 
m2 = lower asymptote, m3 = inflection point and m4 = the gradient at the inflection point. Curve-fitting 
was performed using Kaleidagraph 4.5. Table in the corner (top right) summarizes these parameters and 
compares the gradient m4 to the threshold method using three discrete bins i.e. the 0.1x WT activity    
0.1–1x WT activity and > 1x WT activity 
 
the M447 library that retained partial activity, while there were three mutants in library 
T509 (T509A/G/S) and one mutant in library N412 (N412D) that appeared partially 
active in the pNPGlcA screen. This indicates that N412 is not tolerant of mutations and 
imply that its role in co-ordinating the interaction between E413 and the substrate 
through the bridging water is an important one. We purified M447S/T and T509A, 
which had appeared frequently in our sequencing data. M447T was also chosen for 
further confirmation because it appeared to have lost its partial activity with the pNPGlc 
substrate.   
 
The library R562 stimulated some interest. Although this library appears to be 
totally inactivated in the pNPGlcA assay, it was not so in the pNPGlc assay. This 
 
(a) 
(b) 
 
(c) 
Tolerant library 
with improved 
variants 
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indicates that some of the R562 variants are trading their E-GUS function to acquire 
some glucosidase functionality. We sequenced several R562 clones that appeared to 
have glucosidase activity but not E-GUS activity, and found mutations R562H/P/S/T. 
Of these, the R562S and R562T mutants were isolated twice. They were purified to 
further confirm their activity.  
 
 
Figure 6-5: Mutational tolerance of sites chosen for site-saturation mutagenesis study. E413, which 
should be completely inactivated is a control to represent full library inactivation. Thus, any values more 
negative than E413 signifies inactivation. Error bar represents standard deviation of the inactivation factor 
from two independent screening exercises.  
 
6.2.5. Verification of activity in mutants  
 
We purified T509A, R562S, R562T, M447G and M447S by metal affinity 
chromatography as described in Chapter 2. Kinetic parameters were obtained and are 
given in Figure 6-6. However, we were not able to achieve substrate saturation for the 
glucoside substrate with both M447G/S mutants (Appendix 6-5, Figure A6-7). We did 
not attempt to repeat the kinetics using higher substrate concentrations due to solubility 
concerns. This reflects an increase in Km of the M447 mutants for the glucoside 
substrate, which is interesting as M447 is not known as a substrate binding residue. Its 
position at the entrance of the active-site (Figure 6-3) may contribute to this effect. It 
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suggests that the dynamics at the active-site entrance controls substrate uptake and 
product release and consequently affect substrate binding.  
 
 The enzyme activities of R562 and M447 variants measured at a particular 
substrate concentration were compared with the WT. The substrate concentration was 
chosen such that it would be similar to the one used in the screening experiment and 
was 1.6 mM for the E-GUS assay (1 mM in screening), and 12.8 mM for glucosidase 
assay (9 mM in screening). The variant R562S and R562T were not completely inactive 
in pNPGlcA even though they only retained < 1% of E-GUS activity. M447G retained
 partial E-GUS activity and partial glucosidase activity but M447S retained partial            
E-GUS activity and was almost inactive as a glucosidase (< 1%). In general, the trends 
observed using purified enzymes agreed well with the observations from screening data. 
 
 
We also obtained the kinetic parameters for T509A (Table 6-3) and determined its 
thermostability using the thermal shift assay that was described in Section 2.12.1 
(Figure 6-7). T509A is reported in various literatures as a mutation that can improve the 
xylosidase30 and E-galactosidase31,32 activity of the E-GUS. We found that the 
E-glucosidase activity (pNPGlc activity) of T509A is three-times more efficient  
 
Figure 6-6: Relative improvement of purified enzymes at selected substrate concentrations. 
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compared to the parent. This, along with the other reports, would suggest that this 
mutation is im mutation is important for accepting non-native glycosyl rings.  
 
Although the T509A demonstrated an enhancement in the promiscuous activity 
with pNPGlc, we did not observe any dramatic loss in its native activity (activity 
against pNPGlcA). This is reasonable since it is not directly involved in catalysis, but it 
is located on the same loop, a few residues away from the catalytic residue. Consistent 
with other reports on other similar type of mutations in other enzymes, the enhancement 
of the promiscuous activity by T509A mutation is likely due to its ability to enable the 
accommodation of different substrates through conformational changes33. This mutation  
has also been reported in a thermostability study, but it had appeared together with other 
mutations34. Its effect on stability as a single mutant was not reported. We found that, its 
effect as a single mutant was not important, and is in fact, slightly disadvantageous for 
improving thermostability. This was likely offset by the other mutations that had 
appeared concurrently with T509A in the thermostable variant found in the report34. 
Therefore, the T509A mutation appears to be important for function, but not for 
stability. This exemplifies the activity-stability trade-off trend that has already been 
extensively studied7,19,25,35,36.   
 
6.2.6.  Limitations of the statistical method used for studying mutational tolerance 
of single site-saturation mutagenesis library 
 
Overall, the statistical method that we have developed to describe the mutational 
tolerance of our site-saturation libraries tallied well with the activity distribution of the 
Table 6-3: The kinetic parameters of WT and T509A for 
glucosidase and glucuronidase activities. 
 
  Figure 6-7: Tm of T509A 
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libraries. However, there may be limitations to the method. Of great concern, would be 
the utility of the method when applied to larger screening data and screening data that 
involves mutants with huge activity improvement. Both in our method development and 
in our application, the largest activity improvement we saw was a modest 2.5-fold in 
pNPGlc screen of the T509 library. The method used does not properly account for the 
positive effects of the improved mutants on the mutational tolerance of the site. Further, 
although the data in both cases could still be fitted to the sigmoidal function, the fit 
becomes less ideal. The R-value in the hypothetical library (Figure 6-4c) decreased to 
0.985 compared with the R-values of > 0.999 in the other two hypothetical libraries. 
Additional parameters to incorporate the effects from neutral and significantly improved 
mutations would increase the utility of the model. 
 
It is also important to note that the method is extremely sensitive to the effects of 
screening variation. The replicates of the pNPGlcA screen of T509X library for 
example, showed a high standard deviation. We replotted and recalculated the 
inactivation factor of T509 using only the data of the sequenced mutants (Appendix 6-6, 
Figure A6-6) and found that the inactivation factor for one of the plate was 
underestimated. This is caused by large screening errors (% CV in the plate = 30%), 
which resulted in a huge distribution of the wild-type activity data. A better way to 
implement the method would be to apply the method on data sets whose sequence is 
already verified (Appendix 6-6, Figure A6-6).  
 
 
6.3. Discussion and concluding remarks 
 
We have used the D-value of TEM-1 as a reference for evaluating the mutational 
tolerance of E-GUS. Based on their D-values, it seemed that the E-GUS is slightly less 
tolerant than the TEM-1. However the difference is smaller than expected and may not 
be significantly different. In fact, when we conducted an unpaired t-test analysis, it 
appears that the difference between the two values is not statistically significant at 
confidence interval level above 99% even though they are different below 95% 
confidence level (Appendix 6-7, Table A6-3 and Figure A6-7). Nevertheless, it must be 
noted that the D-value is a subjective quantitative measure as it depends on the criteria 
that is used to plot the y-axis (Wn) in Figure 6-1. Criteria that are less stringent would 
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result in a higher apparent mutational tolerance. Our criteria is different from the one 
used in the TEM-1 study. In our study, two assays were used – the pNPGlcA assay and 
the blue-white screening assay with saturating amounts of X-gluc. The X-gluc assay 
represents the lowest possible stringency level. For the former, the level of stringency in 
our study depended on the activity cut-off that was set in the pNPGlcA assay (1%). This 
cut-off seemed comparable to the X-gluc assay. Hence, both our criteria represent the 
least stringent criteria. Comparing it to the unselected library at the highest fitness level 
(highest antibiotic concentration, D = 0.37) may not be the most suitable comparison. A 
comparison against the unselected library screened with lower antibiotic concentration 
(lower stringency) may be a better reference for us. The D-value of the TEM-1 
approaches 0.1 at lower ampicillin concentration, and is substantially higher than the 
D-value of E-GUS. 
 
It is counter-intuitive that the E-GUS appears less robust or to be only as robust as 
the TEM-1. One expects the larger E-GUS to have more network of interactions that can 
buffer the effects of undesirable mutations. One possible explanation for this is that the 
E-GUS consists of several domains and exists as a tetramer, resulting in regions that are 
more sensitive to mutations. The other is that tetramerization of E-GUS gave rise to a 
higher proportion of buried residues, which are generally known to be less tolerant10, in 
its quarternary structure. Mutations at the interfacial regions may give rise to deleterious 
mutations that disrupt the interaction required to maintain its quarternary structure. 
Therefore, fewer mutations are needed to destabilize the enzyme and henceforth 
inactivating it.  
To test the effects of mutational interactions on the mutational tolerance of 
E-GUS, we fitted the data in Figure 6-1 to a fitness decline model with an epistatic 
parameter (E) (Equation 6-2).  
Wn = K exp (-DP-EP2)                                      (6-2) 
where Wn is the fitness of the sub-libraries, P is the mutation rates or the mutational 
burden and D is the rate of fitness decline, and E is the epistasis parameter. The  E/D 
value indicates the strength of directional epistasis with a lower value corresponding to 
weaker epistasis. When directional epistasis is taken into account, the E-GUS has a E/D 
value of 0.076, and an D-value of 0.33 (Appendix 6-7, Figure A6-8). This D-value is 
lower than the value of 0.46 that was obtained from Equation 6-1 and is much closer to 
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the reported TEM-1 D-value. This indicates again that the mutational tolerance of 
E-GUS may not be significantly different from the mutational tolerance of TEM-1.  
 
We projected the D and D/E values of the E-GUS obtained from Equation 6-2 onto 
the plot that correlates epistasis and mutational tolerance (plot of E/D versus D) in 
Figure 2b of reference (9). The E-GUS appears to be under stronger epistatic influence 
compared to the TEM-1. At D ~ 0.36, the E/D value of the TEM-1 approaches zero 
(~ 0.01), whereas for E-GUS, its E/D value of 0.076 is much greater than zero. This 
supports our inference that interactions within the macromolecule that contributes to a 
proper fold and structure of the E-GUS is a major determining factor of the mutational 
tolerance of E-GUS. This is further supported by an examination of the tetrameric 
E-GUS structure, generated from interposing the dimeric crystal structure, that indeed 
revealed several distinct examples of subunit and inter-domain interactions (Appendix 
6-8, Figure A6-9), including a solvent exposed disordered region that is involved in 
domain swapping  (PDB ID: 3LPF, 3LPG)27.  
 
One of the residues at the interface regions that can totally inactivate an enzyme 
upon mutation is the R562 residue. This residue appears on a mobile loop at the 
interface of two subunits. The intolerance of this residue may be associated with 
destabilization that results from the disruption of the subunit-subunit interaction when 
this residue is mutated. However, this residue also seems to have a better tolerance in 
the presence of pNPGlc (non-native substrate), suggesting that it is capable of 
adaptability. This also suggests that the mutation at this position does not completely 
disrupt the interaction between the two subunits and a weaker interaction between the 
subunits may have given rise to conformation changes that allow the macromolecule to 
accommodate other substrates. The fact that R562 may be capable of adaptability is not 
surprising since R562 is also a glycosyl binding site and hence, mutation on this residue 
may optimize it towards better acceptance of a non-native glycosyl ring. In addition, 
this residue is on a loop and loops in general have been known to be excellent targets 
for modulating enzyme activity20,37,38.  
 
We had also studied the mutational tolerance of several other substrate binding 
residues that are located on loops using site-saturation mutagenesis and compared their 
evolvability. However, none had showed the same ability to adapt as R562. Conversely, 
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the residue T509, which does not participate in substrate binding, seemed the most 
evolvable. This residue was also one of the more tolerant residues, but it showed 
reduced thermostability. This does not agree with the generalization that increased 
mutational tolerance leads to increased stability, which would then increase 
evolvability. Further, M447, that had the highest mutational tolerance, also did not 
appear to be the most evolvable. One of the mutations that had retained partial activity 
with the native substrate was inactive when assayed with the promiscuous substrate. 
These suggest that the general observation - that mutational tolerance promotes 
evolvability - do not constitute as “hard and fast rules”. Interestingly, the tolerant 
residues, M447 and T509, and the residues that seem more pliable (R562 and T509) are 
located on surface areas. This is agreeable with observations thus far that solvent 
accessibility promotes mutational tolerance. It appears that both mutational tolerance 
and solvent accessibility can affect evolvability but, the main driving force of the 
adaptation process of E-GUS depends strongly on mutations that will alter the 
intermolecular interaction within the enzyme and the dynamics of the loop motion so 
that it can adopt a structural conformation that can better accommodate non-native 
substrates33. In other words, these would be the major factors that drive the promiscuity 
of E-GUS. 
 
Taken together, solvent accessibility does increase the mutational tolerance of an 
amino acid residue, but tolerable residues are not always more evolvable. In considering 
library design, protein dynamics such as loop motions that are involved in 
conformational changes may be the more important factors for consideration. This may 
be an even more important factor in larger macromolecules since the inter-molecular 
forces (subunit and inter-domain interactions) within an enzyme will inevitably 
influence its dynamics39. However, with increasing complexity in the structure, it will 
become more difficult to predict the influences of the participating interaction within 
the molecular assemblies of an enzyme. The protein dynamics of large molecules such 
as the E-GUS is more complex due to more possibilities of mutations at the interfacial 
regions that can be sensitive to mutations. This suggests that in directed evolution 
studies of large enzymes, it may be more fruitful to mutate at low mutation rates as 
there will be a higher risk of introducing a deleterious mutation that can totally negate 
the effects of other positive and neutral mutations that may appear together with it.  
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7. Conclusion and future directions  
 
 
This thesis was initiated with the purpose to explore different approaches to 
obtain a glucuronylsynthase for the synthesis of O-glucuronides with enhanced catalytic 
rate. Even though the applicability of the glucuronylsynthase was successfully 
demonstrated by the McLeod group, the kcat of the glucuronylsynthase remains low, 
which left it considerable room for improvement.  
 
The original intent of this thesis was to improve the kcat of the glucuronylsynthase 
a directed evolution methods and a two-stage strategy outlined in Scheme I of Figure 1-
4 (Chapter 1). The two-step approach was designed to facilitate screening processes 
because the screening method for the evolution of glucuronylsynthase would have been 
too involved. This was an unusual approach because most engineering programs will 
choose to engineer the variant that already has the synthetic capability1,2. If this had 
worked, it could have represented a novel way of screening. However, working with the 
wild-type that already has a high activity meant that any improvement was also 
subjugated by the noise in the screens. Subsequently, we added t-BuOH because this 
was found to be advantageous for the chemoenzymatic reactions of the 
glucuronylsynthase. This partially inactivated the wild-type and essentially meant that 
we also introduced an additional selection pressure in the evolution. Consequently, it 
was easier to identify improved variants. Out of this second exercise, we isolated 
mutation L561S that had eight-times higher hydrolytic activity compared to wild-type 
in the presence of t-BuOH. However, conversion of the L561S variant to 
glucuronylsynthase (SynL561S) did not lead to a functional glucuronylsynthase. This 
had then prompted us to focus the evolution on the linear one-step glucuronylsynthase 
engineering approach.   
 
We successfully applied site-saturation mutagenesis to evolve a 
glucuronylsynthase variant that had higher synthetic activity. The best variant contained 
single mutation H162Q that had conferred more than four-fold improvement. 
Considering the limitations that were faced in terms of screening capability, this was a 
decent enhancement. Part of this success was due to the implementation of the strategy 
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that had considered stabilization of the active site conformation as the key factor. Our 
success with this strategy suggests that future semi-rational glucuronylsynthase 
engineering endeavours may target sites that are involved directly or indirectly in the 
active site configuration.  
 
The fold-improvement we obtained compares well with the median fold 
improvement of 5.4, as assessed by Nannemann et al.3 and with other directed evolution 
experiments of glycosynthases that were performed with libraries larger than ours (fold 
improvement 5, 7 and 27)2,4. This paints an encouraging prospect for future attempts to 
further improve the glucuronylsynthase enzyme using directed evolution approach. It 
suggests that the more straightforward direct path approach is more effective than the 
two-step approach i.e. sacrificing screening capacity would have been more worthwhile 
than exercising the first approach.  
 
Our success at isolating the H162Q mutation reopens another possible screening 
route for the future of glucuronylsynthase enzyme engineering. This may also be a 
suitable starting point for a second attempt to optimize the fluoride-selective assay 
discussed at the beginning of Chapter 4 as we may be able to overcome the limits of 
detection. We could not use this assay because of low sensitivity but we may be able to 
optimize the assay to work for continuing the evolution from an improved variant. This 
can replace the slower LCMS method as the main method for primary screening.  
 
The unsuccessful attempt in converting the L561S to a functional 
glucuronylsynthase was against our expectation, which prompted us to ask several 
questions. Was our reasoning that by increasing the base catalysis we would also 
increase the synthetic activity flawed or was there a flaw in the glucuronylsynthase 
system itself that we had overlooked?  Prior to this study, translational misincorporation 
had been reported for the glycosynthase system but was not known to be a major issue. 
We considered this a trivial issue and did not pay much attention to this detail. Our 
experience with L561S suggested otherwise. We set-up a systematic study to study the 
translational misincorporation of the glucuronylsynthase.  
 
The experiments in Chapter 5 indicated that the intrinsic errors during protein 
translation increased the hydrolytic process significantly, indicating the presence of 
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wild-type E-GUS contaminants. In turn, this adversely affected the glucuronylsynthase 
system. The rate of the hydrolysis process could be reduced by at least 103 times by 
manipulating codon bias usage and overexpression conditions. We have found that the 
misincorporation rates increased by a factor of 40 when we increased the expression 
temperature and induction time. Data from cell growth study suggests that at longer 
induction times, the cell growth enters a different phase where cells may start 
competing for food. Assimilating both data, it shows strong evidence that increased 
metabolic stress increases translational misincorporation. In addition, the rate of G504E 
mistranslation when we used a rare codon was 103 times higher that when a common 
codon was used. These two factors could have contributed to the failure of converting 
L561S into a glucuronylsynthase. The E504G/L561S was produced using the rare 
codon gga and at high temperatures for prolonged expression duration. E504G/L561S 
may have to face increased competing hydrolytic activity caused by mistranslated 
products (G504E/L561S), which would explain why it did not work.  
 
The results from translational misincorporation suggest that adopting the linear 
approach would have been the more prudent option. Our current standing shows that the 
linear approach would decrease the risk of introducing a contaminant with higher 
hydrolytic activity that would have resulted from misincorporation. Therefore, despite 
the difficulty in screening method, the linear approach is a more elegant approach and 
may offer a higher chance of selecting better variants.  
 
Regardless of the approach that future endeavours would like to explore, our 
study on the mutational tolerance of the multi-domain, tetrameric E-GUS may provide 
insightful details that may be of use. Higher mutational tolerance can promote 
evolvability because this would mean that the enzyme is less prone to significant 
destabilization, which may cause complete inactivation of the enzyme. The ability of 
enzymes to tolerate mutations is therefore advantageous if we were trying to evolve for 
a new function.  
 
From the mutational tolerance study, we deduced that the intramolecular 
interaction within a subunit and the interactions at the tetramerization interface are 
important in influencing the mutational tolerance of the E-GUS. Our idea that the inter-
domain interaction has significant influence on the mutational tolerance and hence the 
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evolvability of the enzyme is supported by the H162Q mutation found in the 
glucuronylsynthase enzyme engineering program. The mutation that had conferred 
higher glucuronylation activity, H162Q is found on the loop from Domain I that 
participates in inter-domain interaction. Specifically, this loop extrudes into the active 
site space in the TIM-barrel domain. The mutation is located adjacent to D163 that had 
been established as an important substrate binding site. The H162Q mutation had 
increased the binding affinity of the loop in domain I, presumably through its 
neighbour, with the 1FGlcA substrate that is accommodated in the active site cavity in 
the TIM-barrel. The presence of 1FGlcA had offered the variant significantly more 
stabilization effect than for its parent glucuronylsynthase suggesting that there was an 
increased dependence on the enzyme-glucuronyl donor interaction. Hence, the loop 
where the H162Q is located is involved in the binding of the sugar donor substrate 
through inter-domain interaction. This interaction is important for stabilizing the 
enzyme active site conformation and subsequently promoted its ability to adapt 
glucuronylsynthase function.   
 
Other observations that had been pointed out in the mutational tolerance studies 
may also facilitate future enzyme engineering endeavours of the E-GUS enzyme. When 
we performed site saturation mutagenesis on the sites that are implicated in the binding 
of the C6 functional group and tested the tolerance of the enzyme in the presence of the 
E-glucuronide (native) and E-glucoside (non-native) substrates, we found that generally 
the mutational tolerance exhibited in the presence of both substrates were the same. In 
contrast, when we subjected a site (T509) that was not directly involved in substrate 
binding, but that had the potential to modulate the E-GUS catalytic residue E504, 
mutations (T509A and T509S) that conferred higher promiscuous activity were isolated. 
Interestingly, the mutation that had conferred the glucuronylsynthase with higher 
activity is also not an important binding site residue but lies adjacent to the important 
substrate binding residue D163. These suggest that targeting residues adjacent to 
important binding sites may be fruitful endeavours. This notion is not new as it had 
been found that neighbouring residues often coevolve with conserved positions that 
have functional importance to compensate for destabilizing adaptive mutations5. Hence, 
targeting sites that are in the vicinity of an important binding site might also result in 
significant changes in the activity of an enzyme as this would can modulate the 
flexibility of loops where binding sites are found.  
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Overall, this project had been an ambitious one and was complicated due to the 
size of the enzyme, the initial target set for the two-step approach and the unavailability 
of a quick glucuronylsynthase screening method. Interestingly, the initial approach that 
was meant to make it easy had an inversed effect- made the effort more cumbersome 
and complicated. Our experience suggests that it is more efficient to attempt to increase 
very low levels of the non-native synthetic activity. We had made very small progress 
compared to what we would have liked to in terms of fulfilling the original objective. 
However, we did isolate a glucuronylsynthase variant that was better, which can be used 
as the template to continue the glucuronylsynthase evolution and that can be used to 
develop quicker screening method for this future development. More importantly, the 
work undertaken to answer the main aim of this thesis had led to a better understanding 
of translational misincorporation that would apply not only to the glucuronylsynthase 
system but also to the production of biocatalysts in general. Furthermore, the 
penultimate chapter that had explored the mutational tolerance of the enzyme might 
initiate more of such studies. These studies can lead to further consensus that can further 
our understanding of mutational tolerance and evolvability of multi-domain oligomeric 
enzymes.  
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Engineering the glycoside hydrolase β-glucuronidase (β-GUS) to improve a 
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Appendix A: Equipments and Consumable Suppliers 
 
Equipments and consumables Manufacturers and suppliers 
5415 Microcentrifuge Eppendorf 
5804 Centrifuge Eppendorf 
AKTA FPLC Sysyem G.E. Healthcare 
Amicon Ultra-15 Centrifugal Filter Unit Millipore 
ASB270BT Autoclave Astell Scientific 
Bioline II Isolate Plasmid kit Bioline 
C1000 Thermal Cycler Bio-Rad 
Chirascan Circular Dichroism Applied Photophysics 
CO8000 Cell Density Meter WPA Biowave 
GeneAmp PCR System 9700 SLM Instruments 
HisTrap FF Column G.E. Healthcare 
HiTrap Desalting Column G.E. Healthcare 
I-Cycler Bio-Rad 
Liquid Chromatography/Mass Spectrometry Agilent Technologies 
MicroPulser Electroporator Bio-Rad 
MJ Mini Personal Thermal Cycler Bio-Rad 
Multiskan Ascent Thermo Fischer Scientific 
NanoDrop® ND-1000 Spectrophotometer NanoDrop 
NanoITC Texas Instruments 
Orion ROSS Combination pH Electrode Orion Pacific Pty Ltd 
QIAprep Spin Miniprep kit Qiagen 
R20A2 and R9A Rotors for VX22G centrifuge Hitachi 
Rotorfix 32 Centrifuge Hettich 
SE250 Mighty Small II Mini Vertical Electrophoresis 
Unit 
Hoefer 
SpectraMax® M2/M2e Microplate Reader Molecular Devides 
Superdex 200 Size Exclusion Column Amersham Biosciences 
UV transilluminator 254/312 nm with UVItec camera Hanimax Statesman 
Veriti 96-Well Thermal Cycler Applied Biosystems 
VX22G High Speed Centrifuge VWR 
Wide Mini Sub Cell Electrophoresis Tank Bio-Rad 
Wizard® SV Gel and PCR Clean-Up System Promega 
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Appendix B: Chemical suppliers 
 
Chemicals Manufacturers and suppliers 
1 kb DNA Marker New England Biolabs 
2-propanol (IPA) Merck 
4-(2-aminoethyl) benzene sulfonyl fluoride hydrochloride Sigma Corporation 
Acetone Merck 
Acetonitrile Sigma Corporation 
Acryl/Bis 37.5:1 40% (w/v) Amresco 
Agar Sigma Corporation 
Agarose Sigma Corporation 
Ammonium chloride AnalaR 
Ampicilin Amresco 
BigDye® Terminator and Sanger Sequencing Buffer Biomolecular Resource 
Facility, JCSMR 
BioTaqTM Polymerase and PCR buffer Bioline 
Bromophenol Blue Sigma Corporation 
BugBuster® Protein Extraction Reagent Novagen 
Calf Intestinal Alkaline Phosphatase and Buffer New England Biolabs 
Dimethyl Sulfoxide Sigma Corporation 
dNTPs Roche 
DpnI and Buffer New England Biolabs 
EcoRI and Buffer New England Biolabs 
Ethylenediaminetetraacetic acid Ajax Chemicals 
Ethanol Merck 
Ethidium Bromide Sigma Corporation 
Ethyl acetate Merck 
Glycerol Merck 
Glycine Amresco 
Hydrochloric acid Ajax Chemicals 
Imidazole Sigma Corporation 
Isopropyl β-D-1-thiogalactopyranoside Astral 
Kanamycin AG Scientific Ltd 
Low Range SDS-PAGE Marker Bio-Rad 
Methanol Merck 
Magnesium Chloride Sigma Corporation 
Magnesium Chloride, PCR buffer Roche 
Manganese Chloride Ajax Chemicals 
N,N,N’,N’,-Tetramethylethylenediamine Sigma Corporation 
NdeI and Buffer New England Biolabs 
Nutrient Broth Difco 
Orthophosphoric acid – 85% AnalaR® 
p-nitrophenol Sigma Corporation 
p-nitrophenyl galatoside Sigma Corporation/Chem-
Impex International Inc 
p-nitrophenyl glucoside Sigma Corporation/Chem-
Impex International Inc 
p-nitrophenyl glucuronide Acros Organics 
Pfu Polymerase and Buffer Thermo Scientific/Agilent 
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Phenylmethylsulfonyl fluoride Sigma Corporation 
Phusion polymerase and Buffer Finnzyme/New England 
Biolabs 
Potassium phosphate, monobasic Ajax Chemicals 
Potassium phosphate, dibasic Ajax Chemicals 
RedSafeTM DNA Stain Chembio 
rLysozymeTM Novagen 
Sodium Chloride Chem Supply 
Sodium Dodecyl Sulfate Amresco 
Sodium Hydroxide Ajax Chemicals 
Sodium phosphate, monobasic Ajax Chemicals 
Sodium phosphate, dibasic Ajax Chemicals 
T4 DNA Ligase Thermo 
Scientific/Fermentas/New 
England Biolabs 
Taq Polymerase Roche 
tert-butanol Sigma Corporation 
Tris Amresco 
Tryptone Difco 
Yeast Extract Difco 
β-mercaptoethanol Sigma Corporation 
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Recipes for growth media 
 
M9 media 
Na2HPO4  ----- 6.4% (w/v)  
K2HPO4 ----- 1.5% (w/v)  
NaCl ----- 0.5% (w/v)  
NH4Cl ----- 0.25% (w/v)  
Top up to desired volume with MilliQ water (mQH2O) 
For agar plates preparation: add 1.5% (w/v) agar  
Sterilized by autoclaving 
 
LB media 
Yeast extract ----- 0.5% (w/v)  
Tryptone ----- 1% (w/v)  
Sodium chloride ----- 1% (w/v)  
Top up to desired volume with MilliQ water (mQH2O) 
For agar plates preparation: add 1.5% (w/v) agar  
Sterilized by autoclaving 
 
2XYT 
Yeast extract ----- 1.0% (w/v)  
Tryptone ----- 1.6% (w/v)  
Sodium chloride ----- 0.5% (w/v)  
Top up to desired volume with MilliQ water (mQH2O) 
Sterilized by autoclaving 
 
YENB 
Yeast extract ----- 0.75% (w/v)  
Nutrient broth ----- 0.8% (w/v)  
Top up to desired volume with MilliQ water (mQH2O) 
Sterilized by autoclaving 
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Recipes for biochemical solutions and buffers 
 
Sodium phosphate buffer (NaPi) components 
Disodium hydrogen phosphate (Na2HPO4), 200 mM ----- 28.39 g in 1 L MilliQ water 
Sodium dihydrogen phosphate (NaH2PO4), 200 mM ----- 27.58 g in 1 L MilliQ water 
 
Sodium phosphate buffer (NaPi), 200 mM 
200 mM Na2HPO4 ----- ~ 750 mL  
200 mM NaH2PO4 ----- ~ 250 mL (titrant) 
Adjust pH to pH 7.4 with NaOH and H3PO4    
 
Sodium phosphate buffer (NaPi), 50 mM 
Dilute 200 mM NaPi 1:4 v/v in MilliQ water (mQH2O), final pH 7.4 
 
Assay buffer with t-BuOH 
Mix 200 mM NaPi pH 7.4 and neat t-BuOH to desired concentrations 
Top up with mQH2O 
 
Ni2+ affinity column purification (HisTrap) binding buffer (Buffer A) 
NaPi, 200 mM ----- 250 mL (50 mM) 
Sodium chloride (NaCl) ----- 29.22 g (0.5 M) 
Adjusted to pH 7.4 with NaOH and H3PO4    
Top up to 1 L with MilliQ water (mQH2O)    
 
Ni2+ affinity column purification (HisTrap) elution buffer (Buffer B) 
NaPi, 200 mM ----- 250 mL (50 mM) 
Sodium chloride (NaCl) ----- 29.22 g (0.5 M) 
Imidazole ----- 34.04 (0.5 M) 
Adjusted to pH 7.4 with NaOH and H3PO4    
Top up to 1 L with MilliQ water (mQH2O)    
 
10X SB buffer (Sodium Hydroxide-borate) for DNA gel electrophoresis 
Sodium hydroxide ----- 8 g  
Top up with 1 L mQH2O    
Boric acid (to adjust pH to 8.0) ----- ~ 48 g   
To make 1X SB buffer:     
Dilute 100 mL 10X SB buffer in 900 mL mQH2O    
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Bromophenol blue (BPB) loading buffer 
Bromophenol blue ----- 0.05%  
Glycerol ----- 75%  
Tris buffer, pH 8.0 ----- 2.5 mM  
Made up to desired volume with mQH2O    
 
SDS-PAGE running buffer (1X) 
Glycine ----- 14.4 g  
Tris ----- 3.0 g  
SDS ----- 1.0 g  
Made up to desired volume with mQH2O    
 
SDS-PAGE loading buffer 
Tris buffer pH 6.8 ----- 0.31 M  
Sodium dodecyl sulfate (SDS) ----- 10%  
Glycerol ----- 50%  
β-mercaptoethanol (βME) ----- 25%  
Bromophenol blue ----- 0.5%  
Made up to desired volume with mQH2O    
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Table A-1: Table listing oligonucleotide primers used. F: forward primer; R: reverse 
primer; nnk, mnn denotes degenerate codons.	
Primers Sequences (5' – 3') Comments 
GUS 164X F act tcc atg atn nk tta act atg ccg g Site saturation mutagenesis 
GUS 562QC 
R aga tcc ctt tct tgt tac cgc caa cmn nca ata tgc 
Site saturation 
mutagenesis 
GUS D163 
QC F agt taa aga ann nat gga agt aag act gct ttt tct tgc cg 
Site saturation 
mutagenesis 
GUS D163X gtc tta ctt cca tnn ntt ctt taa cta tgc cgg aat cc Site saturation mutagenesis 
GUS D399-
D415 F ata gcg cgt gac aaa aac cac cc 
Site saturation 
mutagenesis 
GUS D399-
D415 R aat aat ccc tgc acc ttg cgg 
Site saturation 
mutagenesis 
GUS D508X 
R aat acg gcg tgn nka cgt tag cc 
Site saturation 
mutagenesis 
GUS 
E413A/G F att gcc aac gst ccg gat acc 
Site directed 
mutagenesis at 
E413 
GUS E413X 
R tat tgc caa c nn kcc gga tac ccg tcc 
Site saturation 
mutagenesis at 
E413 
GUS E504A 
R acg ccg tat gcg gtg atg ata atc ggc 
Site specific 
mutation E504A 
GUS E504G 
(common) R acg ccg taa ccg gtg atg ata atc ggc 
Codon 
optimization at 
E504G 
GUS E504G 
(rare) R acg ccg tat ccg gtg atg ata atc ggc 
Codon 
optimization at 
E504G 
GUS E504S 
R acg ccg taa ctg gtg atg ata atc ggc 
Site specific 
mutation E504S 
GUS E505-
S522 F atc acc gaa tac ggc gtg g 
Fragment library 
construction 
GUS E505-
S522 R gcc atg cac act gat act ctt 
Fragmentlibrary 
construction 
GUS F161X agc agt ctt can nkc atg att tct tta act atg c Site saturation mutagenesis 
GUS F162X agc agt ctt act tcn nkg att tc Site saturation mutagenesis 
GUS G362X tct ctt tan nka ttg gtt tcg aag c Site saturation mutagenesis 
GUS K370 R aag cgg gca can nkc cga aag aac tg Site saturation mutagenesis 
GENERAL APPENDIX 	
	 —A:8 — 
   
Primers Sequences (5' - 3') Comments 
GUS K372E aac aag ccg gaa gaa ctg tac agc Site specific mutation K372E 
GUS L361X 
F taa cct ctc tnn kgg cat tgg ttt cg 
Site saturation 
mutagenesis 
GUS N412 
QC F tat ccg gtt cnn ngg caa tac tcc aca tca cc 
Site saturation 
mutagenesis 
GUS N412 
QC R gag tat tgc cnn nga acc gga tac ccg tcc 
Site saturation 
mutagenesis 
GUS M447 
QC F gcg tca atg tan nnt tct gcg acg ctc aca ccg 
Site saturation 
mutagenesis 
GUS M447 
QC R agc gtc gca gaa nnn tac att gac gca ggt gat cgg 
Site saturation 
mutagenesis 
GUS P371T aag cgg gca aca aga cga aag aac Site specific mutation P371T 
GUS R562X 
QC F aag gca tat tgn nk gtt gcg gta aca aga aag g 
Site saturation 
mutagenesis 
GUS 
R562X F agg cat att gnn ngt tgg cgg taa caa gaa agg g 
Site saturation 
mutagenesis 
GUS T509A 
R ccc ggc taa cgc atc cac gcc gta tt 
Site specific 
mutation T509A 
GUS T509X 
F gcg tgg atn nnt tag ccg ggc tgc act c 
Site saturation 
mutagenesis 
GUS Y160X 
F agc acg tct nnk ttc cat gat ttc ttt aac 
Site saturation 
mutagenesis 
GUS Y469X 
F gaa ccg tta tnn kgg atg gta tgt cca aag c 
Site saturation 
mutagenesis 
GUS Y472X 
F tta cgg atg gnn kgt cca aag cgg cg 
Site saturation 
mutagenesis 
GUS Y478X 
F cct gaa ccg tnn kta cgg atg gta tgt cc 
Site saturation 
mutagenesis 
gusA 1016 F act ggg cag atg aac atg gc Fragment library construction 
gusA 1166 R aag tgc gct tgc tga gtt tcc c Fragment library construction 
gusA 1289 F aag caa cgc gta aac tcg acc cg Fragment library construction 
gusA 1289 R gtc gag ttt acg cgt tgc ttc cg Fragment library construction 
gusA 1339 F atg ttc tgc gac gct cac acc gat a Fragment library construction 
gusA 1339 R gta tcg gtg tga cgc tcg cag aac Fragment library construction 
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Primers Sequences (5' - 3') Comments 
gusA 1364 R' aga gat cgc tga tgg Fragment library construction 
gusA 1448 R ttc tct gcc gtt tcc aaa tcg Fragment library construction 
gusA 1511 F tat cat cac cga ata cgg cgt gga tac g Fragment library construction 
gusA 1511R tat cca cgc cgt att cgg tga tga taa tcg g Fragment  library construction 
gusA 367nt F att gcc ggg aaa agt gta cg Fragmentlibrary construction 
gusA 5' int 
730 R ata acc ttc acc cgg Sequencing 
gusA 544 R tgt tcg gcg tgg tgt aga gc Fragment library construction 
gusA 857 F taa cca caa acc gtt cta ctt tac tgc Fragment library construction 
gusA 857 R aac ggt ttg tgg tta atc agg aac tgt tcg Fragment library construction 
pET28a/GUS 
EcorI R ggt ggt ggt gga att ctc att gtt tgc c 
Construction of 
pET28a/GUS 
WT 
pET28a/GUS 
V2L F cgc ggc agc cat atg tta cgt cct gta gaa acc 
Construction of 
pET28a/GUS 
WT 
pJe01 F cac aat tcc aca acg gtt tc Library construction 
pJe01 R cga ccg gct cag tcg aaa g 
Library 
construction and 
sequencing 
pJe02 F att cca caa cgg ttt ccc Library construction 
pJexp seq F' ctc gaa aat aat aaa ggg aaa atc ag Sequencing 
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Figure A2-1: The standard curves used to calculate the extinction coefficient values for pNP in 50 mM 
NaPi, pH 7.4. The molar coefficient was taken from the average of four curves. 
 
 
Figure A2-2:  The standard curves used to calculate the extinction coefficient values for pNP in 50 mM 
NaPi, pH 7.4 containing 20% t-BuOH, The molar coefficient was taken from the average of four curves. 
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Table A3-1:  Library sizes and the oversampling size required to achieve 95% library coverage in directed 
evolution experiments. They are dependent on the peptide length of an enzyme. Oversampling library 
sizes were calculated according to the to equation described by Patrick et. al.1  	
Length of protein 
or fragment
(no. of AA 
residues)
1 1.80E+03 100
2 5.35E+05 4950
3 1.05E+08 161700
1 5.40E+03 300
2 4.84E+06 44850
3 2.89E+09 4455100
1 1.08E+04 600
2 1.94E+07 179700
3 2.32E+10 35820200
Theoretical5library5size5calculated5by:
nCr5x56r where,5 n5=5 length5of5fragment
r5=5
This5is5calculated5by:
L5=5GVln(1GF) where,5
V5=5total5number5of5possiblemutant5sequences
F5=515G5P(0)5
F5represents5the5probability5of5all5variants5occuring5at5least5once
Hence,5F5=515G5P(0)5555
600
95% 
coverage
100
300
;5where5P(0)5=5probability5that5a5sequence5does5not5
contain5any5mutation5(05substitution)
Theoretical 
library size 
(no. of 
variants)
6.00E+02
1.78E+05
3.49E+07
1.80E+03
9.62E+08
1.61E+06
fmutation
3.60E+03
6.47E+06
7.74E+09
The5oversampling5factor5that5is5required5to5achive595%5library5coverage5is5
approximately5three.
average5mutation5
frequency
	
 
References:  
1. Patrick, W. M., Firth, A. E. & Blackburn, J. M. User-friendly algorithms for 
estimating completeness and diversity in randomized protein-encoding libraries. Protein 
Eng. 16, 451–457 (2003).  
  
APPENDIX: CHAPTER 3 	
	 — A:12 — 
Appendix 3-2 
  
Ta
bl
e 
A
3-
2:
 M
ut
at
io
ns
 a
cc
um
ul
at
ed
 in
 β
-G
U
S 
ev
ol
ut
io
n 
APPENDIX: CHAPTER 3 	
	 — A:13 — 
Appendix 3-2 (cont) 
  
Ta
bl
e 
A
3-
2 
(c
on
t)
: M
ut
at
io
ns
 a
cc
um
ul
at
ed
 in
 β
-G
U
S 
ev
ol
ut
io
n.
 H
ig
hl
ig
ht
ed
 in
 b
lu
e 
de
no
te
s 
th
e 
po
in
t w
he
n 
t-B
uO
H
 w
as
 a
dd
ed
 
APPENDIX: CHAPTER 3 	
	 — A:14 — 
Appendix 3-2 (cont) 
  
Ta
bl
e 
A
3-
2 
(c
on
t)
: M
ut
at
io
ns
 a
cc
um
ul
at
ed
 in
 β
-G
U
S 
ev
ol
ut
io
n.
 H
ig
hl
ig
ht
ed
 in
 b
lu
e 
de
no
te
s 
th
e 
po
in
t w
he
n 
t-B
uO
H
 w
as
 a
dd
ed
 
APPENDIX: CHAPTER 3 	
	 — A:15 — 
Table A3-3: Relative activity of 4GUS mutants. All mutants were more than 3x more active than wild-
type and could not be discriminated. Activities were compared with the wells that had single mutation 
L561S in the same plate instead.  
 
Mutant(s) No. of occurrences Mutations 
Relative WT 
activity 
Relative L561S 
activity 
4dGus.1 1 H313L/K495R/L561S > 3 0.76 
4dGus.3 1 K277Q/L561S > 3 0.70 
4dGus.12 1 K277Q/A431V/L561S > 3 0.74 
4GUS21 2 K495R/L561S > 3 1.11 
4GUS21 5 A431V/L561S > 3 0.63 
L561S 18 L561S > 3 1.00 
4GUS11 2 K277Q > 3 0.70 
4GUS31 1 H313L > 3 0.81 
 
 
Appendix 3-3 
 
Table A3-4: Mutations accumulated in revisited Lp6 libraries after the addition of t-BuOH (Rd 1). Rel 
Act (bfe): relative activity over wild-type in buffer, Rel Act (t-BuOH): relative activity over wild-type in 
t-BuOH. 
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Table A3-5: Mutations accumulated in revisited Lp6 libraries after the addition of t-BuOH (Rd 2). Bfe: 
relative activity over wild-type in buffer, Res: Residual activity when 20 % t-BuOH was included. 
 
 
2Lp6 
clones 
Other 
designations Bfe 
t-
BuOH Res 54
3 
55
7 
56
0 
56
1 
59
4 
59
8 
59
6 
59
3 
56
7 
58
2 
56
6 
4 L561S 0.51 4.353 8.54    S        
6 - 1.53 3.785 2.47   T S  R      
7 - 1.11 4.805 4.32   T S   R     
8 - 1.21 4.68 3.87    S    S    
9 - 0.71 3.265 4.61 I  T S        
10 7GUS10 0.83 3.579 4.30  L  S        
13 7GUS13 0.62 3.45 5.56   T S        
14 7GUS14 0.56 3.52 6.25    S    S    
18 - 1.02 4.99 4.88 I  T S        
20 - 0.80 5.15 6.44    S        
23 7GUS24 0.35 2.41 6.88    S     R   
24 - 0.40 2.95 7.39      R     S 
25 - 0.77 3.64 4.72   T S  R      
26 - 0.37 0.87 2.74 I   S    S    
27 - 1.57 3.15 8.45 I   S        
28 - 1.06 5.56 3.54    S    S    
29 - 0.51 6.30 5.95   V S    S    
31 - 0.98 3.33 7.73 I   S C R      
32 - 0.77 4.55 5.87 I   S   R     
35 - 0.17 1.67 10  L  S C       
36 7GUS7 0.54 3.89 7.15    S  R      
38 - 1.05 5.89 5.58    S    S    
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Figure A4-1: Optimization of the LC/MS ionization parameters. (a) The fragmentation voltage of the 
LC/MS is varied between 100–250 V. (b) The capillary voltage of the LCMS is varied between           
2000–4500 V.  		
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) Variable fragmentation voltage 
(b) Variable capillary voltage 
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Figure A4-2: Resolution of the free CMO-DHEA and CMO-DHEA glucuronide peaks using only the 
guard column at two difference lysate loads. (a) Resolution of the peaks and the peak area of CMO-
DHEA glucuronide with 1x lysate load. (b) Resolution of the peaks and the peak area of CMO-DHEA 
glucuronide with 2x lysate load. The method can discriminate variants that are two-fold improved.  
  
Free CMO-DHEA 
CMO-DHEA glucuronide 
Free CMO-DHEA 
CMO-DHEA glucuronide 
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Table A4-1: Library sizes for various site-saturation libraries. 
No. of AA 
position  Codon degeneracy fmutation 
Theoretical 
library size (no. of 
variants) 
95% coverage1 
   
 
1 
NDT 12 12 36 #NUM! 
NNK 32 32 96 #NUM! 
NNN 64 64 192 #NUM! 
2 
NDT 12 144 432 #NUM! 
NNK 32 1024 3072 #NUM! 
NNN 64 4096 12288 #NUM! 
3 
NDT 12 1728 5184 
 NNK 32 3.28E+04 9.83E+04 
 NNN 64 2.62E+05 7.86E+05 
 
4 
NDT 12 2.07E+04 6.22E+04 #NUM! 
NNK 32 1.05E+06 3.15E+06 #NUM! 
NNN 64 1.68E+07 5.03E+07 #NUM! 
   
   
 
   
   
 The oversampling factor that is required to achive 95% library coverage is approximately three. 
This is calculated by: 
 
   
 L = -Vln(1-F)                    ; where 
 
 
 
 
 
   
   
 V = total number of possible mutant sequences  
 F = 1 - P(0)  
 
   
 F represents the probability of all variants occuring at least once 
  
Hence, F = 1 - 
P(0)     
  
; where P(0) = probability that a sequence does not contain  
 any mutations (0 substitution) 
 
 
 
Reference: 
1. Patrick, W. M., Firth, A. E. & Blackburn, J. M. User-friendly algorithms for 
estimating completeness and diversity in randomized protein-encoding libraries. 
Protein Eng. 16, 451–457 (2003).  
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Figure A4-3: ITC 
binding isotherms of  
glucuronylsynthase and 
its variants (a) SynWT 
(b) SynH162Q (c) Syn 
Y160G. 
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Figure A4-4: Reaction scheme for the glucuronidation of CMO-DHEA (k1) and the competing 
hydrolytic reaction (k-1).   
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Lane 1: M 
Lane 2: 18 °C, 4 h, D1-1 
Lane 3: 18 °C, 4 h, D1-2 
Lane 4: 18 °C, 4 h, D2-1 
Lane 5: 18 °C, 4 h, D2-2 
Lane 6: 18 °C, 8 h, D1-1 
Lane 7: 18 °C, 8 h, D1-2 
Lane 8: 18 °C, 8 h, D2-1 
Lane 8: 18 °C, 8 h, D2-2 
Lane 9: 18 °C, overnight, D1-1 
Lane 10: 18 °C, overnight, D1-2 
Lane 11: 18 °C, overnight, D2-1 
Lane 12: 18 °C, overnight, D2-2 	
 
Lane 1: 30 °C, 4 h, D1-1 
Lane 2: M 
Lane 3: 30 °C, 4 h, D1-2 
Lane 4: 30 °C, 4 h, D2-1 
Lane 5: 30 °C, 4 h, D2-2 
Lane 6: 30 °C, 8 h, D1-1 
Lane 7: 30 °C, 8 h, D1-2 
Lane 8: 30 °C, 8 h, D2-1 
Lane 8: 30 °C, 8 h, D2-2 
Lane 9: 30 °C, overnight, D1-1 
Lane 10: 30 °C, overnight, D1-2 
Lane 11: 30 °C, overnight, D2-1 
Lane 12: 30 °C, overnight, D2-2 
 
Lane 1: M 
Lane 2: 37 °C, 4 h, D1-1 
Lane 3: 37 °C, 4 h, D1-2 
Lane 4: 37 °C, 4 h, D2-1 
Lane 5: 37 °C, 4 h, D2-2 
Lane 6: 37 °C, 8 h, D1-1 
Lane 7: 37 °C, 8 h, D1-2 
Lane 8: 37 °C, 8 h, D2-1 
Lane 8: 37 °C, 8 h, D2-2 
Lane 9: 37 °C, overnight, D1-1 
Lane 10: 37 °C, overnight, D1-2 
Lane 11: 37 °C, overnight, D2-1 
Lane 12: 37 °C, overnight, D2-2 
Figure A5-1: SDS-Page analysis of the expression levels of Syn expressed at different temperature and 
length of time on two different days (D1 and D2). Bradford quantification of protein amounts was also 
compared to the overexpression levels indicated on these SDS-pages. 
	  
Gel 1 
Gel 2 
Gel 3 
APPENDIX: CHAPTER 5 	
	 — A:23 — 
Appendix 5-2 
 
Table A5-1: Activity of the crude lysates measured from samples expressed on two 
different days (intra-day replicate). On each day, duplicate of each samples were grown 
and expressed. D1 = Day 1, D2 = Day 2. Numbers behind D1 or D2 denotes the 
duplicate on each day.    
Induction 
temperature 
Induction 
time 
Activity (nM/min/ug) x 10-2 
D1-1 D1-2 D2-1 D2-2 Average 
18 °C 4 h 2.24 2.34 2.13 2.13 2.21 ± 0.10 
 8 h 2.01 1.37 2.32 2.21 1.98 ± 0.43 
 overnight 2.21 2.16 1.79 2.42 2.14 ± 0.26 
         
30 °C 4 h 5.86 6.02 2.86 2.75 4.37 ± 1.82 
 8 h 6.53 5.24 10.1 12.0 8.48 ± 3.14 
 overnight 33.0 43.1 41.7 37.5 38.8 ± 4.54 
         
37 °C 4 h 9.85 12.07 5.59 6.63 8.54 ± 2.97 
 8 h 25.7 23.3 6.55 10.6 16.5 ± 9.40 
  overnight 79.8 93.3 33.1 24.6 57.7 ± 34.0 
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Figure A5-2: Growth curve of constitutive and inducible host-vector expression system.  (a) Growth 
curve of IPTG inducible expression system harbouring gusA gene in GMS407 (DE3) cell line, 
pET28a/gusA/GMS407(DE3). (b) Growth curve of constitutive expression system harbouring gusA gene 
in BW25142 cell line, pJWL1030/gusA/BW25142. The growth curve of inducible expression system 
harbouring gusA gene in BW25142 (pJ401/gusA:E504G/BW25142) is expected to be similar to both the 
growth curves. 
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A6-1 Mutation rate determination for the random mutagenesis of the whole gene 
 
We evaluated the µ computation by first comparing the empirical standard deviation 
(SD) and the theoretical SD ( µ ) were calculated (Table A6-1). As the library 
distribution is expected to follow Poisson distribution, the empirical SD should fall 
close to the µ.  At higher µ, the SD becomes larger. This is likely caused by small 
sampling size that resulted in insufficient coverage of broader distribution. This method 
may not be the best way to evaluate the µ that was determined. Hence, we also 
projected the trend of µ in response to increasing MnCl2 concentration (Figure A6-1). 
The mutation rate increases proportionally with MnCl2 concentration with an expected 
rate of 11 amino acids per mM MnCl2 and a projected mutation rate of 0.7 AA per gene 
when the MnCl2 is 0 mM (y-intercept). The y-intercept is slightly higher than expected 
as one would expect the mutation rate to be closer to 0 when the MnCl2 is 0 mM. We 
forced the trendline through 0, which resulted in a slightly higher rate of increase in 
mutation rate (~ 14 AA per mM MnCl2) (Figure A6-1, dotted line). This may 
underestimate the empirical µ determined at higher MnCl2 above 0.30 mM and can 
result in slightly lower mutational tolerance computation. Nevertheless, the difference 
between the two expected values is small and we do not expect it to cause significant 
difference.  
 
Table A6-1: Deviation of empirical (experimentally determined) and theoretical SD, and the quartiles of 
the mutation rates in each library.  
Empirical 
µ 
Empirical 
SD 
Theoretical 
SD 
% 
deviation 
of SD 
1.13 0.835 1.061 21.3 
2.50 1.77 1.58 10.7 
1.88 2.10 1.37 53.4 
5.00 1.20 2.24 46.3 
4.38 3.00 2.09 43.3 
7.00 6.28 2.65 137 
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Figure A6-1: Mutation rate increased in a linear manner in response to the amount of MnCl2. Error bars 
represent the deviation from the median values. Dotted line represents the line fit when forced through the 
origin.  
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6.1.  6.2.  
6.3.  
6.4.  
6.5. … 
6.6. …  
Figure A6-2: Location of residues targeted for site-saturation mutagenesis in the E. coli β-GUS crystal 
structure (PDB ID: 3K46). (a) Interaction between M447 and Y469. (b) Position of Y468-Y472 and 
M447 relative to superimposed pNPGlcA (yellow) in the crystal structure. (c) Superimposition of loop 
N466-Y472 of E. coli β-GUS crystal structure without GDL inhibitor bound (apo) over the crystal 
structure with GDL inhibitor bound (PDB ID: 3K4D). (e)-(f) Position and movement of residues     Y468 
(d), Y469 (e) and Y472 (f) in the presence of GDL. The residues Y472 and Y468 flipped in the opposite 
direction. Y472 flipped into the active site and forms interaction with the carboxylate group at C6, while 
Y469 flipped out. Adapted from Wallace et al.1 
 
(a) (b) 
(c) (d) 
(e) (f) 
3.9Å 
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Appendix 6-3 
 
Figure A6-3:  Comparison of profile slopes (m4) with different number of data points. 				 	
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Appendix 6-4 
Activity distribution curves of site saturation 
libraries (pNPGlcA screening data) 
Activity distribution curves of site saturation 
libraries (pNPGlc screening data)	
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Figure A6-4:  Activity distribution curves of site-saturation libraries from screening data with pNPGlcA 
substrate (left) and pNPGlc substrate (right). 	 	
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Table A6-2: Summary of sequenced mutations 
from site saturation libraries. I = Inactive; P = 
retained partial activity (5 – 80%); A = as active 
as WT (80 – 120%); O = Better than wild type 
(>120% WT activity). *nd not determined  
Library / 
Mutations 
Activity 
(pNPGA) 
Activity 
(pNPG) 
D163X A I I 
 C I I 
 E I I 
 G I I 
 L I I 
 M I I 
 P I I 
 Q I I 
 R I I 
 Y I I 
R562X A I I 
 F I I 
 G I I 
 L I I 
 H I P 
 N I I 
 P I P 
 Q I P 
 D I I 
 S I P 
 T I P 
 V I I 
 W I I 
M447X A P I 
 D P nd 
 E P P 
 F P I 
 G P I 
 I I I 
 L I I 
 P P I 
 R I I 
 S P P 
 T I I 
 V I I 
N412X A I I 
 C I I 
 D P P 
 E I I 
 G I I 
 H I I 
 I I I 
 K I I 
 L I I 
 Q I I 
 R I I 
 S I I 
 T I I 
Y468X A I I 
 C I I 
 D I I 
 G I I 
 H I I 
 K I I 
 M I I 
 N I I 
 P I I 
 S I I 
 V I I 
Y469X A I I 
 C I I 
 F I I 
 G I I 
 M I I 
 Q I I 
 R I I 
 S I I 
 V I I 
 W I I 
Y472X D I I 
 G I I 
 K I I 
 L I I 
 M I I 
 N I I 
 R I I 
 S I I 
 T I I 
 V I I 
T509X A A O 
 D I I 
 G P/I P/I 
 I I I 
 K I I 
 L I I 
 N I I 
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N412X P I I 
(cont.) Q I I 
 R I I 
T509X S A O 
(cont.) V I I 
 Y P P 			 	
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Appendix 6-5 
 
Kinetics curve for purified enzyme characterization of glucuronidase activity 
(left) and glucosidase activity (right) 
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T509A 
  
R562S 
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WT 
  
Figure A6-5:  Michalis-Menten kinetic curves of purified enzymes (WT, M447G/S, R562S/T and T509A) 
from with pNPGA substrate (left) and pNPG substrate (right). 			
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Appendix 6-6	
	 	
Figure A6-6: Comparison of activity distribution data between raw screening data and a subset of 
screening data. (a) Activity distribution of T509A replotted based on sequencing data and three control 
wells (Inactivation factor = -8.96) (b) Activity distribution of raw T509A screening data (Inactivation 
factor = -3.48 and -12.0 for each replicate). 
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Figure A6-7: Curve-fitting data to obtain input 
values for unpaired t-test analysis. (a) Fitness 
decay of TEM-1 at the highest fitness level. 
The data used to plot TEM-1 was taken from 
reference 2, supplementary information, Table 
1 (1P0 to 8P0). The mutation rate was 
estimated from Figure 1 of reference 2 and 
may deviate by ±0.2. The α-value compares 
very well with the reported value of 0.37. (b) 
Linear transformation of decay plot in panel a 
according to Equation 6-2 for TEM-1. (c) 
Linear transformation of decay plot, Figure 6-
1, according to Equation 6-2 for β-GUS.   
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Table A6-3: Unpaired two-tailed t-test analysis of TEM-1 and β-GUS α-values. Computing the 
significance of the difference between the α-value of TEM-1 and β-GUS. α-value of TEM-1 was 
obtained from Figure A6-7a The standard error (S.E.) of β-GUS and TEM-1 were obtained from the 
LINEST function of the linear regression in Figure A6-7b. 
Enzyme α  S.E. dF tcrit p-
value 
Significance 
TEM-1 0.33 0.053 7 
2.86 0.014 
Significant at p 
< 0.05; not 
significant at p 
< 0.01 
β-GUS 0.46 0.1 5 
 
 
 
 
Parameter Value S.E. 
K 101 9.7 
α 0.33 0.15 
β 0.025 0.044 
R 0.97 
 
Figure A6-8: The fitness decline of β-GUS fitted with an epistasis parameter (β). This was fitted to 
Equation 6-2. The α-value is 0.33 and the β/α value is 0.078. When fitted to this equation, the mutational 
tolerance of β-GUS appears to be the same as TEM-1 and has a β/α value higher than the TEM-1. These 
values were compared with TEM-1’s value on the plot of β/α versus α in reference 2. β-GUS appears to 
be under larger epistastic influence.  
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(a) 
 
(b) 
 
(c)  
Figure A6-9: Interactions between domains and between subunits in β-GUS. (a) Structure of the active 
site domain (TIM-barrel) of β-GUS. Part of Domain I that intrudes into the active site space in Domain 
III is shown in “salmon red”. In magenta at the bottom of the barrel is a hairpin loop from Domain II, 
which is located at the base of Domain III. The two catalytic residues are highlighted in green and the 
disordered region is colored red. The disordered loop is known to extrude into the active site of an 
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adjacent subunit. This is involved not only in domain-domain interaction, but also in subunit-subunit 
interaction. (b) The disordered loop in is solvent exposed. Red regions represent amino acid residues 
between 361-376 that is disordered in the native structure and the structure with GDL bound, but that 
appears to interact with the active site of an adjacent subunit in the presence of two inhibitors. (c) Subunit 
interaction between mobile loops at the C-terminal of the active site where R562 is located. The region 
(Lp6) in the different subunits (A and D) are colored in yellow and brown.  
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